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ABSTRACT
Bovine coronavirus (BCV) is associated with infection of the
enteric and respiratory tracts of neonatal calves, and is a cause
of neonatal calf diarrhoea. The virus has 4 major structural
proteins: the integral membrane glycoproteins (gps) (M), the
nucleocapsid proteins (N), the spike gps (S) and the
haemagglutinin-esterase gps (HE).
Faecal samples from diarrhoeic calves were tested for BCV using
an enzyme linked immunosorbent assay (ELISA), and attempts made to
isolate the virus from positive samples in tracheal organ culture
(TOC). Growth of the virus was monitored by measurement of
haemagglutination (HA) titres, and confirmed by ELISA. Two out of
17 samples (12%) and 29 out of 60 samples (48%) grew to HA titres
of at least 16 in TOCs obtained from bovine foetuses and young
calves respectively. Seven out of 12 viruses (58%) isolated in
calf TOCs were successfully adapted to growth in human rectal
tumour (HRT-18) cells (MRI BCV isolates).
Eight monoclonal antibodies (MAbs) were raised against S2 strain
BCV (S2 MAbs) and a further 4 MAbs were supplied from the Central
Veterinary Laboratory (CVL MAbs). The isotypes of the MAbs were
determined, and their protein specificities investigated by Western
blotting. One MAb was directed against M, 3 against N, 3 against S
and 5 against HE. The MAbs were also characterised in terms of
their reactions with S2 virus in immunofluorescence (IF),
neutralisation (SN) and haemagglutination inhibition (HAI) tests.
Polyclonal sera and MAbs were used to probe S2 virus proteins in
Western blotting experiments. The MWs of the HE, S, N and M
proteins were found to be 116 (reducible to 64), 98, 52 and 21
(range 19-23) KD respectively. The S2 MAbs were used in
competition ELISAs: the 4 HE MAbs defined a single antigenic region
whilst the 3 N MAbs defined 3 distinct regions.
Five standard strains of BCV and the 7 MRI isolates were
examined for antigenic variations using polyclonal sera and the S2
MAbs. Polyclonal sera raised against the 5 standard strains failed
to detect any strain variations in cross IF and SN tests.
Polyclonal anti-S2 serum also failed to detect any strain
variations when titrated against the MRI isolates in SN tests and
when used to probe the blotted viral proteins of all 12 viruses.
S2 MAbs were used in ELISAs, IF, SN and HAI tests, and strain
variations were detected on the N, S and HE proteins.
Different species were tested for their potential suitabilities
for use as animal models of BCV infection. Forty-three out of 73
mice (59%) developed diarrhoea after oral inoculation with S2
strain BCV, but 27 out of 74 mice (36%) inoculated with mock
infected HRT-18 cells also developed diarrhoea. Oral and
intranasal inoculation of a gnotobiotic piglet failed to result in
diarrhoea, and BCV could not be detected in faecal or nasal swabs.
Diarrhoea was successfully produced in a gnotobiotic calf after
oral and intranasal inoculation with BCV. Virus was detected in
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The first description of a disease caused by a coronavirus (CV)
was published in 1931 by Schalk and Hawn. In this paper avian
infectious bronchitis was differentiated from other respiratory
diseases found in chickens. The causative agent, infectious
bronchitis virus (IBV), was isolated in 1937 by Beaudette and
Hudson. In subsequent years 2 more coronaviruses were described
for the first time. These were mouse hepatitis virus (MHV)
(Cheever et al, 1949) and a virus designated B814 which was the
first of several new viruses to be isolated from the human
respiratory tract (Tyrrell and Bynoe, 1965). In 1968 Almeida et
al proposed that these viruses should be grouped together under the
name coronavirus. This grouping was largely based on the
characteristic surface projections seen when these viruses were
examined using an electron microscope (EM). The name coronavirus
was chosen because this appearance was reminiscent of both the
solar corona and the corona spinarum which surrounds the heads of
figures in religious art.
Further work led to a better understanding of the structure and
properties of CVs and in 1975 the International Committee on the
Taxonomy of Viruses approved the creation of a new family,
Coronaviridae. with a single genus, Coronavirus (Tyrrell et al,
1975). The genus originally contained 9 species of virus with IBV
as the type species, but several new viruses have been added
subsequently.
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DISEASES CAUSED BY THE CORONAVIRUSES
Members of the coronavirus family are probably distributed
worldwide: they infect many species and cause a variety of clinical
diseases. Table 1.1 lists the most commonly recognised CVs and
identifies the diseases they cause. Whilst a few CVs (such as MHV
and feline infectious peritonitis virus FIPV) affect multiple
organs, most CVs are primary pathogens of either the respiratory or
enteric tract. Infection of the epithelial cells at these sites
results in acute clinical syndromes. Some CVs (IBV, bovine
coronavirus BCV, transmissible gastroenteritis virus TGEV, FIPV
and MHV) are able to establish persistent infections which are
either clinically inapparent or lead to chronic disease syndromes
(Underdahl et al. 1974; Wege et al. 1982; Heckert et al. 1990).
The existence of persistently infected animals facilitates survival
and transmission of the virus and is of economic importance as
carrier animals may introduce disease into susceptible populations.
ANTIGENIC GROUPS
The CVs have been divided into 4 antigenic groups: groups I and
II infect mammals and groups III and IV infect avians (Table 1.2).
Viruses within each group show partial serological cross
reactivity. This grouping has been based on results obtained using
polyclonal sera and monoclonal antibodies (MAbs) in standard
serological tests (Pedersen et al, 1978; Wege et al, 1982; Siddell
et al, 1983; Sturman and Holmes, 1983; Holmes, 1990).
6
Table 1.1






































2. Lower respiratory disease
1. Tracheobronchitis
2. Nephritis
3. Reduction in quantity
and quality of eggs
Enteritis
1. Neonatal calf diarrhoea















Pleural effusion disease Rabbit
virus, RbCV
Rabbit enteric corona- Rabbit
virus, RbECV




















Antigenic groups of the Coronaviruses
Group 1 Group 2












Group 3 Group 4
IBV TCV
Recently published data demonstrates that
TCV should be reclassified as a group 2




CVs particles are pleomorphic to rounded in shape, and have a
diameter of 60 to 220 nanometres (nm). The mean diameter of BCV
particles is 100 nm, and individual virions vary in size from 90 -
130 nm (Sharpee et al. 1976; Dea et al, 1980b). The buoyant density
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of CVs in sucrose is about 1.18 grams/centimetre (g/cm ) (Sturman
and Holmes, 1983).
CVs present a characteristic appearance when negatively stained
preparations are examined by EM (Fig. 1.1). The virus envelope is
seen as a distinct pair of electron dense shells. The spike
glycoproteins (gps) radiate from this envelope to form a
characteristic fringe of surface projections (spikes or peplomers).
The spikes are widely spaced, about 20 nm long and are generally
described as being club shaped. Other shapes including rods, cones
and mushroom-like projections have also been reported (Davies and
Macnaughton, 1979). Virus particles are often seen that either
partially or completely lack these surface projections, as they may
be lost during virus storage and preparation. Roseto et al (1982)
found that a freeze-drying technique resulted in better preservation
of BCV particles than that achieved using negative staining.
Virus proteins
Coronaviruses have 3, or less commonly, 4 major structural
proteins. These are the nucleocapsid protein N, the integral
membrane gp M (formerly matrix gp, El), the spike gp S (formerly
peplomer gp, E2) and the haemagglutinin-esterase gp HE (formerly
9
Figure 1.1
BCV particles viewed under the electron microscope
The virus particles in a calf faecal sample were absorbed
onto the EM grid using anti-BCV IgG, and negatively stained
with phosphotungstic acid.
Total magnification x 160,000.






haemagglutinin gp, E3). The N, M and S proteins are found in all
CVs whilst the HE gp is present only on some CVs, including BCV.
A model of CV structure is shown in Fig. 1.2 (Holmes, 1990).
The N protein is associated with the viral ribonucleic acid (RNA)
to form a long, flexible helical nucleocapsid. The M gp spans the
viral envelope, whilst the S and HE gps project from the envelope.
The HE gp forms the second inner fringe of surface projections
which are seen when negatively stained preparations of the viruses
possessing this protein are examined by EM (Bridger e_t al, 1978b) .
King and Brian (1982) examined the arrangement of the structural
proteins of BCV by using pronase enzyme to digest the exposed
regions of the virus proteins. These workers found that the enzyme
removed the HE, S and M gps to leave digestion resistant fragments
with molecular weights (MWs) of 38 and 22 kilodaltons (KD), and
that the N protein was left intact.
Nucleocapsid protein. N
The N protein has a MW of 50-60 KD and can form
disulphide-linked trimers under non-reducing conditions. This
protein is non-glycosylated, but the serine residues are
phosphorylated (Siddell et al, 1982). A protein kinase activity
has been demonstrated in purified virions which specifically
phosphorylates the N protein in vitro. It is unclear whether this
enzyme is of viral or cellular origin (Siddell et al, 1981).
The main function of the N protein is to encapsidate the genomic
RNA. Many molecules of the N protein are associated with the RNA to
form a long, flexible, helical nucleocapsid, with a diameter of
11
Figure 1.2.
A diagraming rip model of coronavirus structure
(Adapted from Holmes, 1990).
See text for explanation.
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10-20 nm (Sturman and Holmes, 1983). Formation of this
nucleocapsid during virus replication facilitates incorporation of
the RNA into virion particles.
Integral membrane glycoprotein. M
The M gp exists as a series of species which have different
levels of glycosylation on an identical protein backbone. They are
seen on protein gels as a series of closely-related bands with MWs
in the region of 20-30 KD. High MW bands may also be seen on
protein gels as the M gp tends to form aggregates when heated to
100 degrees centigrade (°C) in the presence of sodium dodecyl
sulphate (SDS) and 2-mercaptoethanol (ME) (Sturman, 1977).
The M gp is unusual in some CVs such as MHV and BCV because the
carbohydrates are joined by 0-linked glycosidic bonds (Spaan et al.
1988). This type of bond had not previously been found in viruses.
In these CVs the M gp is resistant to the presence of tunicamycin,
a compound which inhibits the formation of N-linked glycosidic
bonds. In other CVs such as IBV and TGEV, N-linked glycosidic
bonds are present (Spaan et al, 1988).
Analysis of sequence data (Armstrong et al, 1984) has led to the
proposal that the M gp has 3 distinct domains. A 5 KD hydrophilic
amino-terminal (N-terminal) domain lies external to the viral
envelope. It contains all the carbohydrate present in the protein
and is the only domain which can be removed by pronase or
bromelain. The next 80 or so residues form 3 hydrophobic alpha («•)
helices which span the lipid bilayer 3 times. The third domain,
the carboxy-terminus (C-terminus), is neither strongly hydrophilic
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nor hydrophobic. It lies on the inner side of the envelope and
interacts with the viral nucleocapsid.
The M gp has several functions. It is structurally important to
the virus since it forms part of the virus envelope. During
replication it determines the site of virus budding by accumulating
at the Golgi and rough endoplasmic reticulum (RER). Here it binds
the nucleocapsid to the virus envelope during virus assembly
(Sturman et al, 1980; Holmes et al. 1981). Antibodies (Abs) to
the M gp have been shown to neutralise virus infectivity in vitro.
but this activity may be dependent on the presence of complement
(Collins et al, 1982) .
Spike glycoprotein, S
The spike gps occur in 2 forms: uncleaved (MW about 200 KD) and
cleaved (MW about 100 KD). Cleavage of the primary translation
product may be performed by host cell proteases or by trypsin in
vitro. The 2 species produced after cleavage may either co-migrate
or migrate as separate species on polyacrylamide gels. The
N-terminal cleavage product is referred to as SI, the C-terminal
product as S2. The extent of cleavage varies with both the virus
and the host cell type. In IBV and BCV the protein is mainly
cleaved, in HCV only some is cleaved and in TGEV, FIPV and CCV no
cleavage occurs. The amount of cleavage in MHV varies from 0 to
100%, depending on the virus strain and the host cell type (Spaan
et al, 1988) .
Analysis of sequence data reveals further information about the
structure of the S gp (Holmes, 1990; Spaan et al, 1988). The
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protein is largely hydrophobic and has carbohydrate side chains
which are attached by N-linked glycosidic bonds. The C-terminus of
the protein is anchored in the lipid bilayer. The rest of the
C-terminus (S2) forms a stalk which supports the outer, bulbous
N-terminus (SI) domain (Cavanagh and Davis, 1986). In IBV, each
spike is made up of a non-covalently linked oligomer of 2 or 3
molecules of the S gp (Cavanagh, 1983). Recent work has
demonstrated that the spike of TGEV is a homotrimer of the S
polypeptide (Delmas and Laude, 1990).
The S gp has a number of important functions. It binds to the
host cell receptor during initiation of infection and is important
in membrane fusion events. At the start of infection it induces
fusion of the virus envelope with the cell membrane. Later on, it
induces cell-to-cell fusion which allows the virus to spread
between cells and leads to the formation of syncytia. In some CVs
such as MHV, activation of fusion activity requires initial
cleavage of the spike gp (Sturman et al, 1985). Other
coronaviruses such as TGEV and FIPV do not require cleavage of the
S protein for fusion activity. The S gp is an important immunogen
as neutralising Abs are directed against this protein (Collins et
al, 1982). During virus replication the S gp is transported to the
plasma membrane of infected cells, rendering them susceptible to
attack by neutralising Abs and cell mediated cytotoxicity (Holmes
et al, 1986) .
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Haemagglutinin-esterase glycoprotein. HE
The HE gp is a disulphide-linked dimer with a MW of 130-140 KD.
In the presence of ME it is reduced to two identical monomers, each
with a MW of about 65 KD (King et al. 1985) . This protein
contains N-linked glycosidic bonds.
The HE gp is present in some but not all CVs, and is thought to
be involved with haemagglutination. It is found in HCV-OC43,
haemagglutinating encephalomyelitis virus (HEV), BCV, turkey
coronavirus (TCV) and some strains of MHV (DVIM and JHM) (Spaan et
al, 1988). HEV, BCV and TCV are able to haemagglutinate red blood
cells (RBCs), whilst some strains of MHV which possess the HE gp
are unable to cause haemagglutiantion. Other CVs either totally
lack the gene for the HE gp or have an incomplete HE gene which is
not expressed. Some of these viruses are totally unable to
haemagglutinate RBCs whilst others such as IBV and TGEV cause weak
haemagglutination which is mediated by the S gp (Cavanagh et al,
1990). Until very recently it was though that the HE gp was
responsible for the ability of the viruses which possessed this gp
to cause haemagglutination. It now seems likely however that the S
gp in these viruses also plays a role in haemagglutination. At
present the precise association of these 2 gps with
haemagglutination is unclear: it is possible that only one of these
gps is involved or that both gps, acting either independently or
together, elicit haemagglutination (Schultze et al, 1991; Storz et
al, personal communication).
The HE gp is also thought to allow some CVs to mediate
haemadsorption, the process by which RBCs are absorbed to the
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membranes of infected cells. In view of recent findings concerning
haemagglutination, this action must also be open to question. Two
possible mechanisms of haemadsorption have been proposed. The
first explanation is that excess HE gp in infected cells is
expressed on the cell plasma membrane where it interacts with RBCs
directly (Kienzle et al, 1990). The alternative explanation is
that virus particles released from infected cells accumulate along
the outer surface of the cell membrane, indirectly allowing RBCs to
adhere to the infected cell monolayer. This latter phenomenon is
termed pseudohaemadsorption (Mcintosh, 1974). The HE gp is an
important immunogen as Abs to this protein neutralise the virus
(Deregt et al, 1983).
Other viral proteins
An additional structural protein (14 KD MW) has been reported
for IBV, MHV-A59 and BCV: it is present in very small amounts in
the virus envelope. A number of non-structural virus proteins have
been demonstrated in infected cells, most notably those having MWs
of 14-17 KD, 30-35 KD, and 200 KD. The latter protein is thought
to be the viral RNA polymerase enzyme (Babiuk et al, 1985).
Virus envelope: lipids
The virus envelope is derived from the membranes of the Golgi
apparatus and RER. The lipid composition of the envelope reflects




The CV genome consists of a single strand of non-segmented RNA
of positive sense. It is 27-30 kilobases (Kb) in size, which is
larger than the genome of any other known RNA virus. The genome is
polyadenylated at the 3' end and has a methylated CAP structure at
the 5' end. There is no extensive sequence reiteration.
The genome is organised into 6 or 7 regions, each of which
contains 1 or more open reading frames (ORFs). These regions are
separated by reinitiation sites (junction sequences) that contain
the signal for the transcription of the subgenomic messenger RNAs
(mRNAs). The 5' end of the genome encodes for non-structural viral
proteins including the viral RNA polymerase enzyme. The gene order
for the structural proteins is 5'-HE-S-M-N-3' (Spaan et al, 1988).
REPLICATION
A large amount of information is now available on the unique
replication strategy of CVs. This work has been summarised in
several recent reviews (Siddell, 1987; Spaan et al, 1988;
Holmes, 1990; Lai, 1990; Spaan et al, 1990). Replication occurs
entirely within the cytoplasm of the cell.
The first stage in replication is the attachment of virus
particles to receptors on the target cell membranes. CVs which lack
an HE gp bind via their S gp: the host cell receptor for MHV has
been recognised as an 110 KD gp (Boyle et al, 1987) . The CVs
which possess an HE gp may attach to cells by either the S or the
HE gp, although a host cell receptor has not been recognised for
the S gp of these viruses. The HE gp binds to 9-0-acetylated
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neuraminic acid residues on RBC membranes, and it may bind to
similar receptors on the host cell plasma membrane (Vlasak et al.
1988b; Schultze et al, 1990). The HE gp also possesses an esterase
enzyme which destroys these residues, leading to virus elution from
the cell. This enzyme is important in virus replication as the
virus grows to a reduced titre if this enzyme is inhibited. It may
be involved during endocytosis or virus uncoating (Vlasak et al,
1988a; Vlasak et al, 1988b; Schultze et al, 1990).
The mechanism of virus entry into cells is controversial and may
vary between different CVs (Payne et al, 1990a). Virus particles
may enter by fusion of the viral envelope with the plasma membrane
of the cell. Fusion is mediated by the S gp, and possibly also by
the HE gp in CVs which possess this protein (Siddell et al, 1982;
Vlasak et al, 1988a). Alternatively entry may be gained by
receptor-mediated endocytosis followed by fusion of the viral
envelope with the membranes of endocytic vesicles.
Once inside the cell, the genomic RNA attaches to ribosomes and
directs the synthesis of RNA dependent RNA polymerase. This enzyme
directs transcription of a complementary full length (-) strand of
RNA from the genomic (+) strand RNA. The (-) strand RNA serves as
a template for synthesis of both full length genomic RNA and also 5
to 7 subgenomic mRNAs. The subgenomic mRNAs have MWs of 0.6 x 10^
to 3.7 x 10^ KD and form a 3' nested set with common 3' ends. Each
mRNA contains all the nucleotide sequence of the next smallest mRNA
plus an extra gene at the 5' end which is referred to as the unique
region. The 3' ends of the genomic and subgenomic mRNAs have poly
A tails. Their 5' ends are capped and have a common leader
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sequence of 60-70 bases which originates from the 3' end of the (-)
strand RNA.
The location of the leader sequence at the 5' end of each
subgenomic mRNA is thought to result from a discontinuous leader
primed transcription of the (-) strand RNA template. The leader
RNA transcribed from the 3' end of the (-) strand RNA separates
from the rest of the template but remains bound to the polymerase
enzyme. The leader sequence-polymerase complex binds by base
pairing at specific non-coding regions called reinitiation sites on
the (-) strand RNA. Here it acts as a primer for synthesis of the
rest of the mRNA. The degree of complementarity between the leader
sequence and the reinitiation site may regulate the expression of
the different mRNAs. The mRNAs are synthesised in unequal amounts
during infection, but the proportion of each remains constant
throughout the replication cycle.
There may be 2 distinct RNA dependent RNA polymerases involved
in CV RNA transcription. The first enzyme is active during the
early stages of virus replication and directs the synthesis of the
(-) strand template. The second enzyme acts later to direct (+)
strand synthesis and requires the presence of a primer for
transcription.
The CV Study Group recently recommended that the mRNAs should be
numbered in order of decreasing size. The genome sized mRNA is
therefore referred to as mRNA 1 (Cavanagh et al, 1990). With the
exception of the smallest species the mRNAs are polygenic, but only
their unique regions are translated. Most unique regions contain a
single ORF which codes for a single protein, which, apart from the
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S gp, is not subsequently cleaved. Exceptions to this do occur:
some unique regions contain more than one ORF which may or may not
be translated and a few proteins undergo post-translational
cleavage.
Translation of mRNAs coding for the non-structural and N
proteins occurs on free ribosomes in the cell cytoplasm. The N
protein interacts with newly synthesised genomic RNA by both
sequence specific and non-specific binding to form fragile helical
nucleocapsids.
The M, S and HE gps are synthesised on ribosomes at the RER. The
M gp is unusual in that it is not glycosylated until it reaches the
Golgi apparatus. It accumulates at this site and is not
transported to the plasma membrane. The S and HE gps are
glycosylated at the RER during protein synthesis. They become
anchored into the membrane of the RER and are incoporated into
virion particles during the process of budding. The carbohydrate
side chains of these proteins are modified by cellular enzymes
during transport through the Golgi apparatus, and the S gp may also
be cleaved at this site. Excess S and HE gps which have not been
incorporated into virions are transported to the plasma membrane of
the cell.
The site of CV assembly is determined by the restricted
intracellular transport of the M gp. Assembly occurs by budding at
the membranes of the RER and Golgi apparatus: budding does not
occur at the plasma membrane. Strands of nucleocapsid align on the
cytoplasmic surface of these membranes due to an interaction with
the M gp. Host cell proteins are replaced by viral gps and whole
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virions are pinched off and released into the lumen. At these
sites the virions are not susceptible to the host's immune system
and this may account for the ability of CVs to establish persistent
infections in immune animals. These cells will however be
susceptible to attack by the host's immune system if virus proteins
are expressed on the infected cell surface.
Some CV particles are released by lysis of dying cells. More
commonly they are released from intact cells using the normal
secretory mechanism of the cell. In this process virions migrate
through the Golgi apparatus and become enclosed in smooth walled
vesicles. These migrate to the periphery of the cell and fuse with
the plasma membrane to release the virus particles. Large numbers
of CVs are often seen on the plasma membrane of infected cells.
These are viruses which have been absorbed to the plasma membrane
after virion release.
STRAIN VARIATION
Some CVs such as MHV and IBV exhibit a high degree of strain
variation. This is due to the frequent occurrence of mutation and
recombination events. The unusual replication strategy involving
multiple subgenomic mRNAs is responsible for the high frequency of
recombination seen in the CVs. Recombination may occur between 2
strains of the same CV, 2 different CVs or between a CV and an
unrelated virus (Spaan et al, 1988; Snijder et al, 1991).
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EVOLUTION
CVs were first thought to be related to orthomyxo- and paramyxo¬
viruses on the basis of similarities in their size and structure
(Berry et al, 1964). More detailed study of CVs revealed that they
were an entirely separate group of viruses (Holmes, 1985).
Recent work on the HE gp of CVs has revealed similarities to the
HE protein of influenza C viruses. The HE gp of BCV has an amino
acid (AA) sequence identity of 29.7% with the HA1 subunit of the HE
protein of influenza C viruses (Kienzle et al, 1990). The
unexpressed gene encoding the HE protein in MHV-A59 also has a 30%
AA sequence homology with this protein in influenza C viruses
(Luytjes e£ al, 1988). The HE proteins of CVs and influenza C
viruses have similar activities: they cause haemagglutination
(although this function in CVs is currently under debate), they
bind to receptors containing N-acetyl-9-O-acetylneuraminic acid and
they possess a receptor destroying acetylesterase enzyme (Vlasak e_t
al, 1988a; Vlasak et al, 1988b; Schultze et al, 1990). The CVs
may have acquired the HE protein by a non-homologous recombination
event from the influenza C viruses (Luytjes et al, 1988).
CVs are also related to the recently recognised Toroviridae
family, which so far comprises enteric viruses from 3 different
species. These viruses are Berne virus (BEV) which was isolated
from a diarrhoeic horse, Breda virus (BRV) which has been detected
in the faeces of diarrhoeic calves, and human toroviruses which
are found in diarrhoeic stools from children and adults.
Toroviruses resemble CVs under the EM as they are pleomorphic and
bear peplomers, but toroviruses have distinctive sausage-shaped
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nucleocapsids. Both groups of viruses contain single strands of
positive sense RNA and have similar replication strategies
involving 3' coterminal nested sets of mRNAs. Their proteins
however have markedly different migration patterns on
polyacrylamide gel electrophoresis (PAGE) and they are
antigenically distinct (Woode et al, 1982; Horzinek et al, 1984;




BCV was first reported in western Nebraska in the spring of
1971. A field experiment was being conducted to assess the
efficacy of attenuated rotavirus as an oral vaccine to prevent
neonatal calf diarrhoea. Whilst the vaccine was effective in
preventing diarrhoea caused by rotavirus, vaccinated calves in
several herds developed diarrhoea at 5-21 days old. No rotavirus
was detected, but a CV-like agent was revealed by EM examination of
semi-purified faeces (Mebus et al, 1972).
Stair et al (1972) established that this agent was a primary
pathogen. Gnotobiotic calves were inoculated with bacteria-free
filtrates of diarrhoeic faecal material containing the virus. The
calves developed diarrhoea and excreted virus in their faeces.
Mebus et al (1973a) were the first to isolate the virus and adapted
it to grow in foetal bovine kidney (FBK) cells. At this stage the
virus was considered to be a CV on the basis of its morphology and
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density. Sharpee et al (1976) further characterised the cell
culture adapted virus and confirmed this classification.
PHYSICOCHEMICAL PROPERTIES
The physicochemical properties of BCV have been described by
Sharpee et al (1976), Sato et al (1977) and Dea et al (1980b).
BCV contains RNA and is therefore insensitive to inhibitors of
deoxyribonucleic acid (DNA) metabolism such as 5-iodo-2'-
deoxyuridine (IDUR), 5-bromo-2'deoxyuridine (BUDR) and actinomycin
D. The virus is surrounded by a lipid envelope and is therefore
sensitive to treatment with ether, chloroform and deoxycholate. It
is heat labile, particularly at temperatures greater than 45°C,
but divalent cations (1 molar (M) magnesium chloride, MgC^)
partially protect the virus against heat. BCV is relatively stable
at pH values between 3 and 11 which allows it to survive passage
through the stomach of infected animals. Respiratory CVs such as
■PBV-encL the human respiratory CVs are acid-labile (Laporte and
Bobulesco, 1981a).
BCV agglutinates RBCs from mice and rats and some isolates can
also agglutinate RBCs from guinea pigs and hamsters (Dea et al,
1980b). Sato et al (1977) demonstrated that BCV could agglutinate
RBCs from chickens but that this reaction was variable and was
dependent on the source of cells. BCV is unable to agglutinate RBCs
from horses, cattle, goats, sheep, pigs, dogs, cats, rabbits,
humans (0), ducks, geese, pigeons or turkeys.
Sharpee et al (1976), Sato et al (1977) and Dea et al (1980b)
demonstrated that the haemagglutinating activity of BCV is largely
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independent of temperature: virus kept at 50°C for 60 minutes
(min) shows a marked drop in infectivity titre (IT) but the
haemagglutination (HA) titre is unaffected. HA titres were shown
by these workers to be constant when measured at 4, 25 or 37°C,
but an incubation temperature of 25°C was preferable since
haemagglutination was more rapid and the end points more clearly
defined. In contrast to these findings, Van Balken et al (1978)
reported that the haemagglutinating activity of BCV was temperature
dependent. Haemagglutination occurred at 4°C, but virus eluted
from the RBCs when incubated at 37°C. The latter group of workers
used faecal and not cell culture adapted viruses and found that
haemagglutination was no longer temperature dependent after the
faecal viruses had been adapted to growth in tracheal organ culture
(TOC). Recently Storz et al (personal communication) reported that
cell culture adapated BCV agglutinated chicken RBCs at 4°C, but
that the haemagglutination pattern completely disappeared when the
temperature was raised to 37°C.
Murine, rat and hamster RBCs adsorb to cell monolayers infected
with BCV. The test may be performed at 4, 25 or 37°C, but RBCs
attach more firmly at 4°C (Sharpee et al, 1976) .
ISOLATION AND GROWTH IN VITRO
BCV is difficult to isolate in cell culture. Some strains such
as LY-138 have proved impossible to grow in vitro and are
maintained by oral inoculation of calves (Hajer and Storz, 1978).
BCV was first grown in cell culture by Mebus et al (1973a).
Virus was isolated in primary FBK cells and successive passages of
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virus were grown in consecutively higher passage numbers of FBK
cells. This virus was later adapted to grow in bovine embryonic
kidney (BEK-1) cells, a continuous cell line (Inaba et al, 1976).
Since then BCV has been isolated and grown in a number of cell
lines, including primary calf kidney (CK) cells (Bridger et al,
1978b), Vero, Madin-Darby bovine kidney (MDBK) and porcine kidney
(PK-15) cells (Dea et al, 1980a), bovine fetal spleen (BFS) cells
(Payne and Storz, 1988), human rectal tumour (HRT-18) cells
(Laporte et al, 1979; King et al, 1985) and a subline of
Madin-Darby canine kidney (MDCK) cells, MDCK 1 (Schultze et al,
1991). Virus growth in early passages is typically without the
production of a recognisable cytopathic effect (CPE). Later
passages in some cultures such as Vero and MDBK cells produce a
marked CPE characterised by vacuolation, shrinkage and detachment
of cells leading to complete destruction of the cell monolayer.
Syncytia formation is a feature of the CPE in some cell lines.
HRT-18 cells have proved suitable for the growth of the enteric
CVs BCV, human enteric coronavirus (HECV) and CCV (Laporte and
Bobulesco, 1981a) and TCV (Dea et al, 1989b). HRT-18 cells were
established from a human rectal adenocarcinoma and have the
properties of differentiated enterocytic cells. Their free surface
is covered in microvilli, upon which the receptors for
enteropathogenic CVs are thought to be located (Tompkins et al,
1974). BCV has been reported to grow to titres as high as 5 x 10^
tissue culture infective dose^/ml (TCID^Q/ml) in this cell line.
Trypsin enhances and promotes growth of BCV in some cell lines.
Dea et al (1980a) found that trypsin treatment of Vero cell sheets
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prior to virus inoculation resulted in a greatly enhanced viral
CPE. Presence of trypsin at 10 microgram/millilitre (ug/ml) in
maintenance medium increased virus production and CPE in bovine
fetal thyroid (BFTy) and bovine fetal brain (BFB) cells (Storz et
al. 1981). In addition to merely enhancing virus replication,
trypsin treatment permits growth of BCV in some cell lines such as
bovine embryonic lung cells (BEL) which are otherwise
non-permissive (Toth, 1982). Addition of exogenous trypsin also
promotes or enhances the ability of BCV to produce syncytia in cell
lines such as BFS (St. Cyr-Coats et al, 1988; Payne and Storz,
1988), BFTy and BFB (Storz et al, 1981).
Some workers have found that BCV produces plaques when
inoculated cultures are overlayed with agarose. Plaques become
visible to the naked eye after 2-4 days incubation. They have been
demonstrated in HRT-18 (Vautherot, 1981), BFTy, BFB (Storz et
al, 1981) and BEK-1 cells (Hirano et al, 1985). The presence of
trypsin in the overlay medium greatly enhanced plaque formation in
BFTy and BFB cells, but was not found to be advantageous in BEK-1
cells.
The problems of BCV isolation in cell culture led some workers
to investigate organ cultures as an alternative system for in vitro
growth. Organ cultures of tracheas removed from bovine foetuses
(late gestation) and newborn calves have proved successful for the
isolation and growth of BCVs (Stott et al, 1976; Bridger et al,
1978b; Thomas et al, 1982; McNulty et al, 1984). BCV does not
cause ciliostasis of infected tracheas but its growth is generally
monitored by the rise in HA titre in the medium bathing the
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cultures (Bridger et al, 1978b). Stott et al (1976) were unable to
detect any histological changes in infected cultures. Viral
antigens were first detected by immunofluorescent (IF) staining in
the cytoplasm of the glandular epithelium at 7 days post infection
(pi) and in the cytoplasm of the ciliated epithelium at 14 days pi.
Bridger et al, (1978a) adapted a virus isolated in TOC to growth
in intestinal organ culture. The cultures originated from the
upper small intestine of a bovine foetus. The virus grew to HA
titres up to 4 fold higher than those reached in TOC.
SMALL ANIMAL MODELS
BCVs have been adapted to grow in the brains of neonatal
suckling mice using the intracerebral route of inoculation. In the
first passage suckling mice develop nervous signs at 3-4 days pi
and die around day 4-5. Death occurs more rapidly when infected
brain emulsions are used to infect mice in subsequent passages
(Kaye et al, 1975; Akashi et al, 1981; Gerna, et al 1981). BCV
inoculated by the intranasal route can also cause encephalitis in a
low proportion of 1 day old mice (Barthold et al, 1990). Akashi et
al (1981) found that virus in the third passage level in suckling
mouse brain was virulent for 1 day old mice, rats and hamsters
when inoculated by the intracerebral or subcutaneous routes.
Bengelsdorff et al (1989) vaccinated mice with BCV by the
subcutaneous route and measured their serum Ab responses.
In contrast to these findings, Dea et al (1980b) failed to
demonstrate virulence of BCV in neonatal mice after intracerebral
inoculation. These workers also failed to demonstrate BCV
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replication in neonatal mice, hamsters and guinea pigs after
intraperitoneal inoculation and in embryonated hen eggs after
inoculation into the chorioallantoic cavity.
STRUCTURE
Morphology
The morphology of BCV and its appearance under the EM is similar
to that described previously for other CVs.
Virus proteins
The molar ratio of the 4 main structural proteins of BCV is 3
S:9 HE (gp 65): 25N: 25M (King and Brian, 1982). These proteins
have been described by several groups, and their reported MWs are
summarised in Table 1.3. A wide variation is apparent in the MWs
of the S and HE gps. This may be because they were measured using
different techniques or it may reflect strain differences. Laporte
and Bobulesco (1981b) found that adaptation of a wild strain (WS )
to growth in cell culture (strain F15) did not alter the MWs of the
proteins.
Nucleocapsid protein. N
The gene encoding the N protein has been sequenced in the Mebus
(M) strain of BCV (Lapps et al, 1987) and in strain F15 (Cruciere
and Laporte, 1988): only minor sequence differences were detected
between these two viruses. The N protein of BCV is closely related
to that of MHV strains A59 and JHM. There is an overall AA




































































The N protein gene contains 2 overlapping ORFs. The smallest
one potentially encodes a protein of 207 AAs with a MW of 23 KD,
but there is no evidence that this protein is expressed. The
larger ORF encodes a protein of 448 AAs with a MW of 49 KD: this is
the N protein. This protein has 5 regions which are rich in basic
AAs and which represent the sites of genomic RNA binding. The N
protein is also rich in serine residues, which are clustered in 2
main areas and may be phosphorylated.
Integral membrane glycoprotein. M
The gene encoding the M gp of M strain BCV has been sequenced by
Lapps et al (1987). The gene contains a single ORF encoding a
slightly basic protein containing 230 AAs with a MW of 26 KD. It
has an AA sequence homology of 86% with MHV strain A59. The
C-terminal has a net positive charge and may interact with either
the negatively charged RNA or with an acidic part of the N protein.
The latter interaction was originally proposed by King and Brian
(1982) because they found a 1:1 molar ratio of M and N proteins in
BCV. The M gp is thought to originate as a 22 KD unglycosylated
precursor. Addition of 1 or 2 0'-linked oligosaccharide side
chains, each of MW about 2 KD, produces species with MWs of 24
and 26 KD. The M gp is therefore seen on PAGE as a series of
closely migrating bands (Deregt et al, 1987) .
Spike glycoprotein, S
Most authors report that the S protein of BCV is largely present
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in its cleaved form (MW about 100 KD), although an uncleaved
precursor (MW about 190 KD) is also described (Brian et al, 1983;
Deregt et al, 1987). Some cells such as BFS and BFB require the
presence of exogenous trypsin to cleave this protein. Cell to cell
fusion of these cells only occurs in the presence of exogenous
trypsin, which demonstrates that cleavage of the S gp is necessary
for activation of its cell fusion activities (Storz et al, 1981b;
St. Cyr Coats et al, 1988). Yoo et al (1991) demonstrated that
fusion is mediated by the S2 subunit.
The gene encoding the S protein has been sequenced in BCV
strains F15 (Boireau et al, 1990), M (Abraham et al, 1990a) and PQ
(Parker et al, 1990). A single ORF codes for a protein containing
1363 AAs with a potential MW of 150 KD and 19-20 potential N-linked
glycosylation sites. Glycosylation occurs at the RER and Golgi to
give an 190 KD gp. Abraham et al (1990) identified a protease
cleavage site, permitting cleavage of the S apoprotein into SI and
S2 subunits having MWs of 86 and 65 KD before glycosylation and 120
and 100 KD after glycosylation. A C-terminal hydrophobic alpha
helix anchors the S protein in the virus membrane, and two
amphipathic alpha helices probably form the stalk of the spike.
Comparison with other CVs demonstrates that the BCV S gene is most
closely related to the S genes of MHV strains A59 and JHM. The BCV
S gene contains a region which is lacking in MHV-A59 and lacking to
a greater extent in MHV-JHM. These 3 viruses may therefore have
arisen from a common ancestor and evolved either by a series of
deletion or recombination events.
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The S gp contains important neutralising epitopes. MAbs
directed against this protein neutralised the virus both in vitro
(Deregt and Babiuk, 1987) and in vivo (Deregt et al. 1989a). Three
antigenic regions were recognised in this protein (Deregt and
Babiuk, 1987). Regions A and B were defined by strongly
neutralising MAbs and analysis of fragments generated by
proteolysis of MAb-antigen (Ag) complexes demonstrated that both
these regions were situated on a 37 KD fragment (Deregt et al,
1989b). Antigenic region C was defined by a single weakly
neutralising MAb. MAbs to antigenic region A lead to in vivo
protection, whilst a MAb directed against antigenic region B
failed to protect in vivo. possibly due to lack of epitope
conservation on the challenge virus isolate (Deregt et al, 1989a).
Haemagglutinin-esterase glycoprotein. HE
The HE gp is a disulphide linked dimer of 2 identical subunits
(a homodimer) (King and Brian, 1982; Hogue et al, 1989). The gene
encoding this protein has been sequenced in the PQ strain (Parker
et al, 1989) and the M strain (Kienzle et al, 1990) . The gene
contains a large ORF encoding the HE protein and also 2 shorter
ORFs which are probably not expressed. The predicted HE protein
contains 424 AAs, has a MW of 47 KD and has 9 potential N-linked
glycosylation sites. The reported sequences for the HE gp of these
2 strains differ by only 2 bases which lead to a change in just 1
AA.
The primary translation product of the HE gene has been
identified as a protein with a MW of 42.5 KD. The 2 subunits are
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synthesised independently and then rapidly undergo dimerisation by
the formation of disulphide bonds. The protein is then
glycosylated and anchored in the membranes of the RER to be
incorporated into virion particles during the process of budding.
The carbohydrate side chains are processed whilst the virus is
transported through the Golgi body (Deregt et al, 1987; Hogue et
al. 1989). Not all the HE gp is incorporated into the virion
particles: some migrates to the cell surface where it may cause
haemadsorption and act as a target for the immune response of the
host (Kienzle et: al, 1990) .
Until recently it was believed that the HE gp was solely
responsible for the ability of BCV to mediate haemagglutination.
Treatment of the virus with bromelain selectively destroyed the S
and M gps, whilst the HE gp and the haemagglutinating properties of
the virus remained intact (King ej; al, 1985) . The existence of MAbs
to the HE gp which inhibited virus induced haemagglutination
supported this hypothesis (Parker et al, 1989). It was found that
BCV requires the presence of receptors containing N-acetyl-9-0-
acetylneuraminic acid (Neu 5, 9Ac^), a sialic acid derivative, on
the surface of RBCs in order to cause haemagglutination. Similar
receptors are required by the CVs HEV and HCV-0C43 and also by
influenza C viruses (Vlasak et al, 1988b; Schultze et al, 1990).
Schultze et al (1991) demonstrated that isolated HE gp of BCV bound
to these receptors, supporting the proposal that the HE gp is
responsible for the haemagglutinating properties of BCV. In
contrast to this finding however, the same authors also
demonstrated that whilst whole BCV particles agglutinated chicken
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RBCs, isolated HE gps were unable to cause haemagglutination. This
may suggest that the HE gp is not responsible for causing
haemagglutination, in which case HE MAbs which cause
haemagglutination inhibition (HAI) must do so either by stearic
hindrance or by inducing conformational changes in an alternative
viral haemagglutinin. It has recently been proposed that the S gp
may be involved in haemagglutination, as S MAbs can also cause HAI
(Vautherot et al, 1984; Storz et al, personal communication). If
the HE gp is indeed the viral haemagglutinin, failure of isolated
HE gps to cause haemagglutination may be due to conformational
changes occurring during protein purification or may reflect the
need for a multivalent attachment of HE gps to RBCs.
A receptor destroying enzyme (RDE) similar to that found in
influenza C viruses has been demonstrated in BCV, and is associated
with the HE gp (Vlasak et al, 1988a; Vlasak et al, 1988b;
Schultze et al, 1991; Storz et al, personal communication). This
is a serine esterase (acetylesterase) enzyme which removes the
acetyl groups from O-acetyl sialic acids. The enzyme inactivates
the cellular receptor for BCV, causing the virus to elute from
RBCs at 37°C. Elution may be prevented by inhibition of the RDE
with diisopropyl fluorophosphate (DFP) or by MAbs directed against
the HE (but not the S) gp (Vlasak et al, 1988a; Storz et al,
personal communication). Inhibition of the RDE with DFP also
reduces the infectivity of the virus, which suggests that the
enzyme is important in early virus replication.
The HE gp is an important immunogen since MAbs directed against
this protein neutralise the virus both in vitro (Deregt e_t al,
36
1983) and in vivo (Deregt et al, 1989a). A panel of 4 neutralising
MAbs defined 4 epitopes on this protein. These were designated
epitopes Al, A2, B and C: epitope B overlapped epitopes A and C.
Epitopes Al and A2 were defined by MAbs which had both high serum
neutralisation (SN) and HAI titres. Epitopes B and C were defined
by MAbs with low SN titres and low or negative HAI titres (Deregt
and Babiuk, 1987; Parker et al, 1989). MAbs directed against
antigenic region A led to in vivo protection, but a MAb directed
against region C failed to protect in vivo (Deregt et al, 1989a).
Non-structural proteins
The genes encoding 5 potential non-structural proteins with MWs
of 4.8, 4.9, 9.5, 12.7 and 32 KD have been sequenced (Cox et al,
1989; Abraham et al, 1990b). The gene encoding the 32 KD protein
lies immediately upstream of the HE gene. The genes encoding the
other 4 proteins lie between the S and M genes. The 9.5 KD protein
is expressed on the surface of virus infected cells and may
therefore be important in the immune response of the host.
Viral genome
The genome of BCV was first described by Guy and Brian (1979) .
It has a MW of 6.8 x 10^ D (King and Brian, 1982; Lapps and Brian,
1985). The gene map is represented diagrammatically in Fig. 1.3.
STRAIN VARIATION
The BCV isolates studied to date all belong to a single
serotype. Attempts to find evidence of strain variation have been
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Figure 1.3
Gene map of the BCV genome
This diagram has been constructed from data obtained
by Lapps et al, 1987; Cruciere and Laporte, 1988;
Parker et al, 1989; Abraham et al, 1990a; Abraham et
al. 1990b; Boireau et al, 1990; Kienzle et al,
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limited to examining a small number of isolates due to problems in
growing the virus in vitro.
Dea et al (1980b) demonstrated minor variations in the
physicochemical properties of 4 BCVs isolated in Quebec and the M
strain of BCV. Antigenic variations amongst these CVs were later
detected in counterimmunoelectrophoresis and immunodiffusion tests
(Dea et al, 1982).
Polyclonal sera have been used in IF, HAI and SN tests to look
for evidence of strain variations. Bridger ej: al (1978b) were
unable to distinguish 4 isolates by IF and HAI tests. El-Ghorr et
al (1989) detected strain variations amongst 5 isolates in HAI but
not IF and SN tests.
MAbs have detected minor strain variations on the S and HE gps
in IF, SN and HAI tests and in enzyme linked immunosorbent assays
(ELISAs) (Vautherot and Laporte, 1983; Vautherot et al, 1984;
Deregt et al, 1989a; El-Ghorr et al, 1989). Czerny and Eichhorn
(1989) used MAbs in a capture ELISA for the detection of BCV in
faecal samples. They demonstrated the advantage of using 2 MAbs in
place of a single capture MAb to compensate for the effects of
strain variation.
Failure to detect major antigenic variation in serological tests
is supported by sequence data. The N, S and HE genes have very
similar sequences in different virus strains (Lapps et al, 1987;
Cruciere and Laporte, 1988; Parker et al, 1989; Abraham et al,




BCV belongs to antigenic group II of the CVs (Table 1.2).
Pedersen et al (1978) investigated the antigenic relationships
between 8 CVs using polyclonal sera in IF tests. They demonstrated
2-way cross reactions between BCV, HCV-0C43, MHV and HEV. No cross
reactions were seen between these CVs and HCV-229E, TGEV, CCV or
FIPV. Polyclonal sera detect cross reactions between BCV, HCV-OC43
and HEV in SN and HAI tests and between BCV, HCV-0C43 and MHV
strain A59 in Western blotting experiments (Kaye et al, 1975;
Sato et al, 1980; Gerna et al, 1981; Brian et al, 1983; Hogue et
al, 1984). MAbs raised against BCV cross react in IF tests with
HECV, HCV-0C43, MHV and HEV (Vautherot et al, 1983).
The antigenic relationships outlined above are consistent with
the results of molecular studies. A 98% genome sequence homology
was demonstrated between BCV and HCV-OC43 by T^ fingerprint
analyses (Brian et al, 1983). A cDNA probe to the N and M genes
of BCV hybridised with HCV-0C43, HEV and to a lesser extent with
MHV in dot blot hybridisation assays (Shockley et al, 1987) .
Sequence data for the S gp suggests that this protein has arisen
from a common precursor in BCV and MHV strains JHM and A59 (Boireau
et al, 1990; Parker et al, 1990).
Recent work has demonstrated a close relationship between TCV
and BCV. TCV was originally placed in its own antigenic group on
the basis of results obtained using immune electron microscopy
(IEM) (Ritchie et al, 1973). Since then both polyclonal sera and
MAbs have demonstrated close similarities between the structural
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proteins of TCV and BCV (Dea e£ al, 1989a; Dea and Tijssen, 1989b;
Dea et al, 1990).
REPLICATION
The precise mechanism by which BCV enters cells is uncertain.
Uptake may be achieved either by direct fusion of the virus
envelope with the plasma membrane of the cell, or by endocytosis
followed by fusion of the virus envelope with the endosomal
membranes. It has been proposed that the former mechanism is the
major route of virus uptake, and that endocytosis represents an
abortive infection as the envelope of endocytosed virions fails to
fuse with vesicle membranes and the viruses are subsequently
degraded by lysosomal enzymes (Payne and Storz, 1988; Payne et al,
1990a). In contrast to these findings, Yoo et al (1991) proposed
that cellular uptake of BCV occurs by endocytosis. The S2 subunit
of the S gp is then activated within this acidic intracellular
compartment, leading to virus internalisation. This proposal was
based on the observation that fusion of insect cells was mediated
by the S2 subunit, and that cleavage of the S precursor was
necessary for induction of cell fusion.
The morphogenesis of BCV infection has been studied by EM
examination of ultra-thin sections of infected intestinal
epithelial and tissue culture cells. The information gained from
these studies suggests that BCV replicates in a similar manner to
the other CVs (Doughri et al, 1976; Tektoff et al, 1983a; Tektoff
et al, 1983b). Viral antigens are expressed on the surface of
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infected cells, rendering them susceptible to attack by the host's
defense mechanisms. Surface expressin of viral antigen may also
induce cell to cell fusion in some cell lines (Payne et al, 1990b) .
Seven subgenomic mRNAs are produced during BCV replication (Keck
et al, 1988). Messenger RNA (mRNA) 3 codes for the HE gp and
mRNA 4 codes for the S gp (Parker et al, 1989). Keck et al (1988)
demonstrated that there is a differential temporal regulation of
synthesis of genomic RNA and the subgenomic mRNAs. During early
infection synthesis of subgenomic mRNAs predominates, coinciding
with peak virus protein synthesis. Later, synthesis of genomic RNA
predominates, coinciding with peak production of infectious virus
particles. This suggests that synthesis of genomic RNA may be the
rate limiting step in BCV replication.
Messenger RNAs of BCV undergo replication through a (-) strand
copy of each mRNA (Hofmann et al, 1990). These (-) strand
subgenomic mRNAs form a 5' nested set. A similar situation has been
described in TGEV and MHV, and this may provide an important
mechanism for amplification of CV mRNA. Since the (+) strand mRNAs
(but not the (-) strands) are packaged into completed virions, the
possibility exists that these are the only templates required for
mRNA replication and that genomic RNA is not therefore necessary
for infectivity. These workers also found that mRNA replication
continues during persistent infections in cell culture. This
suggests that these mRNAs may act in a similar manner to defective
interfering RNAs in attenuating virus replication to allow the
establishment and maintenance of persistent virus infections.
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BCV AND NEONATAL CALF DIARRHOEA
Pathogenesis and pathology
The pathogenesis of BCV in the gastrointestinal tract of the
calf has been summarised by Babiuk et al (1985) and the associated
physiological changes described by Lewis and Phillips (1978). The
resulting pathological findings have been described by Mebus et al
(1973b), Mebus et al (1975) and Langpap et al (1979). The precise
findings at post mortem depend on the stage of infection at the
time of euthanasia or death.
Calves may become infected with BCV by both the oral and
respiratory routes. The incubation period is very short as the
virus does not have to spread systemically before reaching its
prediliction site. Virus infection of the gut starts in the
proximal small intestine and spreads throughout the small and large
intestines.
Virus replication occurs in the surface epithelial cells,
particularly in those on the distal half of the villi in the lower
small intestine. Infected cells die, slough off and are replaced
by immature cells. Histological examination of the small intestine
reveals that the tall columnar epithelial cells of the villi are
replaced by cuboidal and squamous epithelial cells at the sides and
tips of the villi respectively. Similarly the surface epithelial
cells of the large intestine are replaced by low columnar or
cuboidal cells, and there is a decrease in the number of goblet
cells. Scanning EM reveals marked differences in the length and
spacing of the microvilli on individual cells. In the small
intestine these changes result in stunting and fusion of adjacent
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villi, and there is a large decrease in the ratio of length of
villi to depth of crypts. The colonic ridges of the large
intestine also atrophy.
The absorptive capacity of the gut is severely diminished by the
presence of immature cells and loss of surface area caused by
stunting of the villi and atrophy of the colonic ridges. At the
same time there is also a decrease in the digestive capacity of the
gut, as the immature cells are unable to secrete the normal
digestive enzymes. Undigested lactose accumulates in the gut
lumen, and the resulting osmotic imbalance draws more water into
the gut. The decrease in digestive and absorptive capacities leads
to diarrhoea, with loss of water and electrolytes. Gross
examination reveals that affected animals are thin and dehydrated,
the eyes may be sunken and perineal staining is present. There is
also an accumulation of fluid in the small and large intestines.
In severe infections, diarrhoea may lead to dehydration,
acidosis and hypoglycaemia, and death may occur due to acute shock
and heart failure. More commonly the infection is self limiting,
as the virus does not attack the crypt epithelial cells. The
mitotic activity of these cells increases, producing immature
cells which are more resistant to virus infection and which migrate
up the villi to replace the damaged cells. Meanwhile cells
including lymphocytes, plasma cells and macrophages infiltrate the
lamina propria.
Clinical signs
The severity of BCV enteritis varies with the age and
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immunological status of the calf, and the infective dose and
possibly the strain of virus. Diarrhoea develops more quickly and
is more severe in very young or colostrum deprived calves (Mebus et
al, 1973b).
A yellow diarrhoea, possibly containing mucus, develops at
about 24 hours (h) pi with BCV. Diarrhoea lasts 3 to 6 days and
BCV may be detected in the faeces throughout this period. Calves
are often dull and anorexic during the acute stage of infection,
and if diarrhoea is severe they may also become pyrexic and
dehydrated. The majority of calves recover but a few die if
diarrhoea is particularly severe. Discrepancies exist between
reports from North America, which suggest that BCV causes a
relatively severe diarrhoea, and reports from Great Britain,
where BCV strains seem less pathogenic (Mebus et al, 1973b;
Bridger et al, 1978b; Crouch et al, 1984; Reynolds et al, 1985;
Saif et al, 1986).
Epidemiology
BCV was first reported in western Nebraska, United States of
America (USA) (Mebus et al, 1972). Since then it has been reported
in many countries including Belgium (Zygraich et al, 1975), Canada
(Acres et al, 1975) , United Kingdom (UK) and Denmark (Woode et al,
1978), Holland (de Visser et al, 1987) and Switzerland (Battaglia
et al, 1986). The virus is probably distributed worldwide.
Serological surveys demonstrate that BCV is widespread in cattle
populations. Hajer and Storz (1978) detected Ab to BCV in 15 out
of 19 herds in South Dakota by an agar gel precipitation test.
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Rodak et al (1982) demonstrated the presence of Ab to BCV in 12 out
of 12 herds in Saskatchewan using an ELISA test: out of 110 cattle
tested, 109 possessed Abs to BCV.
Wide variations occur in the rate of BCV detection in natural
outbreaks of diarrhoea. Detection rates vary from 8.5 to 69% in
diarrhoeic calves and 0 to 24% in healthy calves (Dea et al, 1979;
Reynolds et al, 1986; Snodgrass et al, 1986). Reynolds et al
(1986) demonstrated a clear association of BCV with diarrhoea in
calves in southern Britain and Wales. BCV was also detected more
frequently in diarrhoeic than healthy calves (13% and 4%
respectively) in Scotland and northern England, although this
difference was not statistically significant (Snodgrass et al,
1986). BCV is often detected in faecal samples from diarrhoeic
calves in conjunction with other enteropathogenic agents,
particularly rotavirus and also Cryptosporidium (Marsolais et al,
1978; Snodgrass et al, 1986).
BCV diarrhoea is more prevalent during the winter months. This
may reflect the greater capacity of the virus to survive in a cool,
moist environment. It may also result from an increase in the
excretion rate of BCV from persistently infected adult cows which
occurs during the winter months and at parturition (Collins et al,
1987; Bulgin et al, 1989). Calves in dairy and beef herds are
equally affected by BCV enteritis (Langpap et al, 1979; Reynolds
et al, 1986). In a survey conducted by Reynolds et al (1986),
diarrhoea caused by BCV was found in calves varying in age from 2
to 27 days, with a mean age of 11 days.
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Outbreaks of BCV diarrhoea often occur in consecutive years on
the same farms. This may be because the virus remains viable in
the ground from year to year, but is unlikely as BCV is relatively
labile. Outbreaks of diarrhoea still occur, however, if cows are
transferred to clean ground at calving. It is possible that
clinically normal adult cows which are persistently infected with
BCV act as a source of infection for susceptible calves. Chronic
shedding of virus can occur from these cows despite the presence of
Abs in faeces and serum. In a herd of 121 cows in Saskatchewan,
5% of the cows excreted free virus particles whilst 70% excreted
BCV-Ig complexes. The infectivity of the virus in these complexes
is unknown (Crouch and Acres, 1984; Crouch et al, 1985). Bulgin
et al (1989) found that calves born to carrier animals had a
significantly higher risk of developing diarrhoea, and that
removal of carrier cows lessened the spread of infection.
Infected calves which persistently excrete virus may also act as
a source of infection for susceptible animals (Kapil et al, 1990).
Heckert et al (1990) demonstrated that infections with BCV are
common in both neonatal and older calves in a closed herd.
Infections are often subclinical and may be recurrent in a single
animal. Circulation of virus in healthy calves maintains a
reservoir of infection for susceptible animals.
Diagnosis: Detection of BCV
BCV infection was originally diagnosed by examination of
negatively stained (phosphotungstic acid, PTA) preparations under
the EM. Faecal samples may be prepared by sucrose gradient
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ultracentrifugation or more simply by microhaematocrit
centrifugation (Stair et al, 1972; Durham et al. 1979).
Diagnosis by EM is adequate if large numbers of BCV particles are
present in the test samples. Virus particles may however be
difficult to recognise as they are pleomorphic and tend to lose
their peplomers during sample storage and preparation and other
fringed particles may also be present in faecal samples. In IEM
Abs specific to BCV are used to agglutinate virus particles in
order to facilitate their recognition (Langpap et al, 1979; Saif
et al, 1986). Protein A gold may be used to highlight these
immune complexes (El-Ghorr et al, 1988; Heckert et al, 1989).
The latter technique is highly sensitive, but in common with the
other EM techniques preparation of the samples is time consuming.
BCV antigen may be detected in intestinal sections using
specific polyclonal antisera or MAbs in IF tests. This was used as
a diagnostic method in the early work on BCV, but since it
necessitates the use of specimens which have been collected from
animals within a short time of death it is now only used as a
research tool (Mebus et al, 1973b; Langpap et al, 1979; Kapil et
al, 1990).
BCV may be detected in faecal samples by virus isolation in
either organ cultures of bovine trachea or in cell culture. Virus
isolated in organ culture may either be detected in cryostat
sections of trachea by IF staining or be detected in the culture
medium by EM or measurement of the HA titre (Stott et al, 1976;
Bridger et al, 1978b). Virus isolated in cell culture is generally
detected by IF staining or haemadsorption, but only the former
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method is specific for BCV antigen (Saif et al, 1986; Mostl and
Burki, 1989). These techniques are not commonly used for
diagnosis of BCV infections, as they are time consuming and very
insensitive due to the difficulties of BCV isolation.
Some diagnostic tests are dependent on the ability of BCV to
haemagglutinate RBCs. The simplest method is to detect virus in an
HA test and use an HAI test to check the positive samples for BCV
specificity (Sharpee et al, 1976). The haemadsorption-elution-
haemagglutination assay is based on the temperature dependency of
CV specific haemagglutinating activity. Virus in faeces is allowed
to adsorb to mouse RBCs for 1 h at 4 degrees centigrade (°C).
Unadsorbed material is washed off and BCV is eluted from the RBCs
by raising the temperature to 37°C. The eluate is then tested in a
standard HA test. This method allows the differentiation of BCV
specific haemagglutinating activity from non-specific
haemagglutinins in the faeces (Van Balken et al, 1978). The
reverse passive haemagglutination technique also distinguishes
between BCV specific and non-specific haemagglutination. In this
technique the test sample is mixed with RBCs coated with BCV
specific Abs (Sato et al, 1984). These 3 tests have not been
widely used for BCV diagnosis because of problems caused by
non-specific haemagglutinins present in faeces and also because
different strains of BCV vary in the temperature dependency of
their haemagglutination reactions.
ELISAs are the most widely used diagnostic test for BCV. The
early tests were based on the use of polyclonal antiserum.
Specificity can be improved by incorporation of a positive blocking
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stage in which an anti-BCV serum is added after incubation with the
faecal samples. A detecting anti-BCV serum is then added which has
been raised in a different species to that in which the positive
block serum was raised. Depression of the optical density (OD)
reading by the positive block serum confirms the specificity of the
reaction of the detecting Ab. (Reynolds et al, 1984). More recently
MAbs have been prepared to improve the specificity of these assays.
They have been used to coat the ELISA plates in an antigen capture
system. A mixture of 2 MAbs compensates for BCV strain variations
(Czerny and Eichhorn, 1989). The MAbs should ideally be directed
against both external and internal viral proteins to allow the
detection of both complete and degraded virions (Crouch et al,
1984). Standard ELISAs in which virus is captured by a MAb and
detected by an anti-BCV conjugated Ab may fail to detect virus-Ab
immune complexes. These are present in faeces in the later stages
of clinical disease and during subclinical infections. The problem
may be overcome by using an anti-bovine IgG for capture and an
anti-BCV conjugated Ab for detection, but this technique will only
detect unsaturated immune complexes (Crouch and Acres, 1984).
Dot blot hybridisation assays for detection of BCV RNA have
recently been described. These are based on the use of a cDNA
probe labelled with either phosphorus - 32 (P32) or biotin. At
present these techniques are not widely used for the detection of
BCV in diagnostic faecal samples (Shockley et al, 1987; Verbeek
and Tijssen, 1988; Verbeek et al, 1990; Verbeek and Tijssen, 1990).
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Diagnosis: Detection of BCV specific Abs
BCV is very widespread in the cattle population, and the vast
majority of adult animals have detectable levels of BCV specific
Abs in their serum (Rodak et al, 1982). Measurement of Ab levels
in adult animals is therefore only of use when studying outbreaks
of winter dysentery (see later). Calves passively acquire
protective Abs from their dams in the colostrum, but a rise in the
level of BCV specific Abs in paired serum samples is indicative of
a recent BCV infection.
The standard range of serological tests may be used to measure
BCV specific Ab titres. SN tests are read by plaque reduction, IF
staining of virus infected cells or by haemadsorption (Sharpee et
al, 1976; Saif, 1987). Serum used in HAI tests must first be
treated to remove non-specific agglutinins and non-specific
inhibitors of haemagglutination (Sharpee et al, 1976). Passive
haemagglutination tests involve the addition of RBCs coated with
BCV to dilutions of serum. Non-specific haemagglutination is again
a problem in this test, particularly in whey samples (Crouch and
Raybould, 1983). ELISAs are widely used to measure the titres of
both total Abs and Abs of specific isotypes (Rodak et al, 1982;
Crouch et al, 1985; Saif, 1987). BCV Ab titres have also been
measured by radioimmunoassay (RIA) (Rodak et al, 1982).
Treatment
The treatment of calves suffering from diarrhoea is aimed at
preventing loss of fluids and electrolytes which can potentially
lead to dehydration and acidosis. This is achieved by fluid
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replacement therapy, which may be accompanied by discontinuing the
feeding of milk. The fluids used should be balanced electrolyte
solutions and may be given via the oral or intravenous (IV) routes.
Oral administration of kaolin mixtures may be used to decrease the
severity of diarrhoea. Affected calves should be segregated from
healthy animals and kept in a warm area with fresh bedding (Babiuk
et al, 1985).
Control
Calves are born agammaglobulinaemic, and initial protection
against disease depends on the acquisition of passive immunity from
their dams. This is provided by the high levels of Ab present in
bovine colostrum at parturition. IgG^ is the predominant isotype
involved, and is largely derived from serum by a selective
transport mechanism operating in the bovine mammary gland (Crouch,
1985; Saif, 1985). The level of specific Ab to BCV in the lacteal
secretions is very high at parturition but then rapidly declines
(Rodak et al, 1982; Crouch and Raybould, 1983).
During the first 24 h of life large amounts of colostral Igs are
absorbed from the gut into the systemic circulation. These
absorbed Abs provide protection against systemic infections.
Protection against enteric infection is dependent on the presence
of high levels of Ab in the gut lumen. This is provided by
unabsorbed colostral and milk Abs. Duration of passively acquired
immunity is prolonged by resecretion of absorbed Abs back into the
gut lumen and by adherence of Igs to the surface of the intestinal
mucosa (Babiuk et al, 1985; Woode and Bridger, 1975; Moon et al,
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1978). Protection against BCV enteric infection correlates better
with the local gut Ab titre than the level of Ab in the circulation
(Heckert et al. 1990).
Enteric disease occurs when the level of gut Ab falls below that
required to protect against the challenge dose of virus. This is
most likely to happen if the level of passively acquired Ab
declines before an adequate level of active immunity has developed.
The offspring of cows, particularly heifers, with low serum Ab
titres and therefore low levels of Ab in colostrum and milk are
especially susceptible to infection (Woode and Bridger, 1975;
Crouch, 1985).
BCV diarrhoea can be prevented either by decreasing the
challenge dose of virus to susceptible animals or by increasing
their levels of specific immunity.
Decreasing the challenge dose of virus may be achieved through
the identification and segregation of carrier cows and calves and
general hygienic measures (Radostits and Acres,1980; Crouch and
Acres, 1984). This is often impossible in practice as BCV infection
may be widespread even in a closed herd (Bulgin et al, 1989;
Heckert e£ al, 1990).
The immune status of susceptible calves to BCV may be raised
either by increasing the level of passive protection they obtain
from their dams or by stimulating active immunity by oral
vaccination. "Calf Guard" (formerly Scourvax II), Norden
Laboratories is a vaccine which is commerically available in the
USA. It contains attenuated live rota and coronaviruses. It is
approved for intramuscular (IM) injection of pregnant cows and oral
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inoculation of newborn calves but its efficacy by either route is
questionable (Myers and Snodgrass, 1982; Babiuk et al, 1985). Other
commercially available BCV vaccines are Coroniffa (Rhone-Merieux)
and Lactovac (Hoechst).
Protection against rotavirus diarrhoea in neonatal calves has
been achieved by parenteral vaccination of pregnant cows. This
raises their circulating IgG^ levels, increasing the amounts of Ab
which are passed to newborn calves in the colostrum. The post
parturient decline in colostral Ig levels still occurs, but
vaccinated animals continue to secrete higher baseline levels of Ab
than non-vaccinates (Snodgrass et al, 1980; Snodgrass et al, 1982).
This approach may be used to protect baby mice against infection
with BCV (Bengelsdorff, 1988), and a similar technique should be
possible in cattle.
Most adult cows have measurable serum Ab titres to BCV as a
result of natural infection (Rodak et al, 1982). The aim of
vaccination is to stimulate a secondary immune response to increase
these Ab levels, raising the levels of protective Abs (mainly IgGl)
which are then passively transferred to the suckling calf via the
colostrum and milk. The resulting levels of passively acquired
immunity in the calf should both prevent disease whilst at the same
time permit subclinical infections to stimulate the development of
active immunity. If the level of passive immunity was such that
infection was totally prevented, then the onset of diarrhoea would
merely be delayed until weaning (Saif, 1985). The efficacy of the
commercial vaccines presently available for controlling BCV
diarrhoea is very questionable (Dauvergne et al, 1983;
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Waltner-Toews et al, 1983). This is not surprising, as
vaccination of cows with experimental or commercially available
vaccines has little or no effect on the levels of BCV specific Abs
in the serum, colostrum or milk (Myers and Snodgrass, 1982; Rodak
et al, 1982; Dauvergne et al, 1983; Collins et al, 1987).
Vaccination may however prevent the increase in shedding of BCV
which occurs from carrier cows at the time of parturition (Collins
et al, 1987).
Active immunisation by oral inoculation of calves with a live
attenuated vaccine against BCV has been investigated. In
experimental trials, colostrum deprived calves were protected
within 2-3 days of inoculation. In field trials the vaccine was
much less effective in preventing BCV diarrhoea (Thurber e£ al,
1977) . This may be due to neutralisation of the vaccine virus by
passively acquired maternal Abs. The immune system of the neonate
is also immature and may fail to respond adequately to the vaccine
(Babiuk et al, 1985; Crouch, 1985).
BCV AND RESPIRATORY TRACT INFECTION
The finding that BCV could be grown in organ cultures of bovine
trachea led to the proposal that the virus may also be a
respiratory tract pathogen (Stott et: al, 1976; Bridger et al,
1978b). This suggestion was supported by the finding that the virus
can be grown in vitro in bovine embryonic lung cells (Toth, 1982).
BCV was first reported to be associated with respiratory disease
by Thomas et al (1982). Virus was observed in lung wash fluids by
EM during a field survey of calf pneumonia outbreaks. The virus
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was isolated in TOC and transmitted to gnotobiotic calves. Other
workers have also isolated BCV from the respiratory tracts of
calves (McNulty et al, 1984), and IF staining of BCV infected nasal
epithelial cells has proved to be a very useful method for
diagnosing BCV upper respiratory tract infections (Reynolds et al,
1985; Saif et al, 1986). An association between BCV infection and
respiratory tract disease has been demonstrated (El-Ghorr, 1988;
Mostl and Burki, 1989; Heckert et al, 1990). A significant
association has also been found between the simultaneous detection
of BCV in faeces and nasal swab samples taken from diarrhoeic
calves (Reynolds et al, 1985).
Examination of tissues from experimentally infected calves has
demonstrated that BCV attacks the epithelial cells of the nasal
cavity and the trachea (Reynolds et al, 1985). Infection may be
subclinical or lead to mild upper respiratory signs such as
rhinitis, sneezing and coughing. Lower respiratory tract signs are
absent, although BCV antigen has occasionally been detected in the
lungs and may be associated with minor lung lesions (McNulty et
al, 1984; Reynolds e£ al, 1985). Respiratory infections with BCV
are not normally sufficiently severe as to require treatment,
although it is possible that they may predispose calves to more
severe secondary lower respiratory tract infections (Saif et al,
1986).
BCVs originating from either enteric or respiratory tracts are
indistinguishable antigenically. Polyclonal serum and MAbs raised
against enteric isolates cross react with respiratory isolates in
IEM, ELISAs, HAI and IF tests (Thomas et al, 1982; Vautherot and
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Laporte, 1983; McNulty et al, 1984). Antisera raised against
viruses isolated from the enteric and respiratory tracts cross
neutralise in vitro and cross protect in vivo (Reynolds et al,
1985).
Experimental investigations demonstrate that the outcome of BCV
infection is largely unaffected by the origin of the virus (enteric
or respiratory) and the route of inoculation (nasal or oral). In
all cases infection of the enteric tract results in diarrhoea
accompanied by shedding of the virus in the faeces. Infection of
the respiratory tract results in virus shedding from the nasal
mucosa in the presence or absence of upper respiratory tract signs
(Singh et al, 1985; Saif et al, 1986; Saif, 1987). The route of
inoculation may affect the time course of disease. Orally infected
calves first excrete virus in the faeces whilst intranasally
infected calves first excrete virus from the nasal mucosa (Saif et
al, 1986).
The epidemiological importance of BCV respiratory tract
infections is unclear. Infection can occur in a wide age range of
calves and is often subclinical. Clinical signs, when present,
are generally seen at about 2-4 months of age (Mostl and Burki,
1989; Heckert et al, 1990). In addition to the faecal-oral route,
aerosol infection of calves may be an important route of virus
transmission. Spread of virus is assisted by prolonged shedding
(up to 2 weeks) of virus from the respiratory tract of infected
calves (Saif, 1987; Heckert et al, 1989). BCV is an enveloped
virus and is therefore relatively labile. Infection of the
respiratory tract may require fewer infectious virus particles than
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infection of the enteric tract. Virus multiplication at the former
site provides a large number of particles protected by mucus which
are then available to seed the enteric tract (Reynolds et al, 1985;
Saif et al, 1986) .
Immunisation of neonatal calves with live attenuated BCV
vaccines given by the respiratory route has been proposed as an
alternative method of stimulating active intestinal immunity
without the need for primary infection of the gut (Reynolds et al,
1985; Saif et al, 1986). The respiratory route would avoid
neutralisation of the vaccine virus by passively acquired Abs
present in the gut lumen, but there is still a danger of the virus
being neutralised by maternal Abs which have been absorbed
systemically. Furthermore, the neonate may fail to respond
adequately to the vaccine virus due to immaturity of its immune
system.
WINTER DYSENTERY
Winter dysentery occurs during the winter months in housed adult
dairy and beef cattle, and is seen most commonly in young adult
dairy cows. The disease is characterised by an acute onset of dark,
bloody diarrhoea which is accompanied by a dramatic fall in milk
production. Animals may also have a nasolacrimal discharge and
cough, and may become depressed and anorexic. The disease spreads
rapidly within an affected herd (50-100% morbidity) but the
mortality rate is very low (1-2%). The clinical disease lasts from
a few days to several weeks, depending on the herd size. Milk
production losses are very high and production may not return to
normal for several months (Saif, 1990).
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The causal agent or agents of winter dysentery have still not
been fully elucidated, but in recent years BCV has been implicated
in some cases. The virus has been detected by EM examination of
faeces from affected cattle in New Zealand (Horner et al, 1975;
Durham et al. 1979), Japan (Takahashi et al, 1980), France
(Espinasse et al, 1982), Belgium (Broes et al, 1984), USA (Saif
et al, 1988) and Canada (Durham et al, 1989). The virus has been
isolated from diarrhoeic faeces in primary bovine kidney cells
(Takahashi et al, 1980) and HRT-18 cells (Broes et al. 1984;
Benfield and Saif, 1990), and has been adapted to grow in the
brains of suckling mice, rats and hamsters (Akashi et al, 1981).
It has yet to be proven whether the virus detected is a causal
agent of winter dysentery, an opportunistic invader or part of the
normal microflora of the gut. BCV has also been detected in the
faeces of normal cows by ELISA and EM, but infectivity of these
particles has not been demonstrated (Crouch et al, 1985; Collins et
al, 1987). Saif (1990) detected CV particles by IEM in 16 out of 17
diarrhoeic cows and 1 out of 9 healthy cows from herds with
outbreaks of winter dysentery. Seroconversion of affected animals
to BCV has been demonstrated (Takahashi et al, 1980; Saif, 1990).
The epidemiology of winter dysentery is consistent with BCV
being a causative agent. Herds with a prevous history of winter
dysentery are more likely to suffer further outbreaks of disease,
possibly due to the presence of carrier animals. CVs survive best
at low temperatures and at low intensities of ultra violet (uv)
light, leading to a higher level of environmental contamination in
winter (Pensaert and Callebaut, 1978). Spread of infection may
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occur via the oral or respiratory routes, and is facilitated by the
close confinement of large numbers of cattle during the winter.
TGEV causes similar explosive outbreaks of diarrhoea in pigs during
the winter months.
The CV associated with winter dysentery in adult cattle is very
closely related to the CV which causes diarrhoea in neonatal
calves. Both viruses cause similar pathological changes (Van
Kruiningen et al, 1987). A virus which was isolated from a case
of winter dysentery (the Kakegawa isolate) is similar in its
morphology and physicochemical properties to the M strain of BCV
which was isolated from the faeces of a diarrhoeic calf.
Neutralisation and HAI tests show that the viruses are
serologically closely related (Akashi et al, 1980). In contrast to
these findings, Benfield and Saif (1990) found that CVs isolated
from cows with winter dysentery in the USA differed from the M
strain of BCV in their ability to haemagglutinate RBCs and in cross
SN tests.
Attempts have been made to reproduce winter dysentery by oral
inoculation of cows with faeces collected from naturally occurring
cases of the disease (Kruiningen et al, 1985). These experiments
failed to consistently induce diarrhoea in the challenge animals,
although CV has been successfully transmitted from adult cows
suffering from winter dysentery to gnotobiotic calves (Benfield
and Saif, 1990). Reproduction of disease in adult cattle may
first require a fuller understanding of the risk factors involved.
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These may include the immune status and reproductive state of the
animal, environmental stress factors such as changes in diet or low
temperatures and the presence of other microorganisms.
ZOONOSIS
It has been reported that BCV may be a zoonotic agent. Storz
and Rott (1981) reported the accidental transmission of BCV strain
LY-138 from experimentally inoculated calves to a human
investigator. Patel et al (1982) reported the replication in a
gnotobiotic calf of a CV which had been isolated from the faeces of
a human neonate suffering from necrotising enterocolitis.
Neutralising Abs against BCV and HCV-0C43 have frequently been
detected in sera from both cattle and man (Gerna et al, 1981; Storz
and Rott, 1981; Storz ejt al, 1981a). This may be due to the
zoonotic potential of BCV. A more likely explanation is that cross
reactions are occurring between these 2 closely related viruses
(Brian et al, 1983; Hogue et al, 1984). The situation is further
complicated by the possible existence of a human enteric CV (HECV),
which is believed to be even more closely related to BCV than HCV
0C43 (Vautherot and Laporte, 1983).
61
AIMS OF THIS STUDY
The main aim of this study was to establish the extent of
antigenic variation amongst BCV isolates. The possibility of
developing a small animal model of BCV infection was also
investigated. These studies were divided into the following areas:
1. Isolation and growth of BCVs
Efficient methods for isolating BCVs from faecal samples and for
adapting these viruses to growth in cell culture were developed.
2. Production and characterisation of MAbs to BCV
MAbs to BCV were raised and characterised. They were then used
to study the viral structural proteins and to investigate the
extent of antigenic variation.
3. Analysis of the structural proteins of BCV
The structural proteins of BCV were characterised on a
functional basis by studying the reactions of MAbs directed against
the different virus proteins in standard serological tests. The
MWs of the structural proteins were determined and their epitopes
partially mapped.
4. Strain variation of BCVs
The availability of a large panel of BCV isolates permitted a
comprehensive investigation of strain variation to be undertaken.
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Serological studies were performed with polyclonal sera and MAbs,
and the viruses analysed using molecular techniques such as
SDS/PAGE and Western blotting.
5. Animal models of BCV infection
The possibility of using conventionally derived neonatal mice,
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RPMI medium: HRT-18 cells
HRT-18 cells were grown in RPMI 1640 medium (Flow Laboratories)
supplemented with 0.025M hydroxyethylpiperazine-N'-2-ethane-
sulphonic acid (HEPES), 0.008M sodium hydroxide, 0.014M sodium
bicarbonate, 0.002M glutamine, 20% heat inactivated foetal bovine
serum (FBS), 100 international units (IU)/ml penicillin, 100 ug/ml
streptomycin and 2 ug/ml fungizone. This medium is referred to as
RPMI growth medium (RPMI GM).
The cells were maintained in the same medium, except that the
FBS was reduced to a concentration of 2%. This medium is referred
to as RPMI maintenance medium (RPMI MM).
RPMI medium: Hvbridoma cells
The hybridoma cells were grown and maintained in RPMI 1640
medium (Flow Laboratories) containing 0.001M sodium pyruvate,
0.002M glutamine, 400 IU/ml penicillin and 400 ug/ml streptomycin.
Heat inactivated FBS was included at a concentration of 5, 10 or
15%, the concentration used depending on the state of cell growth.
Methionine free minimal essential medium (MEM): Radiolabelling
experiments
Methionine free MEM (IX Eagle's MEM with Earle's salts, Flow
Laboratories) was used to maintain HRT-18 cells during virus
radiolabelling experiments. It was supplemented with 0.002M
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glutamine, 2% heat inactivated FBS, 100 IU/ml penicillin, 100 ug/ml
streptomycin and 2 ug/ml fungizone.
199 Medium: TOCs
TOCs were set up in Earle's 199 medium (Flow Laboratories)
containing 0.025M HEPES, 0.008M sodium hydroxide, 0.014M sodium
bicarbonate, 10% heat inactivated FBS, 0.1% lactalbumin hydrolysate
and 0.01% yeast extract. This was supplemented with antibiotics:
200 IU/ml penicillin, 200 ug/ml streptomycin, 4 ug/ml fungizone,
100 IU/ml gentamicin, 50 ug/ml tylosin and 25 ug/ml lincomycin.
The TOCs were maintained in the same medium after virus
inoculation, except that the FBS was replaced by 0.5% bovine serum
albumin (BSA).
Virus transport medium (VTM)
Nasal swab samples were mixed immediately after collection with
VTM, which was supplied by the Service Section at the Moredun
Research Institute (MRI). The VTM consisted of Hanks balanced salt
solution (Gibco) supplemented with 0.005M sodium bicarbonate, 1%
BSA, 0.002% phenol red, 300 IU/ml penicillin, 300 IU/ml
streptomycin and 50 IU/ml polymyxin.
CELLS
HRT-18 CELLS
The HRT-18 cells used at the start of these studies had been
supplied by the Public Health Laboratory Service (PHLS), Bristol.
They were later replaced by cells from PHLS, Birmingham.
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Cell culture
Cell culture was mainly performed by the candidate and 2
assistants. Towards the end of these studies the cells were
supplied by the Cell Culture Unit at MRI. The cells were grown in
2
75 cm plastic tissue culture flasks (Flow Laboratories), and
passaged at a ratio of 1:4 every 2 or 3 days. When the cells had
been passaged about 100 times, new cells were raised from storage
in liquid nitrogen.
Mycoplasma testing and decontamination
The HRT-18 cells supplied from Birmingham were known to be
contaminated with mycoplasma. These were isolated and identified
as Mycoplasma hvorhinis by Dr. A. Rae at MRI. Decontamination
was achieved by maintaining the cells in RPMI MM supplemented with
10 ug/ml ciprofloxacine (CIP) for 15 days, during which time the
medium was changed every 3 days. The cells were then passaged 3
times without antibiotics, tested again for mycoplasma and found to
be negative.
Preparation of HRT-18 cell monolayers for inoculation with virus
Virus stocks were routinely grown in monolayers of HRT-18 cells
2
in 75 cm plastic tissue culture flasks. Viruses were also
grown in HRT-18 cells in coverslip cultures. Confluent cell
monolayers in flat bottomed 96 well microtitre plates (Nunc) were
used for infectivity titrations and SN tests.
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Acetone fixation of cells
Virus infected or mock infected (MI) HRT-18 cells were fixed
with acetone prior to staining by IF. The medium was removed from
the cells, and the cells washed twice with phosphate buffered
saline (PBS). Cells in 96 well plates were fixed by adding 50
ul/well of PBS, and then flooding the wells with acetone at 4°C.
Coverslip cultures of cells were supported in a rack placed in a
bath of acetone. After fixing for 10 min at room temperature, the
cells were dried and then either stained immediately or covered and
stored at -20°C.
RAT RBCs
Blood was collected into Alsevers solution (0.114M dextrose,
0.03M sodium citrate and 0.07M sodium chloride, pH 6.1) from August
or Wistar cross August male rats, and centrifuged at 850g for 5
min at 4°C. The pelleted RBCs were harvested and washed three times
with Alsevers solution. They were then resuspended in PBS
supplemented with 0.5% BSA (PBS/0.5% BSA) and the packed cell
volume (PCV) measured.
RBCs were stored at 4°C for periods of up to 2 weeks for use in
HA and HAI tests. The cells were discarded earlier if haemolysis
occurred.
TRACHEAL ORGAN CULTURES
The tracheas were obtained from bovine foetuses in late
gestation and from neonatal and young Jersey bull calves.
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Preparation of the TOCs
The tracheas were removed aseptically and placed in PBS
supplemented with 200 IU/ml penicillin, 200 ug/ml streptomycin, 4
ug/ml fungizone, 100 IU/ml gentamicin, 50 ug/ml tylosin and 25
ug/ml lincomycin.
50 millimetre (mm) diameter petri dishes (Sterilin Ltd) were
prepared by scoring the bases with a scalpel at appropriate sites
for placing the organ cultures. The loose tissues and central
connective tissue bands were removed from the tracheas, and they
were cut into individual rings. If the trachea had originated from
a calf, each whole ring was placed on its side in a petri dish. If
the trachea had originated from a foetus, each ring was first cut
into 5 pieces and these were placed with their ciliated surfaces
uppermost in a petri dish. The cultures were washed 3 times with
PBS and 3.0 ml of 199 medium added/dish. They were incubated at
37°C in a 5% 002/95% O2 atmosphere for 1 or 2 days prior to
inoculation.
Preparation of the samples
BCVs were isolated in TOO from faecal and nasal swab samples in
order to adapt the viruses to growth in vitro and as a method of
diagnosing BCV infections.
Faecal samples were prepared by making 1:10 dilutions in PBS
containing 100 IU/ml gentamicin and 4 ug/ml fungizone. The
suspensions were clarified by centrifugation at 300g for 5 min at
4°C and the supernates collected. Nasal swabs were vortexed
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immediately on collection with 1.5 ml of VTM and the resulting
suspensions used to inoculate the cultures.
Inoculation of the TOCs
The viability of the organ cultures was confirmed by observing
the beating of the cilia using an inverted light microscope
(Leitz).
The TOCs were washed 3 times with PBS. 200 ul of the inocula
were placed on the epithelial surface of each tracheal ring, 2
rings being inoculated with each sample. The cultures were
incubated at 37°C for 1 h in a 5% C02,/95% 0^ atmosphere. They were
then washed twice with PBS, 3.0 ml of 199 media added per dish and
the cultures incubated again at 37°C in a 5% 00^/95% atmosphere.
To prevent cross contamination of viruses between the cultures,
each pair of petri dishes was kept in a separate sealed plastic
container during all incubation stages. Mock infected negative
control cultures were also set up.
The medium bathing the cultures was harvested twice per week and
replaced with fresh medium. The HA titres of the harvested fluids
were measured and positive samples tested in a diagnostic ELISA for
BCV specificity. When isolation in T0C was being used as a
diagnostic test for BCV, samples were considered BCV positive if
the first or second harvests yielded HA titres of at least 8 and
BCV specificity was confirmed by the diagnostic ELISA.
73
FAECAL SAMPLES
The faecal samples used for virus isolation were sent to the MRI
for routine diagnosis (rotavirus and coronavirus) from the Scottish
Veterinary Investigation (VI) Centres. They were stored at 4°C




SI and S2 strain viruses had been isolated by Dr. A. El-Ghorr at
MRI. They originated from faecal samples collected from 2 field
cases of BCV enteritis in Scotland. SI virus was passaged in 2
gnotobiotic calves (F690 and L965) before being isolated in bovine
foetal TOC and adapted to growth in HRT-18 cells. S2 virus was
isolated directly from the faecal sample in bovine foetal TOC and
adapted to growth in HRT-18 cells (El-Ghorr, 1988).
Three reference strains of BCV had been supplied to MRI from
other laboratories and grown in HRT-18 cells by Dr. A. El-Ghorr.
The CK strain from England was supplied by Dr. Janice Bridger,
Institute for Animal Health, Compton (Reynolds et al, 1985). The
Mebus (M) strain, originally isolated in America, was supplied by
Dr. S. McNulty, Veterinary Research Laboratory, Belfast (Mebus et
al, 1973a). The PQ strain from Canada was supplied by Dr. L.
Babiuk, University of Saskatchewan (Dea et al, 1980b).
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GROWTH OF BCVs IN HRT-18 CELLS
Growth of BCVs in flasks
BCVs were routinely grown in monolayers of HRT-18 cells in 75
2
cm tissue culture flasks. The viruses were prepared for
inoculation by making a 1:10 dilution in RPMI MM containing 10
ug/ml trypsin and incubated at 37°C for lh. The cells in each
flask were washed twice with PBS, 1.0 ml of inoculum added and the
virus allowed to absorb to the cells by incubating at 37°C for lh.
25.0 ml of RPMI MM containing 1 ug/ml trypsin were then added to
each flask, and the flasks incubated at 37°C on a roller for 3
days.
Viruses were harvested by freezing the medium in the flasks at
-20°C followed by thawing at 37°C. Stocks were aliquoted and
stored at -70°C.
Growth of BCVs in coverslip cultures
BCVs isolated in TOC were initially adapted to HRT-18 cells
grown in coverslip cultures. These cultures were inoculated in a
manner similar to that described above, except that the virus
inoculum was used neat or at a dilution of 1:2, 1:5 or 1:10, and
0.2ml of the virus preparation were inoculated per tube. Some tubes
were mock infected (MI) with RPMI MM supplemented with trypsin at
10 ug/ml to act as negative controls. After the virus absorption
stage, 1.0 ml of RPMI MM with trypsin at 1 ug/ml was added to each
tube. The cultures were then incubated at 37°C for 2 to 3 days on
a roller.
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The coverslips were examined under an inverted light microscope
(Leitz) for the presence of a CPE, and they were then removed for
IF staining. Viruses were harvested by freeze/thawing as described
above.
Construction of BCV growth curves
Confluent monolayers of HRT-18 cells grown in 50 mm diameter
petri dishes (Sterilin Ltd) were infected with S2 strain BCV at an
moi of 0.5 or 2.0 (see Virus titrations: Infectivity titres). The
procedure used during inoculation was similar to that described
previously: 0.5 ml of virus was inoculated per dish and 2.5 ml
RPMI MM containing trypsin at 1 ug/ml were added after virus
absorption.
Cultures were harvested at appropriate intervals pi by freezing
at -20°C for 1 h followed by thawing at 37°C for 20 min (total
virus). When using an moi of 0.5, cell-free virus was also
harvested by collecting the medium from a second dish and
clarifying it by centrifugation at 850g for 10 min at 4°C. The
harvests were immediately titrated for infectivity and HA activity
and the results obtained used to construct growth curves.
PREPARATION OF STANDARD ANTIGEN COVERSLIPS AND PLATES
Standard antigen coverslips
Coverslip cultures of HRT-18 cells were inoculated in an
identical manner to that described above with viruses diluted to
ITs of 4.3 log TOID^/ml. The cultures were incubated at 37°C for
20 h and then either fixed with acetone before examining the
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patterns of IF produced by staining with MAbs, or left unfixed for
use in membrane fluorescence tests. MI coverslip cultures were
used as negative controls.
Standard antigen plates
The viruses were diluted to ITs of 3.8 log TCIO^/ml in RPMI MM
supplemented with 10 ug/ml trypsin and incubated at 37°C for 1 h.
The medium was removed from confluent monolayers of HRT-18 cells in
96 well plates and replaced with 150 ul MM/well. 50 ul of the
trypsin activated virus were then added to each well. The plates
were covered and sealed, and incubated at 37°C for 2 days. The
cells were fixed with acetone, and the standard antigen plates
either used immediately or covered and stored at -20°C until
required. They were used to screen hybridoma cell supernates for
the presence of BCV specific MAbs and to measure the IF titres of
polyclonal sera and MAbs. MI antigen plates were used as negative
controls.
CONCENTRATION AND PURIFICATION OF BCVs
Concentration of BCVs by ultracentrifugation
Virus infected cell culture harvests were clarified by
centrifugation at 1500g for 10 min at 4°C. 5.0 ml of a 10%
(weight/weight, w/w) solution of sucrose in TNE buffer (0.01M tris
- hydrochloride, 0.1M NaCl, l.OmM EDTA, adjusted to a pH of 7.5).
were pipetted into 35.0 ml plastic ultracentrifuge tubes and the
clarified supernates gently layered on top. The tubes were
centrifuged in an SW28 rotor on a Beckman L2 or L5 ultracentrifuge
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at 100,000g for 45 min. Pelleted viruses were resuspended in
appropriate volumes of TNE buffer to give an 100 X concentration by
volume of the original viruses. Virus pellets were used immediately
or stored at -70°C.
Sucrose gradient purification of BCVs
Viruses which had been concentrated by ultracentrifugation
through a sucrose cushion were layered onto 20-60% (w/w) sucrose
gradients and centrifuged at 4°C overnight at 52,000g in an SW40 ti
rotor on a Beckman L2 or L5 ultracentrifuge. Fractions were
collected by piercing the base of the tubes with a needle. The
sucrose densities of the fractions were measured on a refractometer
and the fractions titrated in HA tests. The fractions which had
3
peak HA titres with sucrose densities of 1.18 + 0.02 g/cm were
pooled, and the viruses concentrated again by pelleting through a
sucrose cushion.
POLYCLONAL SERA
REFERENCE ANTISERA SUPPLIED BY MRI
A number of reference polyclonal sera and MAbs which had been
produced by the enteritis section, MRI, were used throughout
these studies. They are listed in Table 2.1.
REFERENCE ANTISERA RAISED BY THE CANDIDATE
Some reference antisera were also raised by the candidate.
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Production of gnotobiotic calf hyperimmune anti-S2 serum
Faeces containing S2 strain BCV were prepared for inoculation by
making a 10% suspension in RPMI MM. They were homogenised in
Griffiths tubes, and centrifuged at 300g for 15 min at 4°C. The
supernate was collected and filtered through a pre-filter, followed
by a series of filters with progressively decreasing pore sizes (5
micrometre (um), 1.2um, 0.8um and 0.45um) to ensure bacterial
sterility. 19 ml were inoculated orally and a further 5 ml
inoculated into each nostril of a 2 day old, male, gnotobiotic
calf (day 0).
S2 strain virus grown in cell culture was clarified on a bench
centrifuge, concentrated by ultracentrifugation and emulsified with
Freund's incomplete adjuvant (FIA) at a ratio (by volume) of virus
to adjuvant of 1:2. Emulsification was performed using an
homogeniser (Ystral) by dropwise addition of virus to the adjuvant,
the mixing vessel being held on ice to prevent overheating. A
satisfactory emulsion had formed when it failed to disperse when
dropped onto the surface of water. 2.5 and 3.0 ml of this inoculum
were given to the calf via the intramuscular (IM) route on days 25
and 35. Serum samples were collected at intervals, and a large
volume of serum (serum 5890) was collected on day 50.
Production of gnotobiotic lamb hyperimmune anti-MI HRT-18 cell
serum
To prepare the inoculum, MI HRT-18 cells were harvested by
freeze/thawing, clarified and concentrated by ultracentrifugation
in a manner identical to that described for BCVs. The cell pellets
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were emulsified with either Freund's complete adjuvant (FCA)
(primary inoculation) or FIA (subsequent inoculations) at a ratio
of cells to adjuvant of 1:1 or 1:2. A gnotobiotic lamb was
inoculated by the IM route with 1.0 ml, 0.5 ml, 0.75 ml and 2.5
ml of these preparations, on days 0, 15, 26 and 36 respectively.
Serum samples were collected on days 0, 7, 14, 26 and 36 (sera
5905, 5906, 5907, 5908 and 5923) and a large volume of serum
collected on day 43 (serum 5926) . Sera 5923 and 5926 were used as
negative control probes in Western blotting experiments.
MONOCLONAL ANTIBODIES
PRODUCTION OF MAbs DIRECTED AGAINST S2 STRAIN BCV
Fusion
Two separate fusions were performed by Miss I. Campbell at MRI
to produce hybridoma cells which secreted BCV specific Abs. The
fusion protocol used by Miss I. Campbell is briefly summarised
below.
Balb/c female mice were inoculated via the intraperitoneal (IP)
route with concentrated S2 strain BCV (HA titre = 1280). They were
given 100 ul of the virus preparation on 3 separate occasions at
intervals of roughly 1 month. The virus was emulsified with FCA
for the first inoculation and with FIA for the second and third
inoculations. A final injection of 100 ul pelleted S2 strain virus
(HA titre = 12800) was given by the IV route 3 days prior to the
fusion.
Spleen cells from immunised mice were fused with NS-0 cells in
the presence of polyethylene glycol (PEG). The resulting cells
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were grown in medium consisting of 2 parts RPMI medium supplemented
with 15% heat inactivated FBS and 1% hypoxanthine-aminopterin-
thymidine (HAT, Gibco) and 1 part mixed thymocyte medium (MTM,
produced by Miss I. Campbell). They were incubated at 37°C in a
5% C02/95% air atmosphere. Hybridoma cells were screened for
production of BCV specific Abs by testing the supernates in IF, SN
and HAI tests. Ab positive cells were frozen in liquid nitrogen
prior to being cloned.
Cloning of hvbridoma cells
Cloning of hybridoma cells was performed by both Miss I.
Campbell and the candidate. Three cell lines were successfully
cloned by the candidate, and a further 5 by Miss I. Campbell. Each
hybridoma cell line was cloned 3 times by the method of terminal
dilution. Supernates were harvested at each stage and checked in
the 3 screening tests for the production of BCV specific Abs. Any
unstable cells which ceased Ab production were abandoned. During
cloning the cells were grown in RPMI medium supplemented with
either 10% MTM or heat inactivated FBS at a concentration of 5, 10
or 15%. The precise supplement used depended on the stage of cell
growth. The procedures adopted during cell cloning are described
below.
2
The cells were grown in 25 cm plastic tissue culture flasks
(Corning). When a sufficient number of cells was present for
cloning, the medium was harvested and the cells washed once with
PBS. The cells were detached from the flasks by addition of 0.5ml
PBS containing 0.0005M versene, and the cells centrifuged at 850g
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for 5 min at 4°C. The cells were resuspended in 5.0 ml RPMI medium
and an aliquot diluted 1:10 in 0.4% trypan blue stain. Live cells
(unstained) were counted and the concentration of the original cell
suspension adjusted to 1000 cells/ml. Seven serial doubling
dilutions were made from this stock suspension. MTM was diluted
1:10 in RPMI medium and 100 ul added to all the inner wells of a 96
microwell plate (Flow Laboratories). 100 ul of the cell suspensions
were added/well. The stock cell suspension (1000 cells/ml) was
added to the 10 wells in row B whilst subsequent rows received
increasingly dilute cell suspensions. The plate lid was replaced
and the cells incubated at 37°C in a 5% 00^/95% air atmosphere.
Plate wells were examined daily for the presence of cloned
hybridoma cells. When a single cell had multiplied to produce a
large number of cells, the supernate was harvested and screened for
BCV specific Abs. Ab secreting cells were cultured in 24 well
2
tissue culture plates (Costar) and then in 25 cm tissue culture
flasks. Some of these cells were frozen in liquid nitrogen and the
rest used for subsequent cloning.
Ascitic fluid production
Hybridoma cells which had been cloned 3 times were inoculated
into mice for the production of ascitic fluids. The mice were
Balb/c or Balb/c cross Swiss male or female mice. A group of about
10 mice were inoculated with each batch of cells. They were primed
at least 1 month prior to receiving the cells by the IP inoculation
of 0.5 ml 2,6,10,14-tetramethyl-pentadecane (Pristane, Sigma).
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Hybridoma cells for inoculation of mice were grown in 75 cm
plastic tissue culture flasks (Flow Laboratories). They were
harvested as described above and pelleted by centrifugation at 850g
for 5 min. The cell pellets were washed 3 times with PBS to remove
all traces of FBS and resuspended in 10 ml RPMI (no FBS). The
viable cells were counted and the concentrations of the cell
suspensions adjusted to 2 x 10^ cells/ml. 0.5 ml of these cell
suspensions was inoculated via the IP route into each mouse.
The mice were examined daily for the production of ascitic
fluids. Mice showing signs of distress were culled and the ascitic
fluids collected by opening the abdomens. Mice which developed
swollen abdomens in the absence of other clinical signs were tapped
using a 23 gauge needle and syringe. The ascitic fluids from each
mouse were collected into a 7.0 ml glass bijoux containing 1 drop
(50 units) of heparin sodium (Evans).
Harvested ascitic fluids were centrifuged at 850g for 5 min at
4°C to pellet RBCs and other debris. The clarified ascitic fluids
were collected from beneath the surface layer of pristane and
screened for BCV specific Abs. Ab positive ascitic fluids which
had been produced from the same batch of hybridoma cells were
pooled, aliquoted and stored at -70°C.
Purification of MAbs from ascitic fluids
1.0 ml volumes of ascitic fluids were diluted and filtered
through 0.45 urn pore size filters. A buffer containing 2M glycine,
and 4M NaCl (pH 8.9) was used as the diluent and wash fluid, the
volumes used being such that the original ascitic fluids were
diluted 1:4 after filtration.
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The MAbs were purified by affinity chromatography on a protein A
sepharose 4B column (Pharmacia). This procedure was performed by
Dr. R. Davies at MRI, and is briefly summarised here. Loading
buffer (1.5M glycine, 3M NaCl, pH 8.9) was flushed through the
column and the diluted ascitic fluids applied to the top. The
unbound fractions (mainly albumin) were washed through with more
loading buffer. The bound fractions were eluted off the column
with 0.1M citrate solutions of decreasing pHs. The initial
solution was at pH 6, subsequent solutions were at pHs 5, 4 and 3.
The MAbs eluted off the column at the pHs appropriate to their
isotypes (IgGl, IgG2a, IgG2b and IgG3 respectively). Elution of
the fractions was monitored by measuring the absorbance at 280 nm.
The active fractions were collected in 1M tris (pH 9.0), and
sodium azide solution added to give a final concentration of 0.04%.
The purified MAbs were placed in Sartorius collodion dialysis
bags and supported in baths of distilled water (DW) by Sartorius
filter holders. The MAbs were concentrated by dialysis under vacuum
at 4°C. The concentrated MAb solutions were then placed in
dialysis tubing (size 1 - 8/32", Medicell International Ltd) and
the salt concentrations returned to normal physiological values by
dialysing once against DW and then twice against PBS. Each
dialysis step was performed over a period of about 8 h at 4°C, and
the DW or PBS were stirred throughout.
The purified MAbs were tested for activity in IF, SN and HAI
tests and their protein concentrations estimated using Pierce BCA
protein assay kits. They were concentrated further if necessary to
adjust their protein levels up to at least lmg/ml.
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CVL MAbs
The Central Veterinary Laboratory (CVL), Weybridge, kindly
supplied 4 MAbs which had been raised against their own isolate of
BCV. This isolate was referred to by us as the CVL strain and the
mouse ascitic fluids were identified by the numbers 5528, 5529,
5530 and 5531.
DETERMINATION OF THE MAb ISOTYPES
Binding Site kit
This kit was produced by Binding Site, Birmingham, and was
based on the Ouchterlony immunodiffusion technique. The kit
contained gels with pre-cut wells set in plastic plates and 6
antisera (typing antisera) directed against the mouse heavy chains
IgGl, IgG2a, IgG2b, IgG3, IgA and IgM. 75 ul of test
supernates harvested from hybridoma cells grown in vitro were
pipetted into the central wells of the gels. 10 ul of each of the
typing antisera were pipetted into each of the 6 surrounding wells.
A positive control serum was included which reacted to give an
immunoprecipitation line with each of the typing antisera. RPMI
medium supplemented with 5% FBS was used as a negative control. The
plates were covered and stored flat at room temperature for 24 h.
The gels were then examined with the naked eye for precipitation
lines and the results recorded. To increase the sensitivity of the
tests, the gels were also stained with Coomassie Brilliant Blue.
Prior to staining, the gels were stuck to a piece of gel bond (FMC,
Bio-Products) and washed 4 times for 30 min each in PBS. They were
dried overnight at 37°C, stained with Coomassie Brilliant Blue for
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15 min and destained with ethanol/acetic acid/ DW destainer
solution for about 15 min. They were dried at 37°C for about 20
min and examined again for the presence of precipitation lines.
Amersham kit
The Amersham kit was based on the ELISA principle and was
performed on typing strips. The supplied strips were impregnated
with goat Abs specific for the different classes and subclasses of
mouse heavy chains (typing antisera) and had been treated to
prevent the non-specific binding of other proteins. The typing
strips were incubated at room temperature with 3 consecutive
solutions for 15 min each, the strips being washed thoroughly
between each stage. The first solutions were the hybridoma cell
supernates, tested at dilutions of 1:10. Bound MAbs were detected
with horseradish peroxidase (HRP) conjugated sheep anti-mouse Igs.
The peroxidase enzymes reacted with the third solution,
4-chloro-l-naphthol, to give purple bands in the regions on the
typing strips which corresponded to the isotypes of the MAbs. A
positive control mouse Ab was included on the typing strips to
check the detection system functioned correctly.
BIOTINYLATION OF MAbs
Purified MAbs were dialysed overnight at 4°C against 0.1M sodium
bicarbonate (pH 8.2 - 8.6) and their protein concentrations
adjusted to 1 mg/ml. Immediately prior to use, biotin-N-
hydroxysuccinimide ester (Sigma) was dissolved in
dimethylsulphoxide (DMSO, BDH) to give a concentration of 1 mg/ml.
88
120 ul of biotin/DMSO were added dropwise to each 1.0 ml of MAb
solution, and the reaction mixtures left at room temperature for 4
h. They were dialysed overnight at 4°C against PBS supplemented
with 0.02% sodium azide. The biotinylated MAbs were then aliquoted
and stored at -20°C prior to use.
TESTS
IMMUNOFLUORESCENT STAINING OF VIRUS INFECTED CELLS
IF staining was used to detect viral antigens in infected cell
monolayers as part of several different tests. The exact details
of staining varied between the different tests, but the same basic
procedure was used throughout.
PBS was used as the diluent and wash fluid during IF staining.
The fixed cells were first incubated at 37°C for 30 min with an
anti-BCV detecting Ab. This was washed off with PBS and replaced
with an anti-species fluorescein isothiocyanate (FITC) conjugate.
After incubating at 37°C for a further 30 min the conjugate was
washed off and the cells examined for IF under a Leitz UV
microscope. When staining cells in 96 well plates, 50 ul of each
of the Abs were added to each well and the plates were washed by
flooding the wells twice with PBS. When staining cells on
coverslips or slides, the cells were stained by flooding with Abs
and washed by placing the coverslips or slides in a rack in a bath
of PBS. Stained coverslip cultures were mounted in a drop of
glycerol (pH 8.4) before examining by UV microscopy.
The Abs used for IF staining varied between the different tests.
When mouse MAbs were used as the detecting Abs, bound MAbs were
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stained with FITC-conjugated sheep anti-mouse IgG (anti-mouse IgG
FITC conjugate, Scottish Antibody Production Unit, SAPU). When
rabbit sera were used as the detecting Abs, bound Abs were stained
with FITC-conjugated sheep anti-rabbit Igs (anti-rabbit Igs FITC
conjugate, Nordic). When bovine or ovine sera were used as
detecting Abs, bound Abs were stained with FITC-conjugated pig
anti-sheep Igs (anti-sheep Igs FITC conjugate). This latter
conjugate was produced by Dr. A. Dawson, MRI and was suitable for
staining bovine Abs because it cross reacted strongly with bovine
Igs. The optimal Ab dilutions for IF staining were determined by
titration. The optimal dilutions of the conjugates varied between
batches, but anti-mouse IgG and anti-rabbit Igs FITC conjugates
were generally used at dilutions of 1:50, whilst the anti-sheep
Igs FITC conjugates were used at dilutions of 1:100.
Monitoring virus growth in coverslip cultures of HRT-18 cells
Viral antigens were detected with lamb anti-BCV serum (serum
5000) used at a dilution of 1:50, followed by anti-sheep Igs FITC
conjugate. Virus growth was assessed by comparing the levels of IF
present in virus infected and MI HRT-18 cells.
Detection of BCV in nasal epithelial cells
Nasal swab samples were mixed with 1.5 ml VTM on a vortex mixer
immediately after collection. 100 ul of the cell suspensions were
spun onto clean glass slides in a cytospin apparatus (Shandon
Southern) and the cells fixed in acetone. BCV antigens were
detected by staining the fixed nasal epithelial cells with lamb
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anti-BCV serum (serum 5000) at a dilution of 1:50, rabbit anti-S2
serum (serum 5317) at a dilution of 1:40 or ascitic fluid
containing S2/1 MAbs at a dilution of 1:200. Bound Abs were
detected with an appropriate anti-species FITC conjugate.
Two controls were included for each sample when serum 5317 was
used as the probe Ab. Rabbit anti-rotavirus serum (serum 4381) was
used at a dilution of 1:40 as a negative control probe and binding
of serum 5317 was blocked by first adding lamb anti-BCV serum
(serum 5000) at a dilution of 1:30.
Reading infectivitv titrations and SN tests
The detecting serum was lamb anti-BCV serum (serum 5000), used
at a dilution of 1:50. Bound Abs were stained with anti-sheep Igs
FITC conjugate.
Screening hvbridoma cell supernates for BCV specific Abs
50 ul volumes of neat hybridoma cell supernates were added to
the wells of standard antigen plates, and bound MAbs detected with
anti-mouse IgG FITC conjugate. Each test supernate was scored
positive or negative on the basis of the presence or absence of IF.
A known positive sample was used as a positive control whilst Mabs
were omitted from negative control wells.
MAbs: Patterns of IF and membrane fluorescence
The patterns of IF produced by staining BCV infected HRT-18
cells with MAbs were examined using acetone-fixed standard antigen
coverslip cultures. The cells were left unfixed in membrane
fluorescence tests.
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The coverslips were flooded with MAbs diluted to IF titres of
128. Bound MAbs were detected with anti-mouse IgG FITC conjugate
and the cells examined for IF. MI HRT-18 cells were also stained
with the MAbs to act as negative controls.
VIRUS TITRATIONS
Infectivitv titres (ITs)
Starting from dilutions of 1:10, 10 fold dilutions of the
viruses were made in RPMI MM containing lOug/ml trypsin and
incubated at 37°C for 1 h. RPMI GM was removed from confluent
monolayers of HRT-18 cells in 96 well plates and replaced by 150
ul/well RPMI MM. 50 ul volumes of the virus preparations were
added to duplicate wells. The plates were covered and sealed, and
incubated for 2 days at 37°C. The titrations were read by fixing
the cells with acetone and staining by IF. Wells containing cells
which stained by IF were scored as positive, and the virus IT, log
TOID^/ml, calculated from the Karber formula (Karber, 1931).
Haemagglutination (HA) titres
HA tests were performed in 96 well plates with "V" shaped wells
(Flow Laboratories). Two-fold dilutions of the test virus samples
were made in duplicate wells in 50 ul volumes of PBS/0.5% BSA. 50
ul of rat RBCs at a PCV of 0.5% were added to each well, and the
plates incubated at room temperature for 1 h. The end points were
defined as the reciprocals of the highest dilutions of virus that
still gave clear haemagglutination of the RBCs. RBC control wells
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which lacked the virus were included to check for non-specific
agglutination.
Arklone extraction of organic materials prior to measurement of
HA titres
Attempts were made to detect BCV in guts harvested from mice
experimentally infected with the virus by measurement of the HA
titres of gut preparations. The guts were harvested and
homogenised in Griffiths tubes with appropriate volumes of RPMI MM
to dilute them 1:10. They were then homogenised with equal volumes
of the organic solvent Arklone, to remove non-specific
agglutinins. These mixtures were centrifuged at 200g for 5 min at
4°C. This caused the arklone layers to settle at the base of the
tubes, covered by a surface layer of debris. The upper aqueous
layers were collected and used in HA tests.
ANTIBODY TITRATIONS
IF tests
Doubling dilutions of test polyclonal sera or MAbs were made in
PBS in 96 well plates, and 50 ul volumes transferred to duplicate
wells of standard antigen plates. The plates were incubated at
37°C for 30 min, unbound Abs washed off with PBS and bound Abs
stained by incubating at 37°C for a further 30 min with 50 ul/well
of an appropriate anti-species FITC conjugate. The plates were
washed again with PBS and examined under a UV microscope. Ab
titres were defined as the reciprocals of the highest dilutions
which gave clear IF with virus infected cells. A positive control
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of known IF titre was included in each test, and each sample was
tested with MI HRT- 18 cell control wells to check for non-specific
IF.
SN tests
The medium used throughout these tests was RPMI MM. Serum or
ascitic fluid samples were first diluted (to 1:10 or 1:40), and
heat inactivated at 56°C for 30 min. Hybridoma cell harvests were
used neat without heat inactivation and were not titrated out:
they were simply scored as being SN positive or negative.
Doubling dilutions of 25 ul volumes of the test samples were
made in duplicate in transfer plates (Dynatech). The viruses were
diluted to pre-determined concentrations in RPMI MM containing 20
ug/ml trypsin, 25 ul volumes added to each well of the transfer
plates and the plates incubated at 37°C for 1 h. The RPMI GM was
removed from confluent monolayers of HRT-18 cells in 96 well plates
and replaced with 150 ul/well of RPMI MM. The Ab/virus suspensions
were added, the plates sealed and incubated at 37°C for 2 days.
The cells were then acetone fixed and stained by IF.
Several controls were included in the SN tests. Cell control
wells contained RPMI MM only to check that cell morphology was
normal and that no contamination had occurred. Virus control wells
contained 25 ul of the virus preparations and 25 ul RPMI MM. The
average numbers of fluorescent cells per field of view were
determined from these wells, and used to define the end points of
the tests. The viruses were also titrated to check the
susceptibility of the cells to virus infection. The SN titre of a
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serum control (serum 5000) was determined in each test, to ensure
consistency between the results.
When reading the test, the mean number of fluorescing cells per
field of view in the virus control wells was first determined. A
field of view was defined as the area outlined by the eyepiece
graticule of the microscope. Virus infected cells were often
scattered irregularly in the cell monolayer so the fluorescing
cells were counted in 5 fields of view and the average taken. The
5 fields of view were at the centre, north, south, east and west
positions within the wells. The Ab titres were defined as the
reciprocals of the highest dilutions of sera that gave a 90%
reduction in the average number of fluorescent cells per field of
view. The viruses were used at dilutions which gave between 50 and
200 fluorescent cells per average field of view. The results of
each SN test were accepted if the serum control titre was within a
2 fold range of the standard titre.
HAI tests
Polyclonal sera were prepared for HAI tests in 3 stages. Non¬
specific inhibitors of agglutination were removed by mixing 1.0 ml
of the serum samples with 13.0 ml of a 25% suspension of acid
washed kaolin in PBS. The preparations were left at room
temperature for 30 min and then centrifuged at 200g for 5 min. The
supernates were collected and mixed with 1.0 ml of rat RBCs at 40%
PCV in PBS/0.5% BSA. They were kept at 4°C for 1 h, whilst shaking
every 10 min, and centrifuged at 850g for 5 min. Finally the
supernates were heat inactivated at 56°C for 30 min. Hybridoma cell
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supernates and ascitic fluids were not treated prior to being used
in HAI tests.
The diluent used throughout the HAI tests was PBS/0.5% BSA.
Doubling dilutions of 50 ul volumes of the test samples were made
in duplicate in "V" well plates (Flow Laboratories). Viruses of
known HA titres were diluted to give 8 HA units and 50 ul
added/well. The plates were incubated at 37°C for 1 h, and 50 ul
of rat RBCs at 0.5% PCV added to each well. The plates were held
at room temperature for a further hour, and the HAI titres
determined.
Several controls were included. RBC control wells contained
RBCs and diluent only to check for non-specific agglutination.
Virus control wells contained doubling dilutions of virus, and
diluent instead of the test sera. These wells were used to check
that the correct amounts of virus had been used in the tests. Serum
control wells contained serum, and diluent instead of the viruses.
They were used to check for the presence of non-specific
agglutinins in the serum. A standard serum sample was also
titrated to check for consistency between tests.
The HAI titres of the test samples were defined as the
reciprocals of the highest dilutions of sera which showed clear
inhibition of haemagglutination. The results of each test were
accepted if the serum control titre lay within a 4 fold range of
the standard titre.
ELISAs
Flat bottomed micro ELISA plates (Nunc Maxisorp) were used in
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all the ELISAs. The coating Ab buffer consisted of 0.015M sodium
carbonate and 0.035M sodium bicarbonate (pH 9.6) (carb/bicarb
buffer). Unbound protein binding sites on the plates were then
blocked with 2%FBS/PBS/0.05%Tween 20 (T, Sigma) in the post coat
stage. The Abs used in the subsequent stages were diluted in
PBS/0.05%T, and PBS/0.05%T was also used to wash the plates 3
times after each stage. After the post coat stage the plates were
washed only once. The outer wells of the ELISA plates were not used
in the tests, but were simply filled with PBS/0.05%T at all stages.
At the end of the tests, substrate solution and 2M sulphuric acid
were also added to the first column of wells, which served as
blanks for zeroing the ELISA reader.
In ELISAs which used a standard antigen preparation, (MAb
binding affinity curves, competition ELISAs and epitope blocking
asays, EBAs), S2 virus was harvested from infected HRT-18 cells
by freeze/thawing and used directly in the ELISAs at an appropriate
dilution. MI HRT-18 cell antigens were prepared in a similar
manner.
Diagnostic ELISA for detecting BCV
The diagnostic ELISA had been developed by other members of the
enteritis section at MRI. It was used in these studies for
detecting BCV in faecal samples and for confirming the presence of
BCV in TOC harvests with positive HA titres. Faecal samples were
prepared in advance by making 1:10 dilutions in PBS/0.05%T and
mixing on a vortex mixer. Particulate matter was allowed to settle
and the supernates harvested and used in ELISAs. TOC harvests were
tested neat or at dilutions of 1:2 in PBS/0.05%T.
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The ELISA plates were coated overnight at 4°C with 100 ul/well
of coating Ab in carb/bicarb buffer. At the beginning of these
studies, sheep anti-BCV (strains SI and CK) serum (serum 5000) was
used as the coating Ab at a dilution of 1:12,800. This was later
replaced by MAb S2/1 ascitic fluid, at a dilution of 1:10,000. All
subsequent stages were identical between the 2 tests.
After the Ab coating stage, the plates were washed 3 times and
post coated with 100 ul/well of 2%FBS/PBS/0.05%T. After standing
at room temperature for 1 1/2 h, they were washed once and 100 ul
of the test samples added to appropriate wells. The format
generally used was to add each test sample to a vertical column of
6 wells. Positive and negative control samples were also included
in the tests. The plates were incubated for 3 h at 37 C, washed 3
times and blocking sera added. Wells in rows B and C received 100
ul/well of 2%FBS/PBS/0.05%T, wells in rows D and E received 100
ul/well of a positive block serum and wells in rows F and G
received 100 ul/well of a negative block serum. The positive block
serum was lamb anti-BCV serum (serum 5000) and the negative block
serum was lamb anti-rotavirus serum (serum 3626). Both sera were
used at dilutions of 1:20. The plates were incubated at 37°C for 1
h, washed 3 times and 100 ul/well of rabbit anti-PQ serum (serum
5324) added at a dilution of 1:50,000. After incubation at 37°C
for a further hour the plates were washed 3 times and 100 ul/well
of HRP-conjugated goat anti-rabbit IgG (anti-rabbit IgG HRP
conjugate, Wellcome), added at a dilution of 1:6000. The plates
were incubated at 37°C for 1 h and washed 3 times.
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The substrate working buffer solution was prepared by mixing
12.1 ml 0.091M citric acid solution, 12.9 ml 0.2M disodium
hydrogen phosphate solution and 25.0 ml DW. 0.04g of
O-phenylenediamine dihydrochloride (opd, Sigma) and 40 ul of 30%
hydrogen peroxide solution were added immediately before use. 100
ul/well of the substrate solution were added to the plates and the
colour allowed to develop for about 5 min until the positive
control wells were judged by eye to have optical densities (ODs) of
about 1.0. The reactions were stopped by the addition of 50
ul/well of 2M sulphuric acid. The OD values were read in a
Titertek Multiscan ELISA plate reader using a D492 nm filter. A
*
positive result was recorded if the control wells (rows B and C)
and negative block wells (rows F and G) gave OD values greater than
0.1 and the OD of the positive block wells (rows D and E) was
reduced by at least 50%.
MAb ELISAs for detecting BCV strain variations
BCV isolates were examined for strain variations in ELISAs using
the 8 S2 MAbs in ascitic fluids as coating Abs. The test protocols
were similar to that used for the diagnostic ELISA, but the
blocking stage was omitted from these tests.
The plates were coated overnight with optimal dilutions of the
MAbs in carb/bicarb buffer. The MAbs were washed off and the
plates post coated with 2%FBS/PBS/0.05%T. The test samples were
diluted in PBS/0.05%T to give HA titres of 32, and 100 ul of each
sample added to duplicate wells. Positive and negative controls
were included on each plate. The positive control was S2 strain
99
virus, which had either been grown in TOC or HRT-18 cells,
depending on the origin of the test samples. Harvests from MI TOCs
or MI HRT-18 cells were used as negative controls. Bound viruses
were detected with rabbit anti-PQ serum (serum 5324) followed by
anti-rabbit IgG HRP conjugate.
The substrate reactions were stopped when the ODs of the
positive control wells (S2 virus) were judged by eye to have
reached about 1.0. The mean OD values from the test and control
wells were calculated. The test samples were then compared to S2
virus by expressing the OD values obtained with the test samples as
%s of the OD value obtained with S2 virus (Dea and Tijssen, 1989a).
Non-specific binding of the detecting Abs to MI TOC or MI HRT-18
cell harvests was allowed for by subtracting the mean OD values
obtained from the negative control wells from the mean OD values
obtained with the test samples and S2 virus. The final equation
was therefore:
(test sample - MI )
„ __ ^ n . mean OD mean OD . nn
% OD test sample = ( ) x 100
^^mean OD ^mean OD ^
MAb binding affinity curves
The 8 S2 strain MAbs were titrated in parallel in an ELISA to
construct binding affinity curves. The plates were coated
overnight at 4°C with lamb anti-BCV serum (serum 5000) diluted
1:6400 in carb/bicarb buffer. They were post coated with 2%
FBS/PBS/0.05%T, washed once and S2 virus diluted 1:5 in PBS/0.05%T
added to alternate horizontal rows of the plates. MI HRT-18 cell
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harvests diluted 1:5 in PBS/0.05%T were added to the remaining
wells. The plates were incubated at 37°C for 1 h and washed 3
times. MAbs which had been purified by affinity chromatography
from their ascitic fluids were diluted to give protein
concentrations of 10, 5, 2.5, 1.25, 0.63, 0.31, 0.16, 0.08,
0.01, 0.005 and 0.001 ug/100 ul. lOOul volumes were transferred to
the ELISA plates: each sample was pipetted into 1 well which had
received S2 virus and 1 well which had received MI HRT-18 cells.
The plates were incubated at 37°C for lh, washed 3 times and bound
MAbs detected with HRP-conjugated sheep anti-mouse gamma-globulin
(anti-mouse gamma-globulin HRP conjugate, SAPU), used at a
dilution of 1:30. The plates were incubated for a further hour at
37°C, washed 3 times and opd substrate solution added. The
reactions were stopped after A min and the OD values read. Binding
affinity curves were constructed by plotting the OD values against
log1Q(ug MAb/well).
Competition ELISAs
MAbs which had been purified by affinity chromatography from
their ascitic fluids were used at known Ig concentrations as
competitor Abs in competition ELISAs. The purified MAbs were
biotinylated for use as detecting Abs in competition ELISAs and
EBAs.
Plates were coated overnight at 4°C with lamb anti-BCV serum
(serum 5000) at a dilution of 1:6400 and post coated with 2%
FBS/PBS/0.05%T. S2 virus or MI HRT-18 cell harvests were added to
appropriate wells. They were either used neat or at dilutions of
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1:4, depending on whether biotinylated N or HE/S MAbs respectively
were being used as detecting Abs. The plates were incubated for 1
h, washed and standard dilutions of competitor MAbs added.
Negative control wells received 2%FBS/PBS/0.05%T in place of the
competitor Abs. After incubating for a further hour the plates
were washed and pre-determined optimal dilutions of biotinylated
detecting MAbs added. The plates were incubated for an hour,
washed and incubated for a further hour with appropriate dilutions
of avidin/HRP conjugate. The opd substrate solution was added and
the reactions stopped when the colour intensity in the negative
control wells (no competitor) was judged by eye to have reached an
OD of about 1.0.
The ODs were read on the ELISA plate reader and the average OD
of the negative control wells calculated (OD . ). The N
no competitor
MAbs gave higher levels of non-specific binding to MI HRT-18 cells
than the S and HE MAbs, and this was allowed for in these tests by
subtracting the mean ODs obtained in the MI HRT-18 cell wells from
all OD values used in subsequent calculations. At each value of ug
competitor MAb/well the percentage competition was calculated from:




Each test was performed on 2 separate occasions and the average
% competition values calculated. A series of competition curves
were constructed for each biotinylated detecting MAb by plotting
the % competition values against l°g-^Q (ug competitor MAb/well) .
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Epitope blocking assays
EBAs were performed to quantify the Abs present in polyclonal
sera which were directed against individual viral proteins and
epitopes. The test formats of these assays were identical to those
previously described for competition ELISAs, except that
polyclonal sera were used in place of competitor MAbs.
A mean OD. . value was obtained for each test plate
(no competitor)
from a set of 11 wells to which PBS/0.05%T was added in place of
the competitor Abs. From this value a competition end point OD
value was determined. For the S and HE MAbs, the end point OD was
defined as 50% the mean OD. . value. The N MAbs gave
(no competitor)
lower levels of self-competition in competition ELISAs, so the end
point ODs in these EBAs were defined as 65% and 80% for MAbs S2/6
and S2/8 respectively. Test samples were titrated in duplicate at
5 standard dilutions and OD values obtained. The mean OD values
were plotted against the serum dilutions and the dilutions at the
end point ODs determined. The reciprocals of these values were a
measure of the Abs present in the test samples.
ANALYSIS OF PROTEINS
PROTEIN ESTIMATIONS
Protein estimations were performed using Pierce BCA Protein
Assay kits. The tests were performed in flat bottomed 96 well
microtitre plates (Nunc). These assays were based on the ability
2+ 1+
of proteins to reduce Cu ions to Cu ions, which then reacted
with bicinchoninic acid to give purple solutions whose ODs were
measured on a Multiscan ELISA plate reader using a 562 nm filter.
103
Standard curves were constructed from the readings obtained with
bovine albumin solutions of known concentrations, and the protein
concentrations of the test samples calculated from these curves.
WESTERN BLOTTING
The proteins were separated by Laemmli SDS-PAGE,
electrophoretically transferred to nitrocellulose membranes and
then probed with either polyclonal sera or MAbs (Laemmli, 1970;
Towbin et al, 1979; Burnette, 1981; Gershoni and Palade, 1983).
Gels
Gels were run in a Biorad Protean II apparatus, assembled using
0.75 mm spacers. The gels consisted of 10% polyacrylamide
resolving gels and 3% polyacrylamide stacking gels, with 14.0 cm
length troughs for the test samples and 0.4 cm edge wells for the
MW markers. The test samples were prepared by boiling 200 ul of
the sample with 200ul 2 x Laemmli sample buffer (with or without
ME) (see Appendix) for 90 sec. 10 ul aliquots of the standard MW
markers (Sigma, MW-SDS-70 kit) were also boiled for 90 sec. The
samples were loaded onto the gels supported in tanks filled with
Laemmli electrode buffer (see Appendix) and connected to Bio-Rad
Model 200/2.0 power packs. The gels were run at 200 volts (v) with
a current limit of 0.04 amperes (amps) for about 4 h until the dye
fronts had moved about 14 cm through the resolving gels.
Transfer of proteins to nitrocellulose paper
The proteins separated by PAGE were transferred to 0.2 um pore
104
size nitrocellulose membranes (Sigma) in a trans-blot
electrophoretic transfer cell (Bio-Rad) containing tris/glycine
electrode blotting buffer (see Appendix). The apparatus was
connected to a Bio-Rad Model 200/2.0 power pack, and transfer
carried out overnight at 60v with a current limit of 1.00 amp. A
magnetic bar stirrer and cooling coils containing circulating cold
water were included in the transfer cell.
After transfer, the gels were stained for about 2 1/2 h in
Coomassie Brilliant Blue stain and then destained for about 2 h in
several changes of acetic acid/alcohol/DW destainer solution (see
Appendix). The stained gels were examined to check that most of
the proteins had been successfully transferred. The nitrocellulose
sheets were stained with 0.1% Ponceau S (Sigma) in DW for about 4
min and destained for about 3 min in several changes of DW. The
Ponceau S stained all the proteins a deep pink colour. The stained
nitrocellulose sheets were examined to check that the proteins had
transferred evenly, and any areas where transfer was poor were
marked and not used in subsequent probing experiments. The strips
of nitrocellulose bearing the standard MW markers were removed and
later used to calculate the MWs of unknown proteins. The rest of
the nitrocellulose sheets were either probed immediately or kept
moist with PBS in sealed plastic bags and stored at 4°C.
Probing the nitrocellulose-bound proteins
PBS supplemented with 0.5%T (PBS/0.5%T) was used as the blocking
and washing solutions and as the diluent for the Abs. All
incubation stages were performed at room temperature on a rotary
shaker.
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The unbound protein binding sites on the nitrocellulose paper
were first blocked by incubation in PBS/0.5%T for 1 h. Either one
of two methods was then used to probe the blotted proteins. In the
first method the nitrocelluose sheets were cut into strips. Each
strip was placed in a tube containing diluted probe Ab and
incubated for 1 h. The strips were rinsed 3 times and washed 3
times (5 min per wash) in PBS/0.5%T. Bound mouse MAbs and rabbit
polyclonal Abs were detected by addition of 168 kilobequerel (KBq)
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of I Protein A in PBS/0.5%T. After incubation for 1 h the
strips were again rinsed 3 times and washed 3 times in PBS/0.5%T,
and mounted on filter paper for autoradiography. This was
performed using Kodak Xomat 'S' film with a Dupont 'lightening
plus' intensifying screen. The casettes were stored at -70°C and
the films devloped after a suitable period of time.
In the second method the nitrocellulose sheets were tightly
clamped in an Immunetics Miniblotter 25. The probes were added to
appropriate channels, care being taken to avoid introducing air
bubbles and causing cross contamination between adjacent channels.
After incubating for 1 h the probe Abs were flushed out of the
apparatus with 1 1 of PBS/0.5%T. The nitrocellulose sheets were
removed from the miniblotter, rinsed twice and washed 3 times in
PBS/0.5%T. Bound MAbs were detected with anti-mouse gamma-globulin
HRP conjugate. Bound bovine or ovine Abs were detected with HRP-
conjugated donkey anti-sheep/goat IgG (anti-sheep IgG HRP
conjugate, SAPU), which cross reacted strongly with bovine Abs.
The nitrocellulose sheets were incubated for 1 h in appropriate
dilutions (1:100) of the conjugate, rinsed 3 times and washed 3
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times, and bound conjugate detected with 4-chloro-l- naphthol
substrate solution. This was prepared by dissolving 0.06g
4-chloro-l-naphthol (Sigma) in 20 ml ice cold methanol (solution
A). 100 ml of a 0.02M Tris, 0.5 M NaCl solution were prepared, and
60 ul ice cold 30% hydrogen peroxide solution added immediately
before use (solution B). Solutions A and B were mixed at room
temperature and immediately poured onto the nitrocellulose sheets.
The colour was allowed to develop for 10-30 min, and the reaction
stopped by washing with DW. Probed blots were mounted on filter
paper and photographed the same day before fading could occur.
RADIOLABELLING/RADIOIMMUNOPRECIPITATION
Radiolabelling virus proteins
The media used throughout radiolabelling experiments were
supplemented with trypsin at 1 ug/ml and actinomycin D at 5 ug/ml.
S2 strain BCV was treated for 1 h at 37°C with 10 ug/ml trypsin.
The RPMI GM was removed from confluent monolayers of HRT-18 cells
grown in 24 well tissue culture plates (Costar). The cells were
washed twice with PBS and inoculated with virus at an moi of 10.
Negative control cells were also infected with a mock inoculum.
After incubating at 37°C for 1 h, the inocula were removed and the
cells washed twice with PBS. 1.5 ml of RPMI MM were added to each
well, and the cells incubated at 37°C for 3 h. The RPMI MM was
then replaced with methionine free MEM and the cells incubated for
a further hour.
35
At 5 h pi, 3 MBq of S-methionine were added to appropriate
wells. Unlabelled methionine was also added in some experiments.
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The cells were incubated at 37°C for appropriate lengths of time,
and the radiolabelled materials harvested. The supernates were
collected directly and stored at -70°C for use in subsequent tests.
The cells were first washed twice with PBS and scraped off into
RIPA buffer (see Appendix) at 4°C. This was then clarified by
centrifugation at 100,000g for 60 min in an SW55 rotor on a Beckman
L2 or L5 ultracentrifuge, and the supernates (cell lysates) and
cell pellets collected and stored at -70°C. The level of
incorporation of radiolabel was monitored by scintillation counting
and by autoradiographic detection of proteins separated on gels.
The samples were subsequently used in RIP tests.
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During the radiolabelling experiments, the S-methionine was
omitted from a few wells of virus infected wells, which served as
controls to check for virus growth. The supernates were harvested
and the ITs measured, whilst the cells were fixed with acetone and
virus detected by IF staining.
35
Testing S-methionine incorporation: scintillation counting
2.5 ul samples were pipetted onto 2.5 cm diameter Whatman glass
microfibre filter discs. They were boiled for 5 min in 5%
trichloroacetic acid (TCA) containing 3% casamino acids (cas-AAs,
Difco). The filters were then washed once in 5% TCA/3% cas-AAs,
twice in ethanol and twice in ether. They were dried, put into
vials, and 1.0 ml scintillation fluid (0.018M PPO, 2,5-
diphenyloxazole, BDH and 0.0005M POPOP, l,4-Di-2- (5-
phenyloxazolyl)-benzene, BDH) added to each vial. They were
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counted for 1 min on a scintillation counter, each sample being
counted twice and the mean taken.
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Testing S-methionine incorporation: protein gels
20 ul samples at 1 x 10^ counts/min were boiled for 2 min with 5
ul cracking buffer (10% SDS, 25% ME, 50% glycerol). The samples
were run on protein gels, the gels dried and processed for
autoradiography.
Radioimmunoprecipitation, RIP
Aliquots of test samples (radiolabelled virus or MI HRT-18
cells) containing 4 x 10^ counts/min were diluted in RIPA buffer
(see Appendix) /0.5% SDS to a volume of 75 ul. They were mixed on a
vortex mixer with 25 ul rabbit anti-S2 strain BCV serum (serum
5317) and left at 4°C overnight. 50 ul aliquots of 100 mg/ml
protein A sepharose (Pharmacia) in RIPA buffer were also left at
4°C overnight.
The virus/Ab mixtures were mixed with the aliquots of swollen
protein A sepharose and left on a rocker at 4°C for 2h. The
protein A sepharose complexes were pelleted by spinning at 17,000g
for 1 min on a Centra-M high-speed microcentrifuge. The pellets
were washed 3 times with ice cold RIPA buffer/0.1% SDS and
re-pelleted. They were boiled for 2 min with equal volumes of 2 x
LSB containing 2% SDS and 4% ME, run on protein gels and
precipitated radiolabelled proteins detected by autoradiography.
109
Protein pels: Radiolabelling/RIP experiments
Radiolabelled proteins were run on protein gels and detected by
autoradiography in order to monitor the success of radiolabelling
experiments and to detect precipitated proteins after RIP.
3% stacking and 7.5% resolving polyacrylamide gels were set up
in a BRL gel apparatus, using 1.5 mm spacers and a 20 tooth comb.
The samples were prepared by boiling for 2 min with the
appropriate buffer and loaded onto the gels. The apparatus was
connected to a power pack (Shandon Vokam 400) and the gels run at
0.04 amp for about 4 h.
Gels were stained overnight in Coomassie Brilliant Blue. They
were destained in several changes of destainer solution and soaked
in Amplify (Amersham) for 30 min. The gels were washed again for
30 min in destainer solution supplemented with 3% glycerol. They
were then mounted on filter paper and dried in a vacuum drier.
Autoradiography was performed using Kodak Xomat 'S' film with a
Dupont 'lightening plus' intensifying screen. The casettes were
stored at -70°C and the films developed after appropriate lengths
of time.
CALCULATION OF THE MWs OF PROTEINS SEPARATED BY SDS/PAGE
Standard MW markers (Sigma, MW-SDS-70 kit) were included on all
protein gels. They were either stained on the gels with Coomassie
Brilliant Blue or transferred to nitrocellulose paper and stained
with Ponceau S (0.2% in DW). The relative mobility (Rf) of each of
the MW markers was calculated from:
distance of MW marker migration from top of gel
Rf =
distance of tracking dye migration from top of gel
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The l°g^Q MWs of the markers were plotted against the Rf values, to
give straight line calibration curves. The Rf values of the




Trials were performed to establish whether neonatal mice were
suitable to use as experimental models of BCV infection. The mice
used throughout these tests were Swiss White mice, aged between 2
and 8 days. They were kept under conventional conditions with
their dams.
The baby mice from all the litters were pooled prior to
inoculation. Individuals were then selected at random, inoculated
and returned to a mother mouse. Each mother mouse received a
similar number of baby mice (generally 8-10). Weak or small baby
mice were not used in these experiments. Test mice were each given
0.1 ml of either virus infected or MI HRT-18 cells. The inocula
were prepared by freeze/thawing infected cells. These preparations
were then either used directly or after clarification and
concentration in an ultracentrifuge. The inocula were deposited
into the top of the oesophagus, using a syringe attached to a 23
gauge needle with a plastic tip. Control mice were not given any
inoculum.
The baby mice were monitored clinically each day for up to 6
days pi. The abdomen of each mouse was gently squeezed to check
for the presence of diarrhoea, and any affected mice were marked
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with a pen. Litters of mice which had been inoculated with virus
were always examined last, to prevent transmission of virus between
test groups. In some experiments the baby mice were kept alive
throughout the trial. In other experiments, mice which developed
diarrhoea were culled, and the guts (duodenum to rectum)
harvested. The guts were weighed, and appropriate volumes of RPMI
MM added to dilute them 1:10. They were homogenised in Griffiths
tubes, and the resulting suspensions centrifuged at 200g for 5 min
at 4°C. The supernates were collected and attempts made to detect
BCV by measuring their ITs in HRT-18 cells and by measuring their
HA titres with rat RBCs.
GNOTOBIOTIC ANIMALS (calf, lamb and piglet)
The lamb was delivered by hysterectomy and the calf and piglet
by hysterotomy performed by the Clinical Department at MRI into
sterile environments. The animals were maintained in positive
pressure isolators supplied with filtered air and cared for by
staff belonging to the Gnotobiotic Animal Unit. The animals were
fed on tinned, sterilised milk and handled through sleeves and
gloves attached to the isolators. All materials entering or
leaving the isolation pens did so through an entry port with inner
and outer doors. Incoming materials were autoclaved whenever
possible, sprayed with 0.3% peracetic acid and allowed to stand
for about 30 min in the entry port chamber before entering the
isolation pen.
Inoculation of the gnotobiotic calf and lamb has already been
described under the heading 'Production of polyclonal sera'. The
112
gnotobiotic piglet received 10 ml orally and a further 1.0 ml up
each nostril of a preparation of faeces containing SI strain BCV.
The inoculum was prepared by making a 1:5 dilution of the faeces in
PBS, homogenising in a Griffiths tube and centrifuging at 300g for
15 min at 4°C.
Measurement of % dry matter (% DM) of calf faecal samples
Representative samples of faeces were placed in tin foil dishes.
The dishes were weighed before and after addition of the faeces and
the mass/g of the wet faecal samples calculated. The faeces were
dried to constant weight in a hot air oven. The mass/g of the dry
faecal samples were calculated, and the % DM of the original
faecal samples found from:
mass/g of dry faeces
% DM = x 100
mass/g of wet faeces
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CHAPTER 3




ISOLATION AND GROWTH OF BOVINE CORONAVIRUSES
Introduction
BCVs are notoriously difficult to isolate and grow in cell
culture (Bridger et al. 1978b; Hajer and Storz, 1978). This has
meant that studies to determine the extent of strain variation have
been limited to examining a relatively small number of isolates. A
more efficient method of in vitro growth of BCV would enable a more
comprehensive examination of strain variation to be undertaken.
Tracheal organ cultures (TOCs) derived from bovine foetuses and
newborn calves have been used for the primary isolation and growth
of BCVs derived from diarrhoeic calf faeces and respiratory tract
material (Stott et al, 1976; Bridger et al, 1978b; Thomas et
al, 1982; McNulty et al, 1984). Several continuous cell lines
including BEK-1, Vero, MDBK and PK-15 cells have been used for
the in vitro growth of BCV (Inaba et al, 1976; Dea et al, 1980a).
HRT-18 cells have proved to be particularly susceptible to BCV
infection (Laporte et al, 1979; Vautherot, 1981; King et al, 1985).
Attempts were made to isolate Scottish field BCV strains from
faecal samples in TOCs obtained from bovine foetuses and neonatal
calves. Some of these viruses were then adapted to growth in
HRT-18 cells. The growth kinetics of S2 strain BCV in HRT-18 cells




Faecal samples from diarrhoeic calves were sent from the
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Scottish VI Centres to the MRI for BCV diagnosis by ELISA. The
results obtained from 1987 to 1989 are summarised in Table 3.1. BCV
positive samples were stored at -70°C.
Isolation of BCVs in tracheal organ cultures
BCVs were isolated from the faecal samples in TOC. The tracheas
were obtained from bovine foetuses (mid to late gestation) and
conventional calves (approx 1 to 70 days old). Most of the calves
were bought from markets, so their histories (whether colostrum
deprived or colostrum fed) were unknown. Calves which had
diarrhoea and which were found by ELISA to be excreting BCV in
their faeces were not used as donors. Each faecal sample was
inoculated onto tracheal rings in 2 separate petri dishes. To
prevent cross contamination, each pair of petri dishes was
incubated in a separate sealed plastic container. Uninfected
control cultures were also prepared. The medium bathing the tissues
was harvested twice per week, pooled for each pair of petri dishes,
and BCV growth monitored by measurement of the HA titres.
The HA titres of the harvests obtained from viruses isolated in
TOCs derived from bovine foetuses and neonatal calves are
summarised in Tables 3.2 and 3.3. Peak HA titres were generally
obtained in the first three harvests and declined to low levels by
the fifth harvest. The precautions taken to avoid cross
contamination of viruses between cultures were successful as no HA
activity was ever observed in any of the uninfected controls. A few




Detection of BCV in faecal samples

















Isolation of BCV in bovine foetal TOCs
Faecal HA titres* of harvest numbers :
sample 1 2 3 4




L2755 16 8 4 1
*HA titres are expressed as the reciprocals of the highest dilutions of harvests which
gave clear haemagglutinationwith rat RBCs.
Table 3.3
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Isolation of BCV in calf TOCs
Faecal
sample
HA titres* of harvest numbers :
12 3 4
K2595/1 32 >128 >128 16
K2595/2 >128 >128 >128 64
L1096 — 64 >128 >128
L1121 16 >128 64 64
L1209 64 32 32 32
L1217 64 64 32 32
L1280/2 >128 64 64 32
L1354/2 32 >128 64 32
L3032 16 >128 >128 >128
L3080 64 32 64 32
L3140/1 64 >128 c c




L3228 4 64 >128 64
L.3275 64 64 >128 16
L3318 64 32 c c
L3352 64 64 64 32
L3372 — 16 >128 c
L3472 64 64 c c
N164 >128 >128 64 c
N225 32 64 64 32
N339 >128 >128 32 32
N539 2 32 >128 16
N662 1 >128 64 32
N710 32 >128 32 8
N1193 64 >128 64 32
N1258/2 64 >128 64 64
N1334 32 c c c
0011 64 64 64 64
Mean litre 57 112 106 51
*HA titres are expressed as the reciprocals of the highest dilutions of harvests which
gave clear haemagglutinationwith ratRBCs.
-indicates HA titres < 1.
c = culture contaminated with bacteria or fungi.
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Tracheal organ cultures derived from bovine foetuses were
compared with those derived from neonatal calves for their ability
to support the isolation of BCVs. Eight faecal samples were
simultaneously inoculated into both types of culture (Table 3.4).
The calf TOC proved more successful as BCVs from 3 of the
inoculated samples grew to HA titres of 64 in calf TOCs whilst BCVs
from only 2 samples grew to maximal HA titres of 16 in foetal TOCs.
Table 3.5 summarises the results for virus isolation in TOC. A
total of 17 samples was inoculated onto organ cultures derived from
5 foetuses. Only 2 (12%) of these samples grew to HA titres of 16.
Sixty samples were inoculated onto organ cultures derived from 6
neonatal calves. Twenty-nine (48%) grew to HA titres of at least
16 and all but one of these samples grew to HA titres of at least
64. These results clearly demonstrate that tracheas taken from
neonatal calves are more suitable for isolation of BCVs than those
obtained from bovine foetuses.
The ages of the donor calves and their SN titres to BCV are
summarised in Table 3.6. All were Jersey bull calves. They varied
in age from 1 day to 10 weeks old, but age had no apparent effect
on the isolation rates of BCV. Their SN titres to BCV may have
been more important as lower rates of virus isolation were achieved
using tracheas from calves with high Ab titres. Unfortunately
insufficient data were available for statistical analysis to
determine whether the % of BCVs isolated in TOC could be predicted
from the SN titre of the donor calf.
Table 3.4 120
BCV isolation in TOC
Comparison of tracheas from neonatal calves and bovine foetuses





HA titres* of harvest numbers:
12 3 4
L1096 F
C 2 64 32 16
L1121 F 1 — — —
C 32 64 32 8
L1209 F 1 8 16 4
C 8 64 16 c
L1242 F
C — — — —
L1243 F —
C — — — —
L1275 F __ _
C — — c c
L2755 F 16 8 4 1
C 4 c c c
L2793 F 2 ___
C 2 — — c
*HA titres are expressed as the reciprocals of the highest dilutions of harvests
which gave clear haemagglutination with rat RBCs.
** F = bovine foetus C = calf
- = HA titres <1.
c = culture contaminated with bacteria or fungi.
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Table 3.5
BCV isolation in TOC
Comparison of tracheas from neonatal calves and bovine
foetuses: Overall results
BCVisolationnTOC






























*HAtitresarexp essedthreciprocalsofhigh tdilu onrv twhi havcl arhaemaggluti ationitR8C .
**Numberofsampl sinoculat dn oTOCwhichgrewt ivtle st1h estinHAitr>6r64.
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Table 3.6





Isolation of viruses in TOC*
Viruses Samples % viruses
isolated inoculated isolated
1 1 <100 5 8 63
2 2 NT 9 14 64
3 2 800 3 13 23
4 14 2263 3 8 38
5 35 <100 9 15 60
6 70 <100 4 8 50
* Viruses were considered to have been isolated if the samples inoculated ontoTOC
grew to give at least 1 harvest with an HA titre of > 16.
NT = not tested.
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All TOC harvests with HA titres greater than 32 were tested
using the diagnostic ELISA. These samples all gave positive results
as high OD values (range 0.57 to 1.95) were obtained and binding of
the detecting Ab was blocked by lamb anti-BCV serum (serum 5000).
Negative controls consisted of harvests from both uninfected
cultures and infected cultures with no detectable HA activities.
These samples all gave very low OD readings (range 0.07 to 0.10) on
the ELISA. These results confirmed that the HA activities of the
TOC harvests were due to the isolation of BCV from the inoculated
faecal samples.
Harvests obtained from each inoculated faecal sample with HA
titres of at least 32 were pooled and stored at -70°C. They were
identified by the original faecal sample number followed by "TOC 1"
to indicate the virus had been passaged once in TOC. Twelve TOC 1
viruses were passaged onto a second set of TOCs (TOC 2). They all
grew to an HA titre of at least 128 (results not shown).
Adaptation of BCVs to erowth in HRT-18 cells
Attempts were made to adapt 12 of the viruses isolated in TOC to
growth in HRT-18 cells. Initial passages were performed in HRT-18
cells grown on coverslips. Two tubes were inoculated with each
virus and MI control tubes also set up. The tubes were harvested
after 2 or 3 days, and virus growth monitored by examination of the
cells for CPE, IF staining of acetone fixed cells and measurement
of HA titres. A clearly recognisable CPE was never observed in any
of the cultures but a few syncytia were seen occasionally. The
levels of IF were scored by eye as low (+), moderate (++) or high
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(+++). Viruses failing to produce a moderate number of IF positive
cells after a few passages were abandoned.
Viruses growing in coverslip cultures of HRT-18 cells were then
2
passaged in HRT-18 cells grown in 75 cm flasks. Growth was
monitored by measurement of the HA and infectivity titres. Seven of
the 12 viruses (58%) were successfully adapted to growth in HRT-18
cells (Table 3.7).
Growth curves: S2 strain BCV in HRT-18 cells
HRT-18 cells were infected with S2 strain BCV at an moi of 0.5
or 2.0. Virus was harvested at various times pi and titrated in HA
and infectivity tests. When an moi of 0.5 was used, both total
virus (released after freeze/thawing the cells and medium) and free
virus (in clarified medium) were assayed (Fig 3.1). When an moi of
2.0 was used, only total virus was assayed (Fig. 3.2).
The growth curves obtained using mois of 0.5 or 2.0 were very
similar. Production of infectious virus commenced at 6-9 h pi and
peak titres were reached at about 30 h pi. The IT of total virus
increased before that of free virus due to the slight delay in
virus release from infected cells. HA titres rose (at 48 h when
moi = 0.5 and 24 h when moi = 2.0) and peaked (at 77 h when moi =
0.5 and 54 h when moi = 2.0) later than infectivity titres. This




BCV was detected in 10% of the faecal samples collected from
Table 3.7 125







Passage no. in HRT-18 cells
1 2 3 4 5
L1096 IF + _
HA titre NT NT NT
L1121 IF + + + + + +
HA titre NT NT NT NT NT
L1209 IF + + + NT +
HA titre NT NT NT NT NT
L1217 IF +
HA titre 8 2 0
L3080 IF + + + + NT NT
IT NT NT NT 3.8 5.3
HA titre 16 4 4 16 32
L3352 IF + + + + + + NT
IT NT NT NT NT 6.8
HA titre 8 2 8 4 64
L3372 IF — NT + + + NT NT
IT NT NT NT 5.8 5.3
HA titre 2 8 8 32 32
N164 IF — + + + + + +
HA titre 16 4 0 2 64
N225 IF + + + + NT NT
IT NT NT 6.8 5.8
HA titre 16 16 >128 32
N539 IF + + + + + + + NT NT
IT NT NT NT 5.8 5.8








Passage no. in HRT-18 cells
1 2 3 4 5
N662 IF
HA titre 8 NT
0011 IF — + + + + NT NT
IT NT NT NT 5.3 4.3
HA titre 8 32 16 32 32
*IF = number of cells stained by indirect immunofluorescence scored as none (-),
low(+), moderate (+ +), or high (+ + +).
**fT = logTCID50/ml.
NT = not tested.
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Figure 3,1
Growth curve: S2 BCV in HRT-18 cells
moi = 0.5





Growth curve: S2 BCV in HRT-18 cells
moi = 2.0
Growthcurve 2.56 8.20 7.80
S2 moi







BCVinHRT-18cells =2.0 —HAtitre: totalvirus
80 72
~f64
56 48 40 32 24 16 8 0
496682/ # f / t / •-»—«/
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diarrhoeic calves between 1987 and 1989. These samples were highly
selected due to the system of referral to MRI, but the results are
comparable with those obtained in 2 surveys carried out in 1986.
Reynolds et al (1986) detected BCV in the faeces of 69 out of 490
(14%) diarrhoeic calves in southern Britain and Wales. Snodgrass et
al (1986) detected BCV in the faeces of 24 out of 302 (8%)
diarrhoeic calves in northern England and Scotland.
There was a large increase in the number of samples submitted to
MRI for BCV diagnosis between 1987 and 1989. This was probably
because the success of Rotavec K99 vaccine in preventing diarrhoea
caused by E. coli and rotavirus infections led to an increased
awareness of the other causes of neonatal calf diarrhoea. Prior to
this vaccine becoming available, concurrent rotavirus and BCV
infections were common in diarrhoeic calves, and may have resulted
in more severe clinical disease (Babiuk et al, 1985; Reynolds et
al 1986; Snodgrass et al, 1986). The effects of controlling
rotavirus diarrhoea on BCV infections are at present unknown.
Isolation of BCVs in tracheal organ culture
TOCs derived from conventional calves proved to be a highly
efficient system for primary isolation of BCVs from diarrhoeic calf
faeces. The cultures remained viable for at least 17 days, viruses
grew to high HA titres in their first passage (many > 128) and
viability of these viruses was confirmed by further passage.
Measurement of HA titres provided a rapid and simple method for
monitoring large numbers of culture harvests. ELISAs confirmed
that the HA activities of the harvests were due to BCV.
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Attempts to isolate BCV in TOCs derived from bovine foetuses
proved less successful. Virus was isolated from only 2 out of 17
samples and these isolates grew to low HA titres. Similar results
have been reported by other workers (Stott et al, 1976; Bridger e£
al. 1978b) . In our studies this may have been because the foetuses
were obtained from an abattoir: there was a considerable time lapse
between death of the foetuses and initiation of the cultures. The
neonatal calves were available on site and thus delays were
avoided. An alternative explanation is that the calf epithelial
cells were more mature. Conditions in these cultures were
therefore more similar to those present in the tracheas of young
calves in which the virus multiplies naturally (McNulty et al,
1984).
An overall isolation rate of 48% was achieved in cultures
derived from neonatal calves. An 100% success rate was highly
unlikely, due to a number of factors. Firstly the ELISA used to
detect BCV in faecal samples would also detect non-viable viruses
and virus proteins. As BCVs are relatively fragile, some loss of
viral infectivity was likely to occur during transport and storage
of samples. Specific Abs present in the faeces are likely to bind
the virus and render it non-infectious, although in some instances
low concentrations of specific antiviral Ab can actually enhance
virus growth (Peiris and Porterfield, 1981; Spaan et al, 1990).
Finally, some enteric BCV strains may be incapable of growing in
respiratory tract material. An alternative approach would have
been to use intestinal organ cultures. Bridger et al (1978a) found
that viruses originally isolated in TOC grew to higher HA titres in
intestinal organ culture.
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The ages of the calves from which the tracheas were taken had no
apparent effect on the isolation rates of BCV. The SN titres may
be more important: initial screening of calves to select those
with low Ab titres might be worthwhile in future. The level of
serum neutralising Ab is relevant in older calves at least, as the
presence of serum neutralising Abs in these animals indicates
previous exposure to the virus, which is likely to be accompanied
by an immune response in the respiratory tract.
Adaptation of BCVs to growth in HRT-18 cells
Seven out of 12 viruses (58%) isolated in TOC were adapted to
growth in HRT-18 cells. A higher success rate might have been
achieved if some of the viruses had been passaged further. The
success of virus adaptation may be related to the amount of
infectious virus present in the original inoculum. All the viruses
inoculated onto HRT-18 cells had HA titres of 64 or 128, but HA
titres are not directly related to infectivity titres (Sato et al.
1977) . It is possible that strain variation may also have affected
the ability of some of the viruses to grow in HRT-18 cells. A
large number of other cell lines have been used for in vitro growth
of BCV (Laporte et al, 1979; Dea ejt al, 1980a; El-Ghorr, 1988).
Use of these or different growth conditions might have permitted
the adaptation of more viruses to growth in cell culture.
Growth curves: S2 strain BCV in HRT-18 cells
The growth curves obtained for S2 strain in HRT-18 cells were
similar to those previously described for M strain grown in BEK
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cells, S2 and F15 strains grown in HRT-18 cells and L-9 strain
grown in BFTy cells (Sato et al, 1977; Laporte et al, 1980; Storz
et al, 1981a; El-Ghorr, 1988; Keck et al, 1988). The HA
titres started to rise rather later than the ITs. This was probably
because HA tests lack the sensitivity required to detect the small
amounts of virus released during the early stages of infection. A
similar delay was observed for HCV OC38 grown in baby mice brains
(Kaye and Dowdle, 1969) and BCV grown in BEK-1 cells (Sato et al,
1977). The HA titres continued to rise after ITs had peaked. This
was probably due to release of non-infectious virions and subviral
components in the later stages of infection. The observation that
the distribution of HA activity in fractions collected after
sucrose density gradient centrifugation is not identical to the
distribution of virus infectivity supports the proposal that
non-infectious virions and subviral components may have HA activity
(Sharpee et al, 1976; Takahashi et al, 1983).
The growth curve constructed using an moi of 0.5 demonstrates
that the optimal time to harvest inoculated virus is 48-72 h pi. To
achieve optimal incorporation of radiolabel into virus proteins,
the radiolabel should be added at 5 h pi, shortly before







MONOCLONAL ANTIBODIES TO BOVINE CORONAVIRUS
Introduction
Kohler and Milstein (1975) were the first workers to describe
the production of MAbs using hybridoma technology. They
successfully fused mouse myeloma cells with mouse spleen cells
which had been harvested from an immunised donor. The resulting
hybrid cells retained the ability of the myeloma cells to grow in
vitro and secreted Abs directed against the original antigen used
to immunise the spleen donor mouse. MAbs are now invaluable
research tools in a variety of scientific disciplines. In virology
they offer important advantages over conventional polyclonal or
monospecific antisera. Their unique specificities make them
particularly suitable for analysing virus proteins and for
detecting antigenic variations between different strains of the
same virus. Large quantities of homogeneous Abs can be obtained at
high concentrations from hybridoma cell supernates or ascitic
fluids.
Several groups have raised MAbs against BCV and used them to
study the virus proteins (Deregt et al, 1983; Vautherot and
Laporte, 1983; Deregt and Babiuk, 1987; Czerny and Eichhorn, 1989).
The epitopes on the S and HE gps have been partially mapped (Deregt
and Babiuk, 1987; Deregt et al, 1989b) and preliminary in vivo
protection studies performed (Deregt et al, 1989a). MAbs have been
used to improve the sensitivity and specificity of diagnostic tests
for BCV (Crouch et al, 1984; Czerny and Eichhorn, 1989) and to
detect antigenic variations between different virus isolates
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(Vautherot and Laporte, 1983; Deregt et al, 1989a; El-Ghorr et
al. 1989; Czerny and Eichhorn, 1989).
A panel of 8 MAbs was raised against S2 strain BCV (S2 MAbs) and
a further 4 MAbs were supplied from the CVL, Weybridge (CVL MAbs).
The MAbs were characterised in terms of their isotypes, protein
specificities by Western blotting, and reactions with S2 strain BCV
in IF, SN and HAI tests. They were later used in epitope mapping
studies (Chapter 5), to look for antigenic variations between
different isolates of the virus (Chapter 6) and to study the
immunological response to individual viral proteins (Chapter 7).
Results
Production of MAbs
Spleen cells from mice immunised with S2 strain BCV were fused
with NS-0 cells by Miss I. Campbell at MRI. Two separate fusions
were performed. The hybridoma cells produced were screened for
production of BCV specific Abs in IF, SN and HAI tests, and
attempts made to clone the Ab positive cells 3 times by terminal
dilution. The candidate tried to clone 11 of these cell lines, but
7 rapidly ceased to produce BCV specific Abs after the first
cloning and a further cell line ceased Ab production after the
third cloning. The remaining 3 hybridoma cell lines were
successfully cloned 3 times and the MAbs they produced designated
S2/4, S2/5 and S2/6. A further 5 hybridoma cell lines were cloned
3 times by Miss I. Campbell, and the MAbs produced by these cells
were named S2/1, S2/2, S2/3, S2/7 and S2/8.
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Cloned hybridoma cells were inoculated via the IP route into
pristane-primed mice for ascitic fluid production. A batch of about
10 mice was injected with cells from each hybridoma. Harvested
ascitic fluids were clarified and tested in the 3 screening tests.
BCV Ab positive harvests were pooled, aliquoted and stored at
-70°C. The hybridoma cell lines secreting MAbs S2/4, S2/7 and S2/8
produced relatively small volumes of ascitic fluids so these cells
were inoculated into second groups of mice. The ascitic fluids
containing MAbs S2/1, S2/2 and S2/3 were produced by Miss I.
Campbell.
Isotvpes
The isotypes of the MAbs produced in vitro were investigated.
All 8 MAbs were first tested using a kit based on the Ouchterlony
immunodiffusion technique (Binding Site kit). Test samples were
pipetted into the central wells of a gel and the 6 surrounding
wells received antisera specific to the different mouse heavy chain
classes or subclasses (typing antisera). The gels were held at
room temperature overnight and examined by the naked eye for the
presence of precipitation arcs. The positive control serum gave
precipitation lines with all 6 typing antisera. No precipitation
lines were produced by negative control RPMI media supplemented
with 5% FBS. The 8 test MAbs all gave a single precipitation line
with the typing antisera which corresponded to their isotype (Table
4.1).
To increase the sensitivity of the test, the gels were stained
with Coomassie Brilliant Blue. This resulted in clear staining of
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Table 4.1
Determination of MAb isotypes
MAb isotypes, as determined by :
MAb Binding Site kit
Unstained Stained Amersham kit
gel gel
S2/1 lgG2a lgG2a NT
S2/2 lgG2a lgG2a lgG2a
IgM IgM*
S2/3 lgG2b lgG2b lgG2b
IgM IgM
S2/4 lgG2b lgG2b NT
S2/5 igG2a lgG2a NT
S2/6 lgG2a lgG2a lgG2a
lgG2b*
S2/7 lgG2a lgG2a NT
S2/8 lgG1 lgG1 NT
NT = not tested.
* Pale band only.
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the bands previously visible with the naked eye. Weaker reactions
were also seen between MAbs S2/2, S2/3 and S2/6 and a second typing
antiserum (Fig. 4.1, Table 4.1).
The 3 MAbs which reacted with 2 of the typing antisera were
tested again using the Binding Site kit. This time the reacting
antisera were each put into 2 adjacent wells around the central
test well. After incubation and staining, lines of identity were
seen between wells containing the same typing antisera. Lines of
non-identity were seen between adjacent wells containing different
typing antisera. This demonstrated that the 2 precipitation lines
seen in the original tests were not due to reactions between
identical antigens and Abs. Lines of identity would have indicated
that the typing antisera were not specific for a single class or
subclass of mouse heavy chain (Fig. 4.2).
These 3 MAbs were then tested using a kit based on the ELISA
principle (Amersham kit). The results obtained for MAbs S2/2 and
S2/3 were identical to those previously obtained with the Binding
Site kit after staining with Coomassie Brilliant Blue. MAb S2/6
reacted with a single typing antiserum, the isotype corresponding
to the strong precipitation line seen with the Binding Site kit
(Fig. 4.3, Table 4.1).
Protein specificities
Binding of anti-mouse HRP conjugate to the MAbs
Anti-mouse HRP conjugate was used to detect MAbs bound to
blotted viral proteins in some of the Western blotting experiments.
A preliminary test was therefore performed to check that the
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Figure 4.1
Determination of MAb isotypes : Binding Site kit
The S2 MAbs were tested with an isotyping kit produced by





























Determination of MAb S2/2. S2/3 and S2/6 isotypes :
Binding Site kit
The MAbs S2/2, S2/3 and S2/6 were tested with an isotyping kit
produced by Binding Site, and the gel stained with Coomassie
Brilliant Blue.
Template
lgG2a IgM lgG2b IgM
0 0 0 0
lgG2a Q |S2/2j O lgM '9G2b O (S2/3y O '9M
0 0 0 0
lgG2a lgG2b
o o
lgG2a O (S2/6j O !aG2b
o o
lgG1 lgG2a lgG2a lgG2b
0 0 0 0
IgM O ~j O lgG2b lgG2a O + j O '9G2b
0 0 0 0
IgA lgG3 IgM IgM
+ and - indicates positive (positive control serum) and negative (RPMI/5%FBS) controls.
SK°








Determination of MAb S2/2. S2/3 and S2/6 isotvpes:
Amersham kit
The MAbs S2/2, S2/3 and S2/6 were tested with an
isotyping kit produced by Amersham.
03 G2b G2i 01
G3 G2b G2a 01








conjugate bound to all the MAbs. 5 ul volumes of the S2 strain
MAbs were spotted onto nitrocellulose paper at dilutions of 1:10,
1:100, 1:1000 and 1:10,000, and the paper soaked in PBS/0.5%T to
block unbound protein binding sites. Bound MAbs were detected with
anti-mouse HRP conjugate used at a previously determined optimal
dilution of 1:100, followed by 4-chloro-l-naphthol substrate
solution. The conjugate gave a moderate or strong reaction with
all the MAbs when they were used at dilutions of 1:10 or 1:100 and
a weak reaction with MAbs at dilutions of 1:1000. These results
demonstrated that the conjugate was suitable for detecting bound
MAbs in Western blotting experiments (Fig. 4.4).
Western blotting
The protein specificities of the MAbs were investigated by
Western blotting. Three virus pellets were prepared from S2 strain
BCV grown in HRT-18 cells by freeze/thawing the infected cultures,
clarifying the resulting harvests and concentrating the virus by
ultracentrifugation through sucrose cushions. The infectivity (IT)
and HA titres of the virus pellets are summarised in Table 4.2. The
virus proteins were dissociated by boiling with LSB containing SDS
at a final concentration of 1%. 2-Mercaptoethanol (ME) was included
at a final concentration of 2% in some experiments (reducing
conditions). The proteins were separated by PAGE using 3% stacking
and 10% resolving gels and blotted overnight onto 0.2um pore size
nitrocellulose paper. The gels were stained with Coomassie
Brilliant Blue and the nitrocellulose sheets stained with Ponceau
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Figure 4,4
Binding of anti-mouse HRP conjugate to the MAbs
MAbs were spotted onto nitrocellulose paper at various
dilutions and incubated with anti-mouse HRP conjugate
at a dilution of 1:100. Bound conjugate was detected
with 4-chloro-l-naphthol substrate solution.
1:10' 1:10 1:10 1M0"


















estimation IT HA titre
ug/ml
R 1-125 2350 6.8 3200
NR 1-125 2750 8.8 16000
R HRP 1850 8.8 163840
NR HRP 1850 8.8 163840
R = reducing NR = non-reducing
1-125 = 1-125 protein A HRP = anti - mouse HRP conjugate
IT = log TCID50/ml
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S. A few very pale bands were seen on the stained gels whilst many
darkly stained bands were seen on the nitrocellulose paper. This
demonstrated that the proteins had transferred efficiently to the
nitrocellulose. The remaining protein binding sites on the
nitrocellulose paper were quenched with PBS/0.5%T. The virus
proteins were probed with MAbs present in diluted mouse ascitic
fluids, the test dilutions being chosen to obtain the maximum
feasible concentrations of MAbs for the test system being used.
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Bound MAbs were detected with I protein A or with anti-mouse HRP
conjugate. The MWs of stained bands were calculated by comparison
with the migration patterns of standard MW markers. The identities
of these bands were deduced from comparison with the published MWs
of BCV proteins (Vautherot and Laporte, 1983; Deregt et al. 1987).
The MWs of S2 strain proteins were later confirmed using polyclonal
sera in Western blotting and RIP experiments (Chapter 5).
In the early experiments the nitrocellulose sheets bearing the
blotted proteins were cut into strips. The strips were placed in
tubes and probed with S2 MAb ascitic fluids at dilutions of 1:40.
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Bound MAbs were detected with I protein A and the
autoradiographs developed after 3 days. MAbs S2/5 and S2/8 were
the only MAbs which bound to blotted proteins under reducing
conditions. They both bound to a protein with a MW of about 56 KD,
which corresponds to the MW of the N protein (Fig. 4.5, Table 4.3).
Attempts to renature the blotted proteins by overnight incubation
of the nitrocellulose sheet in PBS at 37°C failed to result in the
binding of any more of the MAbs. Blotting was also performed in
the absence of ME (non-reducing conditions). Autoradiographs
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Figure 4.5
MAb protein specificities determined by Western blotting
(reducing conditions')
The proteins of S2 strain BCV were separated by SDS/PAGE,
blotted onto nitrocellulose paper probed with the
MAbs. Bound MAbs were detected with I protein A.
Template
Lane Probe












13 +ve control: Rabbit anti-S2 serum
(serum 5317)
14 -ve control: PBS/0.5%T
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Table 4.3
Protein specificities of the MAbs determined by Western blotting
Detection system used to detect protein bound MAbs:
MAbs I -125 protein A
Reducing* Non-reducing*
Anti - mouse HRP conjugate
Reducing* Non-reducing*
S2 MAbs
S2/1 - - - -
S2/2 - s - s
S2/3 - HE - HE
S2/4 - HE - HE
S2/5 N N N N
S2/6 - - N N
S2/7 - - - HE
S2/8 N N N N
CVL MAbs
5528 - - / M
5529 - - / S
5530 - - / S
5531 - - / HE
MAb dilutions
S2 MAbs = 1:40
CVLMAbs= 1:1000
S2 MAbs = 1:40
CVL MAbs = 1:200
S2 MAbs = 1:4 S2 MAbs = 1:4
CVL MAbs = 1:10
* Virus proteins separated by SDS/PAGE under reducing or non-reducing conditions.
- = no reaction / = not tested
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developed after 32 days revealed the binding of a further 3 MAbs to
blotted proteins. MAb S2/2 bound to a 97 KD MW protein (S) and
MAbs S2/3 and S2/4 bound to an 116 KD MW protein (HE) (Fig 4.6,
Table 4.3). The CVL MAbs were used at dilutions of 1:1000 to probe
reduced virus proteins and at dilutions of 1:200 to probe
non-reduced virus proteins, the concentrations being increased in
an attempt to obtain positive reactions. Binding of these MAbs to
the blotted viral proteins was never observed under either set of
conditions (Fig. 4.5 and 4.6, Table 4.3).
In subsequent experiments an Immunetics Miniblotter 25 was
available for use when probing the blotted proteins. This allowed
the ascitic fluids to be tested at much higher concentrations
because smaller probe volumes were required. Ascitic fluids
containing S2 MAbs were tested at dilutions of 1:4 and bound MAbs
detected with an anti-mouse HRP conjugate. MAbs S2/5, S2/6 and S2/8
bound to the N protein (52 KD) under both reducing and non-reducing
conditions. MAbs S2/2, S2/3, S2/4 and S2/7 only bound to blotted
proteins under non-reducing conditions. MAb S2/2 bound to the S gp
(98 KD) and MAbs S2/3, S2/4 and S2/7 bound to the HE gp (116 KD).
MAb S2/1 failed to bind to blotted proteins even when neat ascitic
fluid was tested. The CVL MAbs were tested at dilutions of 1:10
under non-reducing conditions only. 5528 bound to the M gps (18-22
KD), 5529 and 5530 bound to the S gp (102 KD) and 5531 bound
weakly to the HE gp (116 KD) (Figs 4.7, 4.8 and 4.9, Table 4.3).
PBS/0.5%T, rabbit anti-rotavirus serum (1776) and ascitic
fluid containing rotavirus MAbs (5328) were used as negative
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Figure 4,6
MAb protein specificities determined by Western blotting
(non-reducing conditions)
The proteins of S2 strain BCV were separated by SDS/PAGE,
blotted onto nitrocellulose paper probed with the
MAbs. Bound MAbs were detected with I protein A.
Template
Lane Probe












13 +ve controls: Rabbit anti-S2 serum
(serum 5317)
14 Cow field serum
(serum 5685)
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Figure 4.7
MAb protein specificities determined by Western blotting
(reducing conditions)
The proteins of S2 strain BCV were separated by SDS/PAGE,
blotted onto nitrocellulose paper and probed with the






























MAb protein specificities determined by Western blotting
(non-reducing conditions')
The proteins of S2 strain BCV were separated by SDS/PAGE,
blotted onto nitrocellulose paper and probed with the


































MAb protein specificities determined by Western blotting
(non-reducing conditions)
The proteins of S2 strain BCV were separated by SDS/PAGE,
blotted onto nitrocellulose paper and probed with the



















control probes in the Western blotting experiments. Faint bands
were sometimes observed in the N protein MW region when either
these negative control probes or the test samples were used to
stain blotted viral or MI HRT-18 cell proteins. They occurred
125
using both I protein A and anti-mouse HRP conjugate as the
detection systems. Binding to blotted viral N proteins may be
explained by the occurrence of non-specific interactions due to the
unusual charge distribution on this protein. Similar non-specific
binding has been reported between S and HE MAbs and the N protein
of TCV (Dea and Tijssen, 1989a). The bands observed after probing
MI HRT-18 cell proteins separated under reducing conditions may
have been due to the presence of ME in the sample buffer during
SDS/PAGE (Tasheva and Dessev, 1983; Herring and Sharp, 1984). A
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more likely explanation is that both I protein A and anti-mouse
HRP conjugate bind non-specifically to cellular proteins via
hydrophobic interactions (Herring and Sharp, 1984; Birk and
Koepsell, 1987). Binding of S2/5, S2/6 and S2/8 MAbs to blotted N
proteins was clearly distinguishable from these non-specific
reactions. These MAbs bound strongly to blotted viral proteins but
failed to give a signal with blotted MI HRT-18 cell proteins.
A faint band at 83-94 KD MW was observed when many of the MAbs
were used to probe virus proteins blotted under non-reducing
conditions. The band was not observed with the negative control
probes. It probably represented non-specific binding of MAbs to
either viral or cellular proteins. The band was only seen when
anti-mouse HRP conjugate was used as the detecting Ab, presumably
because the higher concentrations of MAbs tested with this
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conjugate lead to increased levels of non-specific binding (Birk
and Koepsell, 1987).
Reactions in IF. SN and HAI tests
The MAbs were characterised in terms of their reactions with S2
strain BCV in IF, SN and HAI tests. Titres were expressed as the
geometric means of duplicate results, rounded off to the nearest
10. Protein estimations were performed using a Pierce BCA Protein
Assay kit.
These tests were first used to measure the titres of MAbs in
unpurified ascitic fluids. The results obtained with MAbs raised
against S2 and CVL strains of BCV are shown in Tables 4.4 and 4.5
respectively. The S2 MAbs were subsequently purified by affinity
chromatography through a protein A sepharose column (Chapter 5).
The results obtained using these purified ascitic fluids in IF, SN
and HAI tests are shown in Table 4.6.
The titres obtained in these tests can be compared more easily
if allowance is made for the variations in the Ig concentrations of
the ascitic fluids. In purified ascitic fluids, total protein
estimations roughly equate to MAb concentrations. The limiting
concentrations of MAbs in purified ascitic fluids at the endpoint
titres in IF, SN and HAI tests can be calculated from the titres
and protein estimations given in Table 4.6, knowing that 50 ul of
test samples were used in IF and HAI tests, and 25 ul in SN tests.
These limiting concentrations are expressed in ug/ml in Table 4.7.
The N MAbs all reacted to low titres in IF tests and were
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titres in IF and SN tests and occasionally gave a weak positive
reaction in HAI tests. The 2 MAbs raised against the S gp of CVL
strain BCV reacted strongly with S2 virus in IF tests and were
negative in SN and HAI tests. The 4 MAbs raised against the HE gp
of S2 strain BCV were positive in all 3 tests. MAbs S2/1 and S2/7
reacted strongly in all the tests whilst MAbs S2/3 and S2/4 reacted
to high titres in the IF tests only. The MAb raised against the HE
gp of CVL strain BCV reacted to a high titre in IF tests, a low
titre in SN tests and was negative in HAI tests.
IF staining with MAbs
HRT-18 cells were grown on coverslips and infected with S2
virus. At 20 h pi some of the cultures were fixed with acetone and
probed with the MAbs to study the patterns of IF staining. Other
cultures were left unfixed and immediately probed with the MAbs to
investigate their abilities to stain virus antigens on the
membranes of infected cells. In both procedures, MAbs were tested
at IF titres of 128, and bound MAbs detected with anti-mouse IgG
FITC. The level of non-specific binding of this conjugate was
ascertained by staining cells probed with PBS in place of the MAbs.
No IF was observed when MI HRT-18 cells were probed with the MAbs.
The results obtained in these tests are summarised in Table 4.8,
and the IF patterns demonstrated in Figs 4.10 to 4.15. The 3 N
MAbs gave a fairly even distribution of IF staining throughout the
cytoplasm of the cells. MAb S2/8 gave a particularly distinctive
pattern as the staining was very even throughout the cytoplasm and
cell boundaries were clearly demarcated. The IF staining produced
Table 4,8
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Figure 4.10
Acetone fixed S2 infected HRT-18 cells probed with MAb S2/1
Figure 4.11
Acetone fixed S2 infected HRT-18 cells probed with MAb S2/2.
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Figure 4,12
Acetone fixed S2 infected HRT-18 cells probed with MAb S2/3.
Figure 4.13
Acetone fixed S2 infected HRT-18 cells probed with MAb S2/4.
163
Figure 4.14
Acetone fixed S2 infected HRT-18 cells probed with MAb S2/6.
Figure 4.15
Acetone fixed S2 infected HRT-18 cells probed with MAb S2/8.
i
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by the S and HE MAbs was concentrated in the perinuclear regions of
the cells. All MAbs produced a granular pattern of IF staining:
large distinctive granules were observed with MAbs S2/4 and S2/8.
The S and HE MAbs stained the membranes of unfixed virus infected




Eight hybridoma cell lines were established which secreted MAbs
directed against S2 strain BCV, and a further 4 MAbs directed
against CVL strain of BCV were supplied from CVL, Weybridge.
Isotypes
It was important to determine the isotypes of the MAbs because
this affected their behaviour and choice of reagents in subsequent
experiments. Knowledge of their isotypes was particularly relevant
when choosing the detection systems for Western blotting and IF
tests and when purifying MAbs from ascitic fluids.
The heavy chains of 6 of the 8 MAbs were identified as single
isotypes. MAbs S2/2 and S2/3 reacted weakly with second typing
antisera in both the Binding Site and Amersham kits, possibly
because the typing antisera were not monospecific. These antisera
may have contained Abs to more than one mouse heavy chain isotype,
although this did not appear to be true for the Binding Site kit
because lines of non-identity were observed when the 2 typing
antisera reacting with a single MAb were placed in adjacent wells.
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The typing antisera may also have contained Abs to other proteins
present in the hybridoma cell supernates. These proteins may be
derived either from the media or from the cells. FBS is the most
abundant of these proteins, but no reaction was observed when
RPMI/5% FBS was used as a negative control. The cross reactions
may have occurred because the test MAbs were at high
concentrations. The reactions of S2/2 and S2/3 MAbs with the IgM
typing antisera were abolished when Miss I. Campbell tested the
hybridoma supernates in the Amersham kit at dilutions of 1:100
instead of 1:10.
It is conceivable that the hybridoma cells secreting MAbs S2/2
and S2/3 produced Abs of 2 different isotypes. This may occur if
the cells have not been adequately cloned. Hybridoma cells
secreting S2/2 MAbs were therefore cloned for a fourth time by Miss
I. Campbell but 2 isotypes were still detected. An alternative
explanation is that the hybridoma cells were undergoing a class
switch (Koolen et al, 1984; Aguila et al, 1986).
The MAbs were later purified from ascitic fluids by affinity
chromatography on a Protein A sepharose column. The active
fractions were eluted off the column at the pHs corresponding to
the expected isotypes of the MAbs. There was no evidence that 2
isotypes were present in any of the ascitic fluids. These data and
the fact that similar problems occurred when typing bovine
rotavirus MAbs suggest that the weak reactions of the MAbs with
second typing antisera were due to lack of specificity of the
typing antisera supplied with the test kits.
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Protein specificities
The protein specificities of 11 out of the 12 MAbs were
determined by Western blotting. Three of these MAbs (S2/5, S2/6
and S2/8) bound to the N protein under both reducing and
non-reducing conditions. Probing of blotted viral proteins with
these MAbs revealed a strongly staining broad band around the 52 KD
MW region. A series of less strongly staining bands of slightly
greater electrophoretic mobility was revealed when anti-mouse HRP
conjugate was used to detect bound MAbs. Similar bands were seen
when polyclonal sera were used to detect blotted proteins (Chapter
5). These bands were not observed when blotted MI HRT-18 cell
proteins were probed with test Abs or when blotted S2 proteins were
probed with negative control samples. This suggests that this
series of bands is produced by specific binding of Abs to N protein
precursors or degradation products. Similar bands have been
detected by other groups using both polyclonal sera and MAbs
(Deregt et al, 1983; Vautherot and Laporte, 1983; Keck et al.
1988; Dea and Tijssen, 1989a).
A single MAb was directed against the M gp (5528) , 3 MAbs were
directed against the S gp (S2/2, 5529 and 5530) and 4 MAbs were
directed against the HE gp (S2/3, S2/4, S2/7 and 5531). These MAbs
only bound to blotted proteins under non-reducing conditions,
demonstrating that disulphide bonds are essential for the antigenic
integrity of these epitopes. Deregt and Babiuk (1987) also found
that the majority of MAbs only bind to blotted S and HE gps under
non-reducing conditions.
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MAb S2/1 failed to bind to blotted proteins, despite having a
high binding affinity in ELISAs (Chapter 5). This suggests it is
directed against a conformational epitope which is destroyed by
SDS. Incubation of blotted proteins overnight in PBS at 37°C
failed to renature the epitope. An alternative procedure would
have been to use a gel system incorporating less denaturing
detergents, but there would then have been a danger of incomplete
protein separation (Birk and Koepsell, 1987). Results obtained in
competition ELISAs (Chapter 5) strongly suggest that this MAb is
directed against the HE gp.
The anti-mouse HRP conjugate detected the binding of 6 MAbs to
125
virus proteins which were not detected using I protein A. There
are several possible explanations to account for this behaviour.
Firstly, the HA titre of the virus pellet used with the anti-mouse
HRP conjugate detection system was 10-fold greater than those used
125
with I protein A, facilitating the binding of the HE MAbs.
Secondly, the S2 MAbs were tested at 10-fold higher concentrations
with the anti-mouse HRP conjugate. Finally, the anti-mouse HRP
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conjugate may have been more sensitive than the I protein A for
detecting bound MAbs. The relative sensitivity of the 2 systems is
dependent on both the initial binding of either anti-mouse HRP
conjugate or protein A to the MAbs, and on their subsequent
detection by reaction with substrate solution or by autoradiography
respectively. In theory, anti-species specific conjugates are
more sensitive than protein A for detecting bound Abs because
several molecules bind to each Ig molecule, leading to signal
amplification. In contrast, only 1 or 2 molecules of protein A
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bind to each Ig molecule (Goding, 1978). Protein A also has the
disadvantage that it is unsuitable for detecting certain isotypes.
It binds strongly to mouse IgG2a and IgG2b but only weakly to IgGl
(Goding, 1978; Bjorck and Kronvall, 1984). This was not a problem
in these tests as the strongest signal was produced by MAb S2/8
(IgGl isotype). The enhanced sensitivity of the anti-species HRP
conjugate caused by its favourable binding abilities with Igs is
offset by the fact that detection by autoradiography is a more
sensitive technique than enzymic reaction with a substrate
solution (Towbin and Gordon, 1984).
The anti-species HRP conjugate probe proved to be sufficiently
sensitive for these experiments. The sensitivity of the detection
system could have been increased by using alkaline phosphatase or
colloidal gold conjugated probes, or by amplifying the signal by
incorporating an avidin-biotin or peroxidase-anti-peroxidase stage.
The sensitivity of these experiments could have been improved
further by replacing the nitrocellulose paper with a nylon based
membrane such as Zetabind, which has a greater protein binding
capacity than nitrocellulose (Gershoni and Palade, 1983; Towbin
and Gordon, 1984).
Reactions in IF. SN and HAI tests
The reaction patterns of the MAbs in IF, SN and HAI tests were
similar to those obtained by other groups working with BCV specific
MAbs (Deregt e£ al, 1983; Vautherot et al, 1984; Deregt and
Babiuk, 1987).
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The N MAbs were positive in IF tests only, a result consistent
with published reports. A few MAbs raised against the N proteins
of other CVs are capable of in vitro virus neutralisation and in
vivo protection (Buchmeier et al, 1984; Lecomte et al, 1987).
The M MAb was also positive in IF tests only. Some MAbs directed
against the M gps of other CVs can cause virus neutralisation, but
complement may be required for this activity (Collins et al, 1982;
Laude et al, 1986; Gilmore et al, 1987; Simkins et al, 1989).
The S and HE gps carry the main neutralising epitopes, but MAbs
have also demonstrated the presence of non-neutralising epitopes on
both these proteins (Vautherot et al, 1984; Dea and Tijssen,
1989a). In these experiments all 5 HE MAbs and only 1 out of 3 S
MAbs neutralised S2 strain BCV. The ability of a MAb to neutralise
the virus in vitro does not necessarily correlate with its ability
to protect in vivo (Buchmeier et al, 1984; Talbot et al, 1984;
Deregt et al, 1989a). Due to the lack of a suitable animal model
it was not possible to determine whether these MAbs lead to in vivo
protection.
MAbs directed against the HE gp of BCV vary in their ability to
inhibit virus induced haemagglutination (Deregt et al, 1983;
Parker et al, 1989). In these experiments only the HE MAb raised
against CVL strain BCV failed to inhibit haemagglutination caused
by S2 virus; this may have been due to lack of epitope
conservation. MAb S2/2 also demonstrated weak HAI activity, which
was surprising because this MAb is directed against the S gp. HAI
activity has also been demonstrated with 2 MAbs directed against
the S gp of G110 strain BCV (Vautherot et al, 1984), with 4 MAbs
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directed against the S gp of L9 strain BCV (Storz et al, personal
communication) and with a single MAb directed against the S gp of
TCV (Dea and Tijssen, 1989a). The S gp may carry part or all of
the virus receptor for RBCs and be directly involved with
haemagglutination. An alternative explanation is that some epitopes
on the S and HE gps are structurally or spatially closely related.
The involvement of the S and HE gps in causing virus induced
haemagglutination is discussed in more detail in Chapter 8.
The existence of MAbs with the same protein specificities but
different reaction patterns demonstrates the presence of different
antigenic regions. The MAbs raised against the S and HE gps of S2
strain BCV were all IF+ SN+ HAI+. The MAbs raised against the S
and HE gps of CVL strain were IF+ SN- HAI- and IF+ SN+ HAI-
respectively. These data suggest that there are at least 2
antigenic regions on each of these virus proteins. An alternative
explanation is that the epitopes involved in SN and HAI are not
conserved between the 2 viruses. Unfortunately the CVL strain
virus was not available for testing this theory.
IF staining with MAbs
The patterns of IF staining produced by the MAbs correlated with
their protein specificities. The N MAbs gave an even distribution
of staining throughout the cell cytoplasm. The S and HE MAbs
stained the perinuclear areas of the cells more intensely. These
areas correspond to the positions of the Golgi and RER which are
the sites where the S and HE proteins are glycosylated (Holmes,
1990). Similar patterns of staining have been demonstrated by MAbs
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directed against TCV (Dea and Tijssen, 1989a) and TGEV (Laude et
al. 1986; Welch and Saif, 1988).
Virus antigens were detected on the surface of infected cells
only by MAbs directed against the S and HE gps. Similar results
have been obtained using MAbs raised against TCV (Dea and Tijssen,
1989a), MHV (Collins et al, 1982; Wege et al, 1984) and TGEV (Laude
et al, 1986; Welch and Saif, 1988). However membrane
fluorescence has also been observed with a MAb directed against the
N protein of MHV (Lecomte et al, 1987). Presence of virus
proteins on the infected cell surface is unexpected because CVs
mature in an intracellular location. It is explained by the
transport of excess S and HE gps to the surface of infected cells
(Kienzle et al, 1990; Parker et al, 1990). Here these proteins
may facilitate spread of virus between cells by initiating membrane
fusion events. They may also render the cell susceptible to attack
by the host's defence system, allowing the elimination of infected
cells before infectious virus particles are released. Destruction
of these cells may be achieved by one of several mechanisms.
Cytotoxic T lymphocytes and natural killer cells may lyse virus
infected cells, either directly or in conjunction with
virus-specific Abs (Ab-dependent cell-mediated cytotoxicity).
Binding of Abs to virus antigens on the infected cell surface may
also cause cell lysis by activation of the complement system, and







STRUCTURAL PROTEINS OF BOVINE CORONAVIRUS
Introduction
The structural proteins of BCV have been described by several
groups (King and Brian, 1982; Vautherot and Laporte, 1983; Deregt
et al. 1987), but the antigenic regions of these proteins have not
yet been clearly defined.
Competition ELISAs have been used to study the S and HE gps of
BCV (Deregt and Babiuk, 1987). These tests are based on the
assumption that binding of a MAb to a specific site hinders the
binding of a second MAb which recognises the same or an overlapping
site. The areas defined by these tests should be referred to as
antigenic regions rather than epitopes, as epitopes are defined as
occurring on the surface of native proteins (Laver et al, 1990) .
Deregt and Babiuk (1987) defined 2 antigenic regions (A and B) on
the S gp with 5 strongly neutralising MAbs. Analysis of fragments
generated by proteolysis of Ag-Ab complexes revealed that both
regions were situated on a 37 KD fragment (Deregt et al, 1989b). A
further antigenic region was defined by a single weakly
neutralising MAb. Four MAbs defined 3 antigenic regions (A, B and
C) on the HE gp in competition ELISAs. Region B overlapped regions
A and C, and region A could be subdivided into 2 areas, Al and
A2, on the basis of results obtained in RIP tests. Region A was
defined by MAbs with high SN and HAI titres and regions B and C by
MAbs with low or negative SN and HAI titres (Parker et al, 1989).
MAbs directed against antigenic region A of both the S and HE gps
protected in vivo whilst MAbs directed against region B of the S gp
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and C of the HE gp failed to protect in vivo. Failure of the
former MAb to protect in vivo may have been due to lack of epitope
conservation on the challenge isolate (Deregt e_t al, 1989a) . The
ability of MAbs directed against region B of the HE gp to protect
in vivo has not yet been investigated.
Further analysis of the structural proteins of BCV is required:
the antigenic regions which elicit neutralising Abs are of
particular interest. Viral antigens may be analysed on a functional
or a structural basis and MAbs are ideal tools for these studies
because of their unique specificities. A functional analysis may
be performed by studying the reactions of a panel of MAbs with the
parent virus in a series of serological tests (Chapter 4). Further
information is gained by comparing the results obtained using
different strains of the virus (Chapter 6). This chapter describes
the characterisation of the proteins of S2 strain BCV in terms of
their MWs in Western blotting and RIP experiments. MAbs raised
against this virus were purified from ascitic fluids by affinity
chromatography and their binding affinities assessed in ELISAs.
They were then biotinylated and used in competition ELISAs to map
the antigenic regions of the HE and N proteins. Methods of
analysing antigens on a structural basis are discussed briefly at
the end of this chapter.
Results
MWs of S2 viral proteins
The MWs of the structural proteins of S2 strain BCV were
175
determined by Western blotting and RIP. The former technique
proved to be the more successful.
Western blotting
BCV specific Abs
The proteins of pelleted S2 strain BCV were dissociated by
boiling with LSB in the presence or absence of ME, separated by
SDS/PAGE and electroblotted onto nitrocellulose paper. The proteins
were probed with a variety of polyclonal sera (at dilutions of 1:4)
and MAbs at dilutions of 1:10 (MAb S2/8), 1:20 (CVL MAbs) and neat
(S2/7 MAb). Negative control samples consisted of PBS/0.5%T,
gnotobiotic lamb anti-MI HRT-18 cell sera (sera 5923 and 5926) and
gnotobiotic lamb anti-rotavirus serum (serum 3626): the serum
samples were used at dilutions of 1:4. Bound antibodies were
detected with appropriate anti-species HRP conjugates used at
previously determined optimal dilutions of 1:100, followed by
4-chloro-l-naphthol substrate solution. The MWs of the virus
proteins were determined by comparison with the migration patterns
of standard MW markers.
The results obtained using viral proteins separated under non-
reducing conditions are shown in Fig. 5.1. The MWs of the HE, S, N
and M proteins were calculated to be 116, 98, 52 (range 43 to 62)
and 21 (range 19 to 23) KD respectively. In this figure an extra
band with a MW of 98 KD is observed in the lane probed with MAb
S2/7: this is probably an artefact caused by overflow of MAb 5529
from the adj acent lane.
Viral proteins were also separated under reducing conditions and
probed with neat gnotobiotic calf anti-S2 serum (serum 5890) and
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Figure 5.1
Characterisation of S2 virus proteins by Western blotting
(non-reducing conditions)
The proteins of S2 strain BCV were separated by SDS/PAGE,
blotted onto nitrocellulose paper and probed with




1 Gnotobiotic calf anti-S2 serum (serum 5890)
2 )
3 )
^ ^ Cow field serum samples
5 )
6 Gnotobiotic lamb anti-MI HRT-18 cell serum
(serum 5923)
7 Gnotobiotic lamb anti-MI HRT-18 cell serum
(serum 5926)
8 Gnotobiotic lamb anti-rotavirus serum
(serum 3626)
9 PBS/0.5%T
10 S2 MAb: S2/8 (N)
11 CVL MAb: 5528 (M)
12 CVL MAb: 5529 (S)
13 S2 MAb: S2/7 (HE)
 
177
neat gnotobiotic lamb anti-MI HRT-18 cell serum (serum 5926) (Fig.
5.2). The MWs of the S, N and M proteins were as described above.
The MW of the HE gp was reduced to 64 KD due to breakage of the
disulphide bonds present in the original dimer molecules.
Significantly fewer cellular proteins were detected in this
experiment because the virus had been sucrose gradient purified
prior to SDS/PAGE, although serum 5926 still bound to a cellular
protein with a MW of 64 KD.
To confirm that the proteins detected were virus specific, MI
HRT-18 cell proteins were also separated by SDS/PAGE,
electroblotted onto nitrocellulose paper and probed with
gnotobiotic calf anti-S2 serum (serum 5890) (Fig. 5.3) and the MAbs
(data not shown). No bands were detected apart from that obtained
due to non-specific binding of the HRP conjugate, demonstrating
that the proteins described above are virus specific.
Gnotobiotic lamb anti-MI HRT-18 cell sera
To further confirm that these proteins are virus specific,
anti-MI HRT-18 cell sera were raised in a gnotobiotic lamb and used
as negative control probes in Western blotting experiments. The
lamb was inoculated by the IM route with MI HRT-18 cells emulsified
with FCA (first inoculation, day 0) or FIA (second, third and
fourth inoculations; days 15, 26 and 36). Serum samples were
collected on days 0, 7, 14, 26, 36 and 43 and used at dilutions
of 1:4 to probe MI HRT-18 cell proteins (Fig. 5.3) or S2 virus




Characterisation of S2 virus proteins bv Western blotting
(reducing conditions)
The proteins of sucrose gradient purified S2 strain BCV
were separated by SDS/PAGE, blotted onto nitrocellulose
paper and probed with gnotobiotic lamb anti-MI HRT-18
cell serum (serum 5926) (lane 1) and gnotobiotic calf
anti-S2 serum (serum 5890) (lane 2). Bound Abs were






MI HRT-18 cell proteins probed with gnotobiotic lamb
anti-MI HRT-18 cell sera
(non-reducing conditions)
MI HRT-18 cell proteins were separated by SDS/PAGE,
blotted onto nitrocellulose paper and probed with
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7 Controls: Gnotobiotic calf anti-S2 serum (serum 5919)
8 Gnotobiotic calf anti-S2 serum (serum 5890)









S2 virus proteins probed with gnotobiotic lamb anti-MI HRT-18
cell sera (non-reducing conditions')
The proteins of S2 strain BCV were separated by SDS/PAGE,
blotted onto nitrocelluose paper and probed with
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HRT-18 cell specific Abs were first detected clearly by probing
blotted proteins with serum collected on day 36 (serum 5923) . The
serum collected on day 43 (serum 5926) stained these proteins much
more strongly. The most obvious bands had MWs of 116, 102, 94,
51-->61, 38 and 22 KD (Figs. 5.3 and 5.4). The 102, 51-->61 and
22 KD bands lay in the regions corresponding to the S, N and M BCV
proteins respectively, but they were unlikely to be confused with
viral proteins as the cellular bands were narrower and stained less
strongly (Figs. 5.1 and 5.4). The 116 KD MW cell protein stained
strongly with anti-MI HRT-18 cell serum, and could potentially be
confused with the HE gp (Figs. 5.1 and 5.4). Under reducing
conditions anti-MI HRT-18 cell serum detected a protein with a
similar MW to that of the HE gp monomer (Fig. 5.2). These results
emphasised the importance of using adequate controls in Western
blotting experiments.
Radiolabelling/Radioimmunoprecipitation
Attempts to determine the MWs of viral proteins by RIP were less
successful. Growth curves demonstrated that release of infectious
virus particles from HRT-18 cells commenced at 6-9 h pi(Figs. 3.1
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and 3.2). In radiolabelling experiments S-methionine was
therefore added 5 h pi.
Radiolabelling time course
A radiolabelling time course experiment was conducted to
determine the optimal duration of radiolabelling viral proteins.
35
The radiolabel, S-methionine, was added 5 h pi and cell lysates
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from MI and S2 virus infected cells harvested 0, 1, 3, 6, 9, 21,
28, 45 and 49 h later. Scintillation counts revealed that the
uptake of radiolabel increased with the duration of radiolabelling
but there were no significant differences between MI and S2
infected cells (data not shown). The harvests were run on protein
gels, and though autoradiography revealed many bands, none were
virus specific (Fig. 5.5).
Solubilised cell lysates were immunoprecipitated with rabbit
anti-S2 serum (serum 5317) and protein A sepharose and run on
protein gels. Autoradiography revealed a series of proteins which
had been precipitated from both MI and virus infected cells.
Precipitation of cellular proteins was expected because serum 5317
had been raised against unpurified S2 virus. A virus specific
doublet of bands with MWs of 50 and 52 KD was detected (N protein).
These bands were first observed 6 h after adding the radiolabel and
increased in intensity until around 28 h (Fig. 5.6). Subsequent
experiments employed a 26 h period of radiolabelling.
Titration of unlabelled methionine
Better radiolabelling of the virus proteins was required. In an
35
attempt to increase cellular uptake of S- methionine, unlabelled
methionine was included at concentrations of 0, 5, 10, 15, 20
and 50% relative to the levels normally present in media. The
supernates and cell lysates were harvested 26 h after adding the
radiolabel. Scintillation counts demonstrated that uptake of
radiolabel was roughly constant when unlabelled methionine was
included at levels of 0 to 15%, but dropped rapidly beyond these
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Figure 5.5
Radiolabelling time course: Protein gel (reducing conditions)
35
S-methionine was added to MI and S2 virus infected HRT-18
cells at 5 h pi. The cell lysates were harvested after appropriate
incubation periods and run on a protein gel. Radiolabelled
proteins were detected by autoradiography: the autorad was
developed after 7 days.
Template
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Radiolabelling time course: RIP (reducing conditions')
35
S-methionine was added to MI and S2 virus infected
HRT-18 cells at 5 h pi. The cell lysates were harvested
after appropriate incubation periods and immuno-
precipitated with rabbit anti-S2 serum (serum 5317) .
Precipitated proteins were separated by SDS/PAGE and
radiolabelled proteins detected by autoradiography: the
autorad was developed at 14 days.
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levels. There were no significant differences between S2 infected
and MI cells (data not shown). Autoradiography revealed many bands
when the radiolabelled harvests were run on protein gels, including
a single virus specific band with a MW of 53 KD (N protein) which
was detected in the supernates only. This band was very intense
when unlabelled methionine was included at levels of 0 to 15%, but
was less obvious in the presence of higher concentrations of
methionine (Fig. 5.7).
The cell lysates and supernates were immunoprecipitated with
serum 5317 and protein A sepharose and run on protein gels.
Autoradiography revealed a doublet of virus specific bands with MWs
of 50 + 52 KD (N protein). The concentration of unlabelled
methionine had little effect on the precipitation of this protein
but the signal was stronger from supernates than cell lysates (Fig.
5.8).
Epitope mapping
MAb purification and biotinvlation
The MAbs directed against S2 strain BCV were purified from their
ascitic fluids by affinity chromatography on a protein A sepharose
column. This procedure was performed by Dr. R. Davies. The MAbs
all eluted off the column at the pHs predicted from their isotypes
(Table 4.1). Small peaks were also observed which represented the
elution of the other Igs present in mouse ascitic fluids. Purified
MAbs were titrated in IF, SN and HAI tests (Table 4.6).
Successful purification had been achieved as the MAbs retained
their original activities in these tests.
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Figure 5.7
Titration of unlabelled methionine: Protein gel
(reducing conditions')
35
S-methionine was added to MI and S2 virus infected
HRT-18 cells at 5 h pi. Unlabelled methionine was
included in the incubation media at various
concentrations. The supernates were harvested 26 h
after adding the radiolabel and run on a protein gel.
Radiolabelled proteins were detected by autoradiography:
the autorad was developed after 14 days.
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Titration of unlabelled methionine: RIP (reducing conditions)
35
S-methionine was added to MI and S2 virus infected
HRT-18 cells at 5 h pi. Unlabelled methionine was
included in the incubation media at various
concentrations. The cell lysates and supernates were
harvested 26 h after adding the radiolabel and
immunoprecipitated with rabbit anti-S2 sera (serum 5317) .
Precipitated proteins were separated by SDS/PAGE and
radiolabelled proteins detected by autoradiography: the
autorad was developed at 40 days.
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The purified MAbs were used in ELISAs to construct binding
affinity curves and as competitor Abs in competition ELISAs.
Aliquots of each MAb were biotinylated (MAb-B) and used as
detecting Abs in both competition ELISAs and epitope blocking
assays (EBAs).
MAb binding affinity curves
Purified MAbs were titrated in ELISAs using anti-mouse HRP
conjugate as the detecting Ab. Binding affinity curves were
constructed by plotting the OD readings against log ug MAb/well
(Figs. 5.9 and 5.10). The OD values reached at the plateaux of
these curves are an approximate measure of binding affinity (Deregt
and Babiuk, 1987). The curves obtained with the 4 HE MAbs were
almost identical, demonstrating that these MAbs all have similar
binding affinities. The 3 N MAbs and the single S MAb all gave
lower OD readings than the HE MAbs. Two of the 3 N MAbs failed to
reach saturation levels at the concentrations tested. Non-specific
binding of the MAbs to control wells coated with MI HRT-18 cell
harvests was negligible (OD readings <0.12 at 5 ug Ig/well).
Competition ELISAs
The optimal conditions for performing competition ELISAs were
first determined. Chequerboard titrations were performed to
determine the maximal dilutions of coating Ab (lamb anti-BCV serum,
serum 5000) and S2 virus which gave OD readings of about 1.0 in the
absence of competitor Abs. Serum 5000 was used at a dilution of
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with biotinylated N MAbs and at dilutions of 1:4 with biotinylated
HE and S MAbs. Chequerboard titrations were also performed with
the biotinylated MAbs and avidin/HRP conjugate and appropriate
dilutions chosen to give approximately 90% saturation of the virus
(Table 5.1).
The biotinylated MAbs were used as detecting Abs in competition
ELISAs. MAbs directed against the same proteins were tested in
2-way competition tests whilst the other MAbs were used as negative
control competitor Abs. ODs were measured at standard
concentrations (ug/ml) of competitor MAb/well, and % competition
values calculated by comparison with the OD readings obtained in
the absence of competitor Abs. Binding of biotinylated HE and S
MAbs to MI HRT-18 cells was found to be negligible (OD values
<0.04) and was therefore ignored in these calculations. The N MAbs
gave higher levels of non-specific binding to MI HRT-18 cells (OD
values <0.10), so the average OD values obtained from these wells
were subtracted from the OD values used in the calculations.
Competition curves were constructed by plotting the % competition
values against ug competitor MAb/well. The % competition at the
plateaux of these curves was defined as strong ++ (>70%), moderate
+ (<70% and >20%) or weak - (< 20%).
Each MAb was tested for its ability to compete with itself by
using the same MAb as competitor and detecting Abs. High levels of
self competition were achieved with all the HE and S MAbs (>85% at
the plateau level) and rather lower levels with the N MAbs (69% at
1 ug/well for MAb S2/6 and 54% at 2 ug/well for MAb S2/8) (Figs.




Dilutions of detecting MAbs and avidin / HRP conjugate
Protein Detecting Dilution






S S2/2 1:800 1:2000
S2/5* - -
N S2/6 1:400 1:2000
S2/8 1:800 1:2000
































Results obtained using MAb S2/3 as the detecting Ab
CompetitionELlSAs
MAbS2/3detectingA












Results obtained using MAb S2/4 as the detecting Ab
CompetitionELISAs
MAbS2/4detectingA































Results obtained using MAb S2/2 as the detecting Ab
CompetitionELISAs
MAbS2/2detectingA




























Results obtained using MAb S2/8 as the detecting Ab




























HE and S gps
The results obtained using the HE and S MAbs as biotinylated
detecting Abs in competition ELISAs are shown in Figs. 5.11 to
5.15. The curves obtained using N MAbs as competitor Abs have been
omitted for the sake of clarity as competition with these Abs was
negligible (<10% at 2 ug competitor MAb/well). Strong 2-way
competition occurred between all the HE MAbs, which therefore
mapped to a single antigenic region (Table 5.2). The HE MAbs also
showed strong to moderate levels of competition with biotinylated S
MAb (S2/2), but competition did not occur in the reverse direction.
N protein
The results obtained using the N MAbs S2/6 and S2/8 as
biotinylated detecting Abs are shown in Figs. 5.16 and 5.17 and
summarised in Table 5.3. The 3 N MAbs failed to compete with each
other (<5% competition at 2 ug competitor MAb/well), so they mapped
to 3 distinct antigenic regions. As expected, the S MAb (S2/2)
failed to compete with these MAbs (<1% competition at 2 ug
competitor MAb/well) as did the HE MAbs with MAb S2/8 (<1%
competition at 2 ug competitor MAb/well). An unexpected finding
was that the 4 HE MAbs showed moderate levels of competition with
MAb S2/6 (22 to 51% competition at 2 ug competitor MAb/well) - data
shown for S2/1 and S2/7 in Fig. 5.16.
It proved impossible to use MAb S2/5 as a biotinylated detecting
Ab in competition ELISAs, as it bound strongly to MI HRT-18 cell
harvests and failed to show self competition. Binding affinity
curves were constructed before and after biotinylation, using
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Table 5.2
Summary of results obtained in competition ELISAs.



































Summary of results obtained in competition ELISAs.
Antigenic regions defined by the N protein MAbs
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anti-mouse HRP conjugate and avidin/HRP conjugate respectively to
detect bound Abs (Fig. 5.18). Its binding affinity for both virus
and MI HRT-18 cell harvests increased dramatically after
biotinylation, but relatively low OD values were obtained when
anti-mouse HRP conjugate was used in place of avidin/HRP to detect
bound biotinylated S2/5. A control MAb (S2/8) behaved as expected
throughout these tests. There are 2 possible explanations to
account for the abnormal behaviour of S2/5 MAb after biotinylation.
The first possibility is that the high OD values obtained using
avidin/HRP conjugate were due to the presence of free biotin which
had not bound to the Ab. This free biotin somehow prevented
binding of anti-mouse HRP conjugate to virus bound MAb.
Alternatively, biotinylation of the MAb increased the binding
affinity of the MAb for both virus and MI cells, but it also
prevented binding of anti-mouse HRP conjugate to the MAb.
Discussion
MWs of S2 viral proteins
Western blotting
The MWs of the S2 virus proteins determined using gnotobiotic
calf anti-S2 serum (serum 5890) and cow field sera as probes in
Western blotting experiments confirmed the values previously
obtained using MAbs (Chapter 4). These figures were similar to
those reported for other strains of BCV (King and Brian, 1982;
Vautherot and Laporte, 1983; Deregt et al. 1987). Minor
variations in reported MWs may reflect genuine strain variations
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been grown in different cell lines. There are also often artefacts
caused by the use of different experimental procedures.
In the Western blotting experiments, the N and M proteins were
both seen as a series of closely migrating bands. This phenomenon
has already been discussed for the N protein in Chapter 4. The M
gp exists as a series of species which have different levels of
glycosylation on an identical protein backbone: the M gp is
therefore seen as a series of bands after SDS/PAGE (Deregt et al.
1987) .
Viral specificity of the detected proteins was confirmed by
using BCV specific sera and MAbs to probe blotted MI HRT-18 cell
proteins, and using MI HRT-18 cell specific sera to probe blotted
viral proteins. An alternative method of demonstrating that the
polyclonal sera were detecting viral rather than cellular proteins
would have been to absorb out Abs directed against cellular
proteins prior to using these sera as probes.
Radiolabelline/Radioimmunoprecipitation
Attempts to investigate the MWs of the viral proteins by RIP
were less successful. The N protein was the only virus specific
35
protein which was successfully radiolabelled with S-methionine
and detected in RIP assays. The long exposure times required to
detect this protein by autoradiography demonstrated that only low
levels of incorporation of the radiolabel had been achieved.
Radiolabelling was optimal when using a prolonged labelling period
(about 26 h) in the presence of unlabelled methionine at levels of
up to 10-15% the concentration normally present in media.
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Radiolabelled N protein was detected on protein gels in cell
supernates only: in cell lysates it was obscured by cellular
proteins. In RIP assays the N protein occurred as a doublet of
bands with MWs of 50 and 52 KD. A similar pattern has been reported
by other groups (Deregt et al, 1983; Vautherot and Laporte, 1983;
Keck et al, 1988). The M, S and HE gps failed to incorporate
sufficient amounts of radiolabel to allow them to be detected in
these assays and they may also have been obscured by cellular
proteins. Other groups have encountered similar problems in
detecting radiolabelled S and HE gps of BCV (Deregt et al, 1983;
Keck et al, 1988).
Problems arose in the radiolabelling experiments largely because
most of the radiolabel taken up by the cells was used in cell
protein synthesis. Inclusion of actinomycin D at levels of up to 5
ug/ml failed to resolve this problem. Better radiolabelling might
have been achieved if the virus had been grown in a cell line with
a slower rate of synthesis of cell proteins. Immunofluorescent
staining of acetone fixed cells and measurement of the infectivity
titres of unlabelled controls demonstrated that failure to detect
radiolabelled M, S and HE gps was not due to failure of virus
growth. Radiolabelled N protein was probably successfully detected
because it is the most abundant viral protein (King and Brian,
1982) .
Shortage of time precluded further attempts to improve the
radiolabelling of virus proteins. The successful labelling and
immunoprecipitation of the N protein suggests the methods adopted
were sound. The next step would be to purify radiolabelled virus
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prior to use in RIP assays. In vitro radiolabelling of purified
125
virus with I could also be attempted (King and Brian, 1982).
The problems of achieving successful radiolabelling can be avoided
by using silver staining to detect immunoprecipitated proteins.
This method is suitable when the proteins have been precipitated by
MAbs but gives high levels of background staining when using
polyclonal sera (Utter et al, 1986).
Epitope mapping
Interpretation of results obtained in competition ELISAs
Competition ELISAs are widely used for analysing viral antigens
and for mapping biological activities to specific regions on a
protein. The number of antigenic regions defined by these tests is
dependent on the number of MAbs available. Best results are
achieved using a large panel of MAbs which have been generated by a
variety of procedures to ensure the panel is as diverse as
possible. The results of competition ELISAs should be interpreted
with caution as they are influenced by a number of factors.
The capture Ab and antigen preparations may influence the
availability of certain epitopes, particularly because the
conditions employed in ELISAs lead to some degree of antigen
denaturation. The same stocks of capture Ab and antigen were
therefore used throughout these tests.
Biotin/avidin was chosen as the detection system in the
competition ELISAs for several reasons. Firstly, biotinylation is
a simple procedure. Biotin is a relatively small molecule and is
therefore less likely to affect the antigen binding site than
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larger molecules such as enzymes. Biotin binds very strongly to
avidin, forming complexes which are stable during subsequent
procedures. The biotin/avidin system is a safer technique than the
alternative method of using radiolabelled Abs (Guesdon et al, 1979;
Kendall et al, 1983). Successful biotinylation of MAb S2/5 was not
achieved. Alternative approaches would have been to conjugate the
MAb with an enzyme such as HRP or to radioiodinate it for use in
competition RIAs.
The results of competition ELISAs may be affected by variations
in the levels of non-specific binding of biotinylated MAbs. Binding
of biotinylated HE and S MAbs to negative control MI HRT-18 cells
was negligible and was therefore ignored. The higher levels of
non-specific binding which occurred with the N MAbs was allowed for
in subsequent calculations. MAb isotypes and binding affinities
can also affect the interpretation of results obtained in
competition ELISAs. These MAbs all belonged to the IgG class of
immunoglobulins and binding affinity curves demonstrated that MAbs
directed against the same proteins had similar binding affinities.
Absence of competition between 2 MAbs may indicate that they are
directed against different antigenic regions. MAbs directed
against a single antigenic region may also fail to compete if they
have widely differing binding affinities. Competition between 2
MAbs may indicate that they are directed against the same or
overlapping regions, particularly if competition is reciprocal and
occurs over a wide range of competitor MAb dilutions. Competition
may also occur between 2 MAbs which are directed against different
antigenic regions due to structural similarities in their binding
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sites, stearic hindrance or Ab induced conformational changes
(Yewdell and Gerhard, 1981).
Epitope mapping of the HE gp
In these experiments the 4 HE MAbs all competed strongly with
each other, defining a single antigenic region. This region may be
subdivided into 3 sites on the basis of results obtained in other
tests. MAb S2/1 was unique in its failure to bind to blotted viral
proteins (Chapter 4) and in its reactions in ELISAs, IF and HAI
tests with certain BCV isolates (Chapter 6). MAbs S2/3 and S2/4
were differentiated from MAbs S2/1 and S2/7 by their failure to
neutralise certain virus isolates (Chapter 6). One antigenic
region is therefore defined by MAb S2/1, a second by MAbs S2/3 and
S2/4 and a third by MAb S2/7. The competition ELISAs demonstrate
that these 3 regions are structurally or spatially closely related.
The 3 epitopes (A, B and C) defined in competition ELISAs by Deregt
and Babiuk (1987) were also in close spatial proximity to each
other, as region B was found to overlap regions A and C. MAbs S2/1
and S2/7 probably map to antigenic region A, as they have high SN
and HAI titres. MAbs S2/3 and S2/4 have lower SN and HAI titres,
and may be directed against region B.
The single S MAb (S2/2) demonstrated high levels of self
competition. The 4 HE MAbs also competed with this Ab, possibly
because they had higher binding affinities. An alternative
explanation is that binding of the HE MAbs induced conformational
changes in the S gp, preventing binding of S2/2 detecting MAb
(Cepica et al, 1990). This finding supports a recent proposal
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made by Storz et al (personal communication) which suggested that
the S gp is directly involved with haemagglutination, and that HE
MAbs which cause HAI do so by a stearic effect on the S gp. This
suggestion was based on the finding that HE MAbs inhibit virus
induced haemagglutination of chicken RBCs, but isolated HE gp
cannot agglutinate RBCs from this species (Schultze et al, 1991).
Epitope mapping of the N protein
The N MAbs S2/6 and S2/8 were successfully biotinylated and used
in competition ELISAs. No competition was observed between these 2
MAbs, demonstrating that they mapped to distinct antigenic sites.
The HE MAbs also showed moderate levels of competition with
biotinylated S2/6 detecting MAb, possibly because they had higher
binding affinities. This may also have been due to stearic
hindrance, as the N protein is relatively small compared to the
large projecting HE gps. It was not possible to test MAb S2/5 as a
biotinylated detecting Ab, but the failure of this MAb to compete
with MAbs S2/6 and S2/8 suggests that it is directed against a
third antigenic region. This was supported by results obtained in
IF tests with certain BCV isolates (Chapter 6). Three antigenic
regions were thus defined on the N protein: this is the first time
different antigenic regions have been demonstrated on the N protein
of BCV.
Future studies: structural analysis of epitopes
Further analysis of the structural proteins of BCV is required,
as their antigenic regions have so far only been partially defined
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on a functional basis. A structural analysis may be achieved by
several methods. One approach is to digest the virus proteins with
enzymes and to detect the peptide fragments with MAbs.
Alternatively, proteolysis may be performed on Ag-Ab complexes and
the Ab bound fragments detected by PAGE (Deregt et al. 1989b).
Antigenic structure may also be investigated by testing the binding
of MAbs to synthetic peptides. These peptides are in a denatured
state so MAbs directed against conformation dependent epitopes are
unlikely to bind (Posthumus et al, 1990). Another common approach
is to use neutralising MAbs to generate escape mutants. An
antigenic map may then be constructed on a functional basis by
studying the reactions of MAbs in a series of tests with the
mutants. This technique has yet to be applied to BCV, but has been
used to study a number of other CVs (Delmas et al, 1986; Wege et
al, 1988) . Sequencing of the escape mutants allows a structural
definition of the epitopes. Precise structural definition of
epitopes is only possible using X-ray crystallography, but so far
very limited use has been made of this technique (Yewdell and






STRAIN COMPARISON OF BOVINE CORONAVIRUSES
Introduction
The BCVs studied to date all belong to a single serotype.
Isolates have shown only minor variations in their physicochemical
properties (Dea et al, 1980b), in their behaviour with polyclonal
sera in counterimmunoelectrophoresis and immunodiffusion tests (Dea
et al, 1982), and in their reactions with polyclonal sera and MAbs
in ELISAs, IF, SN and HAI tests (Vautherot and Laporte, 1983;
Czerny and Eichhorn, 1989; Deregt et al, 1989a; El-Ghorr et al,
1989). MAbs have detected variations in both the S and HE gps in
these tests. Studies undertaken so far have been limited to
examining a relatively small number of viruses because of the
problems associated with BCV isolation. The in vivo significance
of these antigenic variations is unclear at present, but Deregt et
al (1989a) found that a MAb which neutralised the parent strain of
BCV in vitro failed to protect against a heterologous strain in
vivo. probably due to lack of epitope conservation between the 2
strains.
Five standard strains of BCV (SI, S2, CK, M and PQ) were
first examined with polyclonal sera in cross IF and SN tests, and
with MAbs raised against S2 strain BCV (S2 MAbs) in IF, SN and HAI
tests. In order to widen the investigation, 28 viruses were
isolated from diarrhoeic calf faecal samples in TOC (TOC isolates)
and screened against the MAbs in ELISAs and HAI tests. From the
results of these tests, 7 viruses were chosen for adaptation to
growth in HRT-18 cells (MRI BCV isolates). The S2 MAbs were
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titrated against these isolates in IF, SN and HAI tests, and
rabbit anti-S2 serum (serum 5317) was also titrated in SN tests.
The MWs of the structural proteins of the 5 standard BCV strains
and the 7 MRI isolates were then compared by separating the
proteins by SDS-PAGE, blotting them onto nitrocellulose paper and
probing with calf anti-S2 serum (serum 5920).
Results
Tabulation of Ab titres
Duplicate titres were obtained in all IF, SN and HAI tests, and
were found to lie within 4-fold (generally 2-fold) ranges. The
values given in the tables (Tables 6.1, 6.2, 6.5, 6.6, 6.7, 6.11,
6.14, 6.15, 6.16, 6.17 and 6.18) are the geometric means of these
duplicate titres, rounded off to the nearest 10. Homologous titres
are shown underlined. Heterologous titres which differ by more
than 8-fold from homologous titres are taken to indicate the
presence of antigenic variations, and these titres are shown boxed.
An 8-fold difference was chosen as the level of significance
because this was twice the maximum difference ever detected between
duplicate tests.
Standard BCV strains: Polyclonal sera
IF and SN tests
Rabbit polyclonal sera had previously been raised by Dr. A.
El-Ghorr at the MRI against the 5 standard BCV strains (SI, S2,
CK, M and PQ). These were titrated by the candidate in cross IF and
SN tests (Tables 6.1 and 6.2). Cross HAI tests were not performed,
as the HAI titres were very low (< 40).
215
Table 6.1
Mean IF titres with standard BCV strains and polyclonal sera.
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216
Table 6,2
Mean SN titres with standard BCV strains and polyclonal sera.



























*Geometricmeansfduplicateresults,oundedffthn are t10. Homologoustitresareunderlined.
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The antigenic relationships (R values) between the 5 BCV strains
determined in IF and SN tests were calculated from a formula
similar to that used by Archetti and Horsfall (1950):
R = 100 J rl x r2 %
where rl = heterologous titre (strain 2)/homologous titre (strain 1)
r2 = heterologous titre (strain 1)/homologous titre (strain 2)
The closer the R values to 100%, the greater the antigenic
similarity between the viruses. R values < 12.5% indicate the
presence of antigenic variations between 2 viruses, as this
corresponds to heterologous titres which differ by more than 8-fold
from homologous titres. The results shown in Tables 6.3 and 6.4
indicate that these 5 strains are serologically very closely
related.
Standard BCV strains: S2 MAbs
IF tests
The 8 S2 MAbs were titrated in IF tests against the 5 standard
BCV strains (Table 6.5). Strain variations were only detected with
MAb S2/5 (N), which reacted to a significant titre with the parent
(S2) virus only.
SN tests
The 4 HE MAbs and the single S MAb were titrated in SN tests
against the 5 standard BCV strains (Table 6.6). All the MAbs
neutralised all the virus strains, apart from MAbs S2/3 and S2/4
which both failed to neutralise strains CK and M (SN titres <100).
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Table 6.3
The antigenic relationships (R values) of the 5 standard BCV
strains as determined by IF tests.




























The antigenic relationships (R values) of the 5 standard BCV
strains as determined by SN tests.
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Table 6.6
Mean SN titres with standard BCV strains and S2 MAbs.
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HAI tests
The 4 HE MAbs were titrated against the 5 standard BCV strains
in HAI tests (Table 6.7). No strain variations were detected, as
heterologous titres were all within 8-fold ranges of the homologous
(S2) virus titres.
TOC isolates: S2 MAbs
The S2 MAbs were used in ELISAs and HAI tests to screen 28 TOC
isolates for strain variations.
ELISAs
The 8 MAbs were used as coating Abs to capture the test viruses
in ELISAs. Chequerboard titrations of the coating MAbs and
detecting Ab (rabbit anti-PQ serum, serum 5324) were first
performed to find the optimal dilutions which gave OD values of
about 1.0 with a positive control antigen. The optimal dilutions
of the MAbs are shown in Table 6.8. Serum 5324 was used at a
dilution of 1:50,000 in all tests. The specificities of the tests
were confirmed by including MI TOC harvests as negative controls
and by blocking positive signals with lamb anti-BCV serum, serum
5000.
The 28 TOC isolates were tested against the 8 MAbs in the ELISAs
at standard HA titres of 32. Positive control wells containing S2
virus and negative control wells containing MI TOC harvests were
included on all test plates. The mean OD values obtained from
duplicate test and control wells are shown in Table 6.9. The first
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Table 6.7
Mean HAI titres with standard BCV strains and S2 MAbs.










































Mean OD values obtained in ELISAs with TOC isolates and S2 MAbs
MAbs
Virus HE s N
S2/1 S2/3 S2/4 S2/7 S2/2 S2/5 S2/6 S2/8
K2595/1 0.96 1.09 1.15 1.26 0.58 0.84 1.21 0.61
K2595/2 1.13 1.10 1.23 1.32 0.60 0.91 1.27 0.68
L1096 0.98 0.73 1.10 1.24 1.01 1.19 1.30 0.67
L1121 1.04 0.98 1.23 1.30 1.09 1.48 1.40 0.50
L1209 1.00 1.13 1.26 1.37 1.07 1.49 1.47 0.61
L1217 0.93 0.85 0.97 1.16 0.21 0.73 1.07 0.68
L1280/2 0.67 0.56 0.92 1.12 0.42 0.75 0.93 0.55
L1354/2 0.83 0.88 1.03 1.17 0.51 0.70 0.99 0.55
L3080 0.75 0.82 0.97 1.11 0.15 0.68 1.03 0.58
L3I40/1 0.73 0.62 0.89 1.06 0.74 1.02 1.14 0.96
L3140/2 0.73 0.75 0.92 1.07 0.46 0.62 0.92 0.70
L3140/3 0.88 0.86 1.06 1.20 0.71 1.10 1.27 0.98
L3228 1.02 1.05 1.12 1.23 0.54 0.79 1.12 0.64
L3275 1.02 1.08 1.16 1.22 0.27 1.13 1.31 0.72
L3318 0.96 1.06 1.19 1.26 0.73 1.14 1.32 0.69
L3352 0.13 1.01 1.06 1.22 0.75 0.80 1.02 0.57
L3372 0.21 0.84 1.02 1.19 0.70 0.79 1.15 0.91
L3472 0.95 0.98 1.03 1.26 0.70 0.92 1.12 1.00
S2 1.27 1.23 1.14 1.32 1.44 0.80 1.13 0.61
Ml TOC 0.17 0.16 0.11 0.09 0.23 0.25 0.12 0.23




Virus HE s N
S2/1 S2/3 S2/4 S2/7 S2/2 S2/5 S2/6 S2/8
N164 0.56 0.66 0.93 1.10 0.15 0.73 1.08 0.87
N225 0.22 0.80 1.02 1.15 0.59 0.84 1.09 0.46
N1193 1.09 0.99 1.15 1.34 0.80 1.13 1.26 0.74
N1334 0.32 1.12 1.21 1.37 1.14 1.26 1.31 0.89
N1258/2 1.05 1.05 1.15 1.34 0.94 1.26 1.31 0.75
0011 1.18 1.27 1.26 1.40 0.14 0.87 1.37 0.68
S2 1.27 1.23 1.14 1.32 1.44 0.80 1.13 0.61
MITOC 0.17 0.16 0.11 0.09 0.23 0.25 0.12 0.23
L3032 0.94 0.63 1.07 1.23 0.55 1.19 1.34 0.85
N339 1.05 0.76 1.18 1.39 0.60 1.31 1.39 0.47
N539 0.78 0.80 1.26 1.45 0.65 1.21 1.47 0.93
N710 0.91 0.64 1.06 1.26 0.47 1.21 1.30 0.59
S2 1.49 0.99 1.34 1.48 1.32 1.13 1.50 0.64
MITOC 0.18 0.10 0.10 0.09 0.17 0.29 0.14 0.24
OD values obtained with the homologous virus are underlined.
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24 samples (K2591/1 to 0011) were tested on a different set of
ELISA plates to the remaining 4 samples (L3032 to N710). The OD
values obtained in the positive and negative control wells differed
slightly between the 2 sets of plates, so the control OD values
obtained with each batch of samples have been indicated in this
table.
The binding of the test samples with each MAb was compared with
that of the parent S2 virus by expressing the mean OD values (ODt)
obtained in duplicate test wells as percentages of the mean OD
values (ODs) obtained with S2 virus grown in TOO (%0Dt) (Dea and
Tijssen, 1989a; Taguchi and Fleming, 1989). Since there were
variations in the degree of non-specific binding of MI TOO harvests
to the different MAbs (ODc values - 0.09 - 0.29), the mean ODc
values were subtracted from the OD values used to calculate the %
ODt values. The final equation was therefore:
(ODt - ODc)
%0Dt = x 100
(ODs - ODc)
Where ODt = mean OD with test sample
ODc = mean OD with MI TOC harvest
ODs = mean OD with S2 virus
The calculated %0Dt values are given in Table 6.10, and the
number of TOC isolates having %0Dt values within appropriate ranges
are shown in Figs. 6.1 and 6.2. %0Dt values <25% were taken to
indicate the presence of significant antigenic variations from S2
virus. This cut off value had previously been used by Dea and
Tijssen (1989a) during a series of similar ELISAs designed to
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Table 6.10
% OD values* obtained in ELISAs with TOC isolates and S2 MAbs
MAbs
Virus HE S N
S2/1 S2/3 S2/4 S2/7 S2/2 S2/5 S2/6 S2/8
K2595/1 72 86 101 94 29 106 107 99
K2595/2 87 87 109 100 31 119 114 117
L1096 73 53 96 93 65 170 117 114
L1121 79 76 108 98 71 224 127 70
L1209 76 90 111 103 70 226 133 100
L1217 69 64 84 87 0 87 94 118
L1280/2 46 37 79 83 16 90 80 84
L1354/2 60 66 89 87 23 81 86 83
L3032 58 59 79 82 33 107 89 151
L3080 52 61 83 83 0 78 90 91
L3140/1 51 43 75 78 42 139 100 192
L3140/2 56 55 79 79 19 66 79 122
L3140/3 64 65 92 90 39 154 114 197
L3228 77 83 97 92 26 98 99 107
L3275 77 85 102 91 3 159 118 129
L3318 72 84 104 95 41 162 119 121
L3352 0 79 92 91 43 100 89 88
L3372 4 63 88 89 39 98 97 178
L3472 71 76 89 95 39 121 99 203




Virus HE S N
S2/1 S2/3 S2/4 S2/7 S2/2 S2/5 S2./6 S2/8
N225 4 60 88 85 29 107 96 59
N339 66 73 87 93 37 121 92 56
N539 46 78 95 98 41 109 98 173
N710 55 60 78 84 26 109 85 88
N1193 83 77 100 101 47 159 112 134
N1334 14 89 106 104 76 183 117 174
N1258/2 80 83 101 101 59 183 118 137
0011 92 104 111 106 0 112 123 117
S2 100 100 100 100 100 100 100 100
* % OD values given by : ODt - ODc x -j 0g Where ODt = mean OD with test sample
ODs-ODc ODc = mean OD with Ml TOC
ODs = mean OD with S2 virus
For the HE and N MAbs, % OD values < 3.5 % are shown by:
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Figure 6,1
Distribution of %0Dt values obtained in ELISAs with TOC
isolates and MAbs S2/1, S2/3, S2/4 and S2/7.
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investigate the extent of antigenic variation amongst TCVs. The
results obtained with MAb S2/1 clearly demonstrate that this cut
off value was also appropriate to these studies, as it defined 2
distinct populations of viruses. The majority of TOC isolates
bound strongly to this MAb giving relatively high %ODt values,
whilst 4 isolates either failed to bind or only bound very weakly
to this MAb (%ODt values < 14). The other 3 HE MAbs (S2/3, S2/4
and S2/7) and the 3 N MAbs (S2/5, S2/6 and S2/8) failed to detect
antigenic variations amongst the TOC isolates. The results
obtained with MAb S2/2 were more difficult to interpret, as a wide
range of %ODt values were obtained which failed to define distinct
populations of viruses. For this MAb, it was clearly
inappropriate to take <25% as a cut off value indicative of the
presence of antigenic variation.
HAI tests
Ascitic fluids containing the 4 HE MAbs (S2/1, S2/3, S2/4 and
S2/7) were titrated against 8 HA units of each of the TOC isolates.
The geometric mean titres obtained from duplicate wells are shown
in Table 6.11. MAb S2/8 (N) was used as a negative control: at a
dilution of 1:10 it failed to inhibit the haemagglutination caused
by any of the test viruses. S2 virus grown in TOC was used as a
positive control. HAI titres which lay beyond an 8-fold range of
those obtained with S2 virus were taken to indicate the presence of
antigenic variations. MAbs S2/3 and S2/4 failed to detect any
strain variations, but 7 viruses reacted weakly with MAb S2/1, 2
of which also reacted weakly with MAb S2/7.
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Table 6.11
Mean HAI titres* with TOC isolates and S2 MAbs
Virus
S2/1
Mean HAI titres to MAbs :
HE
S2/3 S2/4 S2/7
K2595/1 160 450 450 160
K2595/2 450 1280 640 450
L1096 320 450 320 230
L1121 320 640 1280 910
L1209 160 640 450 230
L.1217 160 640 640 160
L1280/2 30 320 320 60
L1354/2 80 640 640 160
L3032 450 640 640 450
L3080 640 1280 1280 640
L3140/1 230 640 640 320
L3140/2 320 910 640 320
L3140/3 640 640 640 450
L3228 160 450 640 160
L3275 230 910 640 450
L3318 320 2560 1280 1280
L3352 30 910 910 450








L3472 910 1280 1280 640
N164 30 640 640 110
N225 40 1280 1280 640
N339 320 910 910 640
N539 160 2560 2560 910
N710 450 910 640 450
N1193 640 1280 640 640
N1334 30 640 640 450
N1258/2 230 1280 1280 320
0011 <10 1280 910 640
S2 640 640 640 1280
*Geometric means of duplicate results, rounded off to the nearest 10.
Homologous litres are underlined, and titres > 8 - fold different from the homologous
titres are shown by I I .
235
On the basis of the results obtained in the ELISAs and HAI
tests, 7 of the TOO isolates were chosen for adaptation to growth
in HRT-18 cells (Chapter 3). These viruses were then referred to as
the MRI BCV isolates.
MRI BCV isolates: S2 MAbs
ELISAs
The 7 MRI BCV isolates were tested against the 8 S2 MAbs in
ELISAs at standard HA titres of 32. The mean OD values obtained
from duplicate test and control wells are shown in Table 6.12. The
viruses were again tested in 2 batches, so the control OD values
obtained with each batch are indicated on the table. These results
were then used to calculate the %ODt values shown in Table 6.13,
and these have been plotted as histograms in Figs 6.3 and 6.4. The
results were similar to those previously obtained using TOC
harvests. MAb S2/1 again defined 2 distinct populations of virus,
with 3 viruses (L3352, L3372 and N225) reacting weakly with this
MAb. The other 3 HE MAbs and the 3N MAbs failed to detect
antigenic variations. A wide range of %ODt values were obtained
with MAb S2/2, but a clear cut off value could not be defined.
IF tests
The 8 S2 MAbs were titrated against the 7 MRI BCV isolates in IF
tests (Table 6.14). The results were consistent with those obtained
in the ELISAs. Three viruses (L3352, L3372 and N225) reacted weakly
with MAb S2/1 (HE) and 2 viruses (N164 and 0011) reacted weakly
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Table 6.12
Mean OD values obtained in EUSAs with MRI BCV isolates and S2 MAbs
MAbs
Virus HE S N
S2/1 S2/3 S2/4 S2/7 S2/2 S2/5 S2/6 S2/8
L3352 0.13 1.24 1.56 1.50 1.01 1.18 1.50 0.73
L3372 0.14 1.33 1.65 1.56 1.20 1.21 1.69 0.79
N539 0.80 1.05 1.39 1.49 0.62 0.48 1.08 0.71
0011 0.72 1.06 1.43 1.63 0.33 0.53 1.41 0.64
S2 1.21 1,53 1.54 1.66 1,58 0-86 1.34 0.85
MIHRT-18
cells
0.08 0.10 0.08 0.08 0.19 0.17 0.15 0.16
N225 0.05 0.43 0.62 0.62 0.40 0.46 0.74 0.18
L3080 0.39 0.49 0.67 0.62 0.19 0.37 0.69 0.20
N164 0.34 0.39 0.49 0.50 0.15 0.34 0.58 0.20
S2 0.48 0.57 0,66 0.63 0.55 0.23 0.54 0.29
MIHRT-18
cells
0.02 0.02 0.01 0.02 0.04 0.01 0.02 0.02
OD values obtained with the homologous virus are underlined.
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Table 6.13
% OD values* obtained in EUSAs with MRI BCV isolates and S2 MAbs
MAbs
Virus HE S N
S2/1 S2/3 S2/4 S2/7 S2/2 S2/5 S2/6 S2/8
L3352 4 79 101 90 59 93 113 83
L3372 5 86 108 94 72 151 129 91
N225 m 75 94 98 71 205 136 65
N539 63 66 90 89 31 45 78 80
L3080 80 85 102 98 29 164 127 71
N164 68 67 74 80 22 150 107 69
0011 56 67 92 98 10 51 106 69
S2 100 100 100 100 100 100 10Q 100
* % OD values given by : ODt - ODc x -| 00 Where OD t = mean OD with test sample
ODs - ODc ODc = mean OD with Ml HRT-18 cells
ODs = mean OD with S2 virus
For the HE and N MAbs, % OD values < a.5% are shown by:
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Figure 6,3
Distribution of %ODt values obtained in ELISAs with MRI
BCV isolates and MAbs S2/1, S2/3, S2/4 and S2/7.
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Distribution of %ODt values obtained in ELlSAs with
MRI BCV isolates and MAbs S2/2, S2/5, S2/6 and S2/8.
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L3352 L3372 N225 N539 L3080 N164 0011 S2
1600 4530 1130 >102400 >102400 >102400 >102400 102400
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with MAb S2/2 (S). The titre obtained with MAb S2/2 and L3080 was
on the edge of the previously defined limit of significance.
HAI tests
The 4 MAbs directed against the HE gp of S2 strain BCV were
titrated against the 7 MRI isolates in HAI tests (Table 6.15). The
ascitic fluids containing MAbs S2/1, S2/4 and S2/7 were from
different stocks to those previously used in Table 6.7: the titres
reported for S2 virus are therefore different. Strain variations
were only detected in these tests by MAb S2/1, which reacted to low
titres with L3352, L3372 and N225. These results were consistent
with those obtained in ELISAs and IF tests.
SN tests
The 5 MAbs directed against the HE and S gps of S2 strain BCV
were titrated against the 7 MRI isolates in SN tests (Table 6.16).
The 4 HE MAbs distinguished all the MRI isolates from S2 strain
virus, and 3 viruses (L3080, N164 and 0011) were also distinguished
by the S MAb (S2/2).
MRI BCV isolates: Polyclonal sera
SN tests
Rabbit anti-S2 serum (serum 5317) was titrated against the MRI
BCV isolates in SN tests (Table 6.17). Strain variations were not
detected with this polyclonal serum, as the SN titres obtained with
the heterologous isolates all lay within an 8-fold range of that
obtained with the homologous (S2) virus.
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Table 6.15
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Table 6,16
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*Geometric means of duplicate results, rounded off to the nearest 10.
The homologous titre is underlined.
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Standard BCV strains and MRI isolates: CVL MAbs
IF tests
The MAbs directed against BCV strain CVL were titrated in IF
tests against the 5 standard BCV strains and 4 of the MRI isolates
(Table 6.18). The titres obtained were difficult to interpret
because the parent virus was not available for comparison. The
maximum variations in the titres obtained with MAbs 5528 (M), 5529
(S), 5530 (S) and 5531 (HE) were 6, 8, 11 and 64-fold respectively.
This strongly suggests that MAb 5531 (HE) at least is detecting
antigenic variations amongst these isolates.
Western blottine
Ultracentrifuge pellets of the 5 standard strains of BCV and the
7 MRI isolates were prepared. The infectivity (IT) and HA titres
were measured and the protein concentrations estimated using a
Pierce BCA Protein Assay Kit (Table 6.19). The results demonstrate
that the preparations showed some variation in the amounts of virus
present, particularly the SI and L3080 pellets which had low
infectivity and HA titres.
30 ul of each pellet were boiled for 90 sec with 30 ul 2 x LSB
(no ME). The proteins were separated by SDS/PAGE and
electrophoretically transferred to nitrocellulose paper. Staining
of the blotted proteins with Ponceau S revealed many bands (Fig.
6.5). Efficient protein transfer had occurred as bands stained on
the gel with Coomassie Brilliant Blue were extremely faint.
Blotted proteins from the SI virus preparation stained particularly




Mean IF titres with standard BCV strains or MRI isolates
and CVL MAbs.




























































S2 960 8.8 51200
S1 2135 5.8 800
M 1130 7.8 25600
PQ 2015 8.8 12800
CK 3100 6.8 12800
L3352 1440 7.3 12800
L3372 1430 7.3 6400
0011 1080 7.3 6400
N539 2185 7.8 12800
N225 2425 6.8 12800
N164 2040 7.3 12800
L3080 1460 6.3 3200
* IT measured as log TCID50 / ml.
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Figure 6.5
Comparison of 12 isolates of BCV by Western blotting:
Blotted proteins stained with Ponceau S
(non-reducing conditions')
The virus proteins were separated by SDS/PAGE and
electroblotted onto nitrocellulose paper. Blotted
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The viral proteins were probed with gnotobiotic calf anti-S2
serum (serum 5920) at a dilution of 1:4. Bound Abs were detected
with anti-sheep HRP conjugate and 4-chloro-l-naphthol substrate
solution (Fig. 6.6). Bands corresponding to the HE, S, N and M
proteins of the majority of virus isolates were clearly visible
after probing. No bands were detected with a PBS negative control
probe (data not shown). This experiment confirms that the proteins
of the heterologous viruses are antigenically related to those of
S2 virus. The MWs of the HE, N and M proteins of the 13 viruses
were very similar. Slight variations in the MWs of the S gps were
apparent, but these may have been artefacts of protein separation.
Shortage of time precluded probing blotted viral proteins with the
MAbs.
Discussion
Antigenic variations amongst virus isolates are most efficiently
detected using a combination of polyclonal sera and MAbs.
Polyclonal sera detect broad differences between viruses and MAbs
detect minor antigenic variations. The results obtained using MAbs
should be interpreted with caution. They may emphasise antigenic
similarities between viruses which are otherwise largely dissimilar
and they may detect minor variations which are of no relevance in
vivo.
Standard BCV strains
Polyclonal sera raised against the 5 standard BCV strains failed
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Figure 6,6
Comparison of 12 isolates of BCV by Western blotting:
Virus proteins probed with gnotobiotic calf anti-S2
serum
(non-reducing conditions')
The virus proteins were separated by SDS/PAGE and
electroblotted onto nitrocellulose paper. Blotted
proteins were probed with gnotobiotic calf anti-S2 serum
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to detect antigenic variations in cross IF and SN tests. MAbs
raised against S2 virus detected antigenic differences on the HE gp
in SN tests (MAbs S2/3 and S2/4 failed to neutralise strains CK and
M) and on the N protein in IF tests (MAb S2/5 only reacted with the
parent S2 virus). This is the first time that antigenic variations
have been reported on the N protein of BCV.
TOC isolates
The TOC isolates were first screened for antigenic variations
using the S2 MAbs as coating Abs in ELISAs. Polyclonal rabbit
anti-PQ serum (serum 5324) was chosen as the detecting Ab for all
tests. None of the TOC isolates gave low OD readings with all the
MAbs, which demonstrated that this polyclonal serum bound
adequately to all the test viruses. Low %ODt values were therefore
indicative of variations detected by the MAbs.
The viruses were standardised in the ELISAs by testing them all
at the same HA titre. This method was chosen as measurement of HA
titres was the simplest means of quantifying the viruses present in
TOC harvests. At the time these experiments were performed, this
was considered to be appropriate for the HE MAbs but less
appropriate for the S and N MAbs. Since then, questions have been
raised as to whether the HE gp is indeed the viral haemagglutinin,
or whether the S gp is responsible for haemagglutination (Storz et
al. personal communication). The method of standardisation may
account for the rather low %ODt values obtained with MAb S2/2 (S)
and the high (often >100) values obtained with the N MAbs. Seven
of the TOC isolates were later adapted to growth in HRT-18 cells
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(MRI BCV isolates). These viruses gave very similar results when
tested in ELISAs and IF tests, which suggests that adequate
standardisation of the ELISAs had in fact been achieved.
Antigenic variations were detected in the ELISAs by MAbs S2/1
and S2/2 only. Two clear populations of viruses were defined by
MAb S2/1, as either moderate to high (>35) or very low (<14) %ODt
values were obtained. This suggests that the epitope recognised by
this MAb is either present or absent on these viruses. The results
obtained with MAb S2/2 are harder to interpret, as a wide range of
%ODt values were obtained with no clear cut off point. These
results suggest that the epitope recognised by this MAb shows a
range of variation amongst different virus isolates. An
alternative explanation is that the fragile peplomers were lost to
a greater extent from some of the viruses.
The TOC isolates were also screened against the S2 MAbs in HAI
tests, and the results were similar to those obtained in the
ELISAs. The 4 TOC isolates (L3352, L3372, N225, N1334) which
reacted weakly with MAb S2/1 in ELISAs also reacted weakly with
this MAb in HAI tests. Three viruses (L1280/2, N164 and 0011)
reacted moderately or strongly with MAb S2/1 in ELISAs but gave
only weak reactions with this MAb in HAI tests. Two of these
viruses, L1280/2 and N164, also reacted strongly with MAb S2/7 in
ELISAs but gave only weak reactions with this MAb in HAI tests.
Both MAbs S2/1 and S2/7 reacted to high HAI titres with 2 of these
viruses (N164 and 0011) after they had been adapted to growth in
cell culture. The low HAI titres obtained with the TOC harvests
may have been artefacts caused by the presence of high levels of
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subviral components or non-specific haemagglutinins. An
alternative explanation is that the viruses were modified by
adaptation to cell culture.
MRI BCV isolates
The MAbs behaved very similarly with the MRI isolates in ELISAs,
IF and HAI tests (Table 6.20). Three viruses (L3352, L3372 and
N225) reacted weakly with MAb S2/1 in all 3 tests and another 3
viruses (L3080, N164 and 0011) reacted weakly with MAb S2/2 in
ELISAs and IF tests. SN tests were the most sensitive method for
detecting antigenic variations. Four of the MRI isolates (L3352,
L3372, N225 and N539) were strongly neutralised by the S MAb
(S2/2) but were not neutralised by the HE MAbs. The remaining 3
MRI isolates (L3080, N164 and 0011) were not significantly
neutralised by any of the MAbs. These tests demonstrate that the
former group of viruses differ antigenically from S2 strain virus
in their HE gp whilst the latter group of viruses differ in both
their HE and S gps.
Comparison of the results obtained in ELISAs and IF tests with
those obtained in SN tests demonstrates that the HE MAbs can bind
to virus particles without neutralising them. This phenomenon has
also been reported by Iorio and Bratt (1984). In contrast to the
HE MAbs, the S MAb (S2/2) only bound in ELISAs and IF tests to
virus isolates which it also neutralised (Table 6.20). There are
several possible explanations to account for why the HE MAbs could
bind to certain virus isolates whilst failing to neutralise them.
The epitopes to which these MAbs bound may have had slight
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Table 6.20
Summary of results of IF,HAI and SN tests
with MRI BCV isolates and S2 MAbs
This table only includes the MAbs which detected antigenic variations
+ = titres within 8 - fold range of S2 titre
- = titres beyond 8 - fold range of S2 titre
Test IF HAI SN
HE S HE HE s
MAb
S2/1 S2/2 S2/1 S2/4 S2/7 S2/2
L3352 — + — — +
L3372 - + - - +
N225 - + - - +
Virus N539 + + + - +
L3080 + + + - -
N164 + - + - -
0011 + - + - -
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structural alterations or been present in reduced numbers in these
virus isolates, thereby preventing binding of sufficient levels of
MAb to cause neutralisation. If neutralisation was mediated by
binding of Abs to cell receptor sites on virus particles, failure
to neutralise may have been caused by the MAbs binding to sites
other than the cell receptor sites. Alternatively, if
neutralisation was mediated by an Ab induced change in virus
surface configuration, failure to neutralise may have been caused
by failure of bound Ab to initiate the appropriate structural
changes.
Rabbit anti-S2 serum (serum 5317) failed to detect antigenic
variations amongst the 7 MRI isolates in SN tests. This suggests
that the antigenic differences detected by the MAbs may not be
relevant when using polyclonal sera, and may not therefore be
important in vivo. Shortage of time precluded purifying these
viruses and raising polyclonal sera for use in cross SN tests.
Conclusions
This is the most comprehensive investigation of BCV strain
variation which has been undertaken to date. The results support
those obtained by other groups: strain variations do occur, but
they are not sufficiently great as to suggest the existence of more
than one serotype of the virus (Vautherot and Laporte, 1983;
El-Ghorr et al, 1989). In these experiments strain variations
were never detected with polyclonal sera in IF and SN tests, and
extensive cross reactions occurred when gnotobiotic calf anti-S2
serum (serum 5920) was used to probe blotted viral proteins of
heterologous isolates.
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MAbs raised against S2 strain BCV detected antigenic variations
on the N, S and HE proteins. Antigenic variations were only
detected on the N protein of standard strains SI, CK, M and PQ, and
not on any of the TOC or MRI BCV isolates. It may have been
significant that the latter viruses were all isolated from faecal
samples collected in Scotland between 1987 and 1989. In contrast,
whilst SI strain was also isolated in Scotland, strains CK, M and
PQ originated from England, America and Canada respectively, and
these strains were all isolated from faecal samples collected
before 1987.
MAbs detected wide antigenic variations on the S and HE gps of
BCV isolates. These proteins are likely to vary more than the N
protein, as the host's immunological responses exert a greater
selection pressure on proteins bearing neutralising epitopes.
Antigenic variations were more commonly detected on the MRI
isolates than on the standard BCV strains. This was not unexpected
as the MRI isolates had been selected from a large number of TOC
isolates on the basis of results obtained in ELISAs and HAI tests.
The significance of the antigenic variations detected by the
MAbs is unclear at present. Antigenic variations which are only
detected using MAbs can be important clinically. The CVs TGEV and
PRCV are indistinguishable with polyclonal sera but may be
differentiated with a MAb (Callebaut et al, 1989) . Some field and
vaccine strains of rabies virus are only distinguished using MAbs:
these antigenic variations may be responsible for apparent vaccine
breakdowns (Yewdell and Gerhard, 1981). The variations detected
amongst the BCV isolates may affect viral pathogenicity (virulence
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and organ tropism) and may explain the occurrence of the different
clinical syndromes associated with BCV. It is important to
establish whether heterotypic immunity occurs between different
BCV strains as this affects the choice of antigens for vaccine
production.
Any study of strain variation is limited by the number of virus
isolates and the availability of polyclonal sera and MAbs. In
these experiments all the viruses had been isolated from diarrhoeic
calf faeces. The MRI isolates all originated from faecal samples
which had been collected in Scotland between 1987 and 1989, and
which were found to contain BCV on the basis of the results
obtained in a diagnostic ELISA. At the start of this period, lamb
anti-BCV (strains SI and CK) serum (serum 5000) was used as the
capture Ab in this assay. This polyclonal serum was later replaced
by MAb S2/1, which may have influenced the BCV strains detected.
The study could have been improved by including more MAbs and by
examining isolates which had been obtained from a larger
geographical area and collected over a longer period of time.
Future work should aim at establishing whether BCVs associated with
respiratory infections in calves and winter dysentery in adult
cattle are identical to the calf enteric strains. Limited
investigations with polyclonal sera and MAbs suggest that the calf
enteric and respiratory strains are identical (Thomas et al, 1982;
Vautherot and Laporte, 1983; McNulty et al, 1984; Reynolds et
al, 1985). Reports comparing calf enteric isolates with winter
dysentery isolates offer conflicting results (Akashi et al, 1980;
Benfield and Saif, 1990).
258
The antigenic variations detected on the BCV isolates in these
experiments also provide information on the epitope specificities
of the MAbs. This has already been discussed in conjunction with








ANIMAL MODELS OF BOVINE CORONAVIRUS INFECTION
Introduction
The ability to reproduce infectious diseases in animals kept
under experimental conditions facilitates study of the disease and
permits challenge experiments to be performed in which protective
antigens can be identified and different strains of the agent
examined for their abilities to cross protect. Animal models of
infection are also essential for vaccine development.
Gnotobiotic, SPF and colostrum-deprived conventional calves
have been widely used as models of BCV infection. Following oral
or intranasal inoculation, calves develop diarrhoea 1-5 days
later. Diarrhoea lasts for 2 to 5 days, and is accompanied by
virus excretion in the faeces. Virus is also excreted from the
upper respiratory tract, but excretion is only occasionally
accompanied by mild clinical signs (Mebus et al, 1975; Bridger et
al. 1978b; Crouch et al, 1984; McNulty et al, 1984; Reynolds e_t
al, 1985; Singh et al, 1985; Saif et al, 1986; Saif, 1987;
Heckert et al, 1989; Kapil et al, 1990).
Attempts have been made to establish a small animal model of BCV
infection, which would enable experiments to be performed on larger
numbers of animals at a greatly reduced cost. In the ideal small
animal model, oral inoculation with BCV would result in diarrhoea,
accompanied by virus excretion in the faeces. El-Ghorr (1988)
investigated the possibility of reproducing diarrhoea in
gnotobiotic lambs and neonatal mice by oral inoculation with BCV.
Gnotobiotic lambs proved unsuitable as models of BCV infection, as
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only 1 out of 5 lambs developed diarrhoea after inoculation with
the virus. Neonatal mice have been used as a model system for
bovine rotavirus infections (Ramig, 1988), but attempts made by
El-Ghorr (1988) to produce diarrhoea by oral inoculation with BCV
were inconclusive. Fifteen percent of mice (12 out of 79 mice)
developed diarrhoea after inoculation with cell culture harvest
virus. This proportion increased to 70% (7 out of 10 mice)
following inoculation with concentrated virus, but 50% of control
mice (5 out of 10) inoculated with concentrated MI HRT-18 cell
harvests also developed diarrhoea.
In common with many CVs (Wege et al, 1982), BCV has been
successfully adapted to grow in the brains of suckling mice
following intracerebral inoculation (Kaye et al, 1975;
Bengelsdorff, 1988). The mice generally develop symptoms of
encephalitis followed by death 4-5 days pi (Akashi et al, 1981;
Gerna et al, 1981). Barthold et al (1990) demonstrated that
intranasal inoculation of 1 day old mice could also cause
encephalitis. No lesions were detected in either the respiratory
or enteric tracts after intranasal inoculation. BCV at the third
passage level in mouse brain caused death in 1 day old mice, rats
and hamsters when inoculated by the intracerebral or subcutaneous
routes (Akashi et al, 1981). These model systems are of very
limited use for studying BCV infections, as they bear no
resemblance to the disease which occurs under natural conditions.
Bengelsdorff (1988) did however demonstrate that female mice
vaccinated against BCV successfully transferred maternal immunity
to their offspring, rendering them immune to challenge with the
adapted BCV strains.
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Further trials were performed to assess the possibility of using
neonatal mice as experimental models of BCV enteric infection, and
attempts were also made to infect a gnotobiotic piglet. A
gnotobiotic calf was then inoculated with BCV by the oral and
intransal routes. Virus excretion from the respiratory and enteric
tracts was monitored, and the serological response studied.
Results
Neonatal mice
The possibility of using neonatal mice as models of BCV enteric
infection was investigated. Litters of neonatal mice derived from
stocks supplied to the MRI as MHV-free were raised under
conventional conditions. Each mouse was inoculated with 0.1 ml of
virus or control (MI HRT-18 cell harvest) preparation into the
upper oesophagus, and monitored daily for up to 6 days for the
presence of diarrhoea. When diarrhoea was present, gentle
abdominal pressure resulted in the excretion of semi-fluid, yellow
faeces. Unaffected mice either failed to excrete any faeces or
excreted firm yellow or brown faeces when abdominal pressure was
applied. Mice which died within 2 days of inoculation were
excluded from the results. The percentage of mice which developed
diarrhoea for at least 1 day of the trial was calculated, and the
results obtained from non-infected mice and mice inoculated with
virus or the control preparation compared.
In preliminary trials, 6 out of 26 mice (23%) developed
diarrhoea after inoculation with PQ virus harvested from cell
culture (IT = 5.3, HA titre = 80), whilst 13 out of 18 mice (72%)
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developed diarrhoea after inoculation with concentrated PQ virus
(IT =7.8, HA titre = 400). S2 strain BCV was used in subsequent
experiments because it could be grown to a higher titre than PQ
virus. It was grown on HRT-18 cells, and concentrated by
ultracentrifugation prior to inoculation.
Two trials (A and B) were conducted, and in each the baby mice
were split into 3 groups of litters. One group did not receive any
inoculum. The mice in a second group were each given 0.1 ml of
concentrated MI HRT-18 cells (IT = <2.3, HA titre = <10), whilst
those in the third group were each given 0.1 ml of concentrated S2
virus (in trial A, IT = 7.8, HA titre = 25600; in trial B, IT =
8.8, HA titre = 163,840). The mice were monitored daily for 4 days
for the presence of diarrhoea. In trial A the mice were monitored
by the candidate, whilst in trial B the mice were monitored by Dr.
F. Scott of the MRI who had had considerable experience in
monitoring mice infected with bovine rotavirus.
The results of trials A and B are summarised in Table 7.1.
Statistical analysis was performed by Dr. Frank Wright of the
Scottish Agricultural Statistics Service. 71% of the mice in trial
A and 51% in trial B developed diarrhoea after inoculation with S2
virus. A high proportion of mice inoculated with MI HRT-18 cells
also developed diarrhoea: 21% in trial A and 47% in trial B.
Three mice in trial A which had not received any inoculum also
developed diarrhoea. The results obtained in the 2 trials were
pooled and analysed. Inoculation of mice with either MI HRT-18
cells or with S2 strain BCV had a significant effect on the number
of mice which developed diarrhoea compared to the untreated
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Table 7.1
Incidence of diarrhoea in mice inoculated with BCV.











controls (probability (P) < 0.00001 for either group, using
2-tailed Fishers exact tests). A significantly greater proportion
of mice developed diarrhoea after inoculation with S2 strain BCV
than after inoculation with MI HRT-18 cells (P = 0.0052, using a
1-tailed Fishers exact test).
The results obtained in trials A and B were also pooled in order
to compare the times of onset and the duration of diarrhoea between
mice of the 3 groups (Figs. 7.1 and 7.2). All mice which
developed diarrhoea did so within 4 days of inoculation, with the
majority developing diarrhoea on the first or second day. Diarrhoea
generally lasted for only one or sometimes two days, regardless of
the inoculum given. The figures obtained for the onset of
diarrhoea were analysed using a Generalised Linear Model, with
binomial variance and a logit link. Differences between the 3
groups were tested by checking the statistical significance of the
onset group interaction term in the model. This term was not found
to be significant (F. „ = 0.65; F0 . P — 0.05 (tables) = 19.37). A
Z , o z , o
stastical analysis of the duration of diarrhoea was inappropriate,
as only small numbers of mice had diarrhoea for more than one day.
Study of these histograms (Fig. 7.2) however suggests that mice
inoculated with BCV developed diarrhoea which lasted for a similar
duration as mice inoculated with MI HRT-18 cells.
In 2 further trials attempts were made to detect BCV in the
intestines harvested from mice with diarrhoea. Mice were
inoculated orally with BCV or MI HRT-18 cells, and any mice which
developed diarrhoea were immediately culled. The small and large
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Figure 7.1
The onset of diarrhoea, days after inoculation, in
mice either given no inoculum or inoculated with MI
HRT-18 cells or S2 strain BCV. (Figures obtained from
trials A and B: see text).
The % of inoculated mice in each group which
developed diarrhoea 1, 2, 3 or 4 days after
inoculation is indicated by the heights of the
cross-hatched areas.
No irtoouium
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Figure 7.2
The duration of diarrhoea in mice either given no
inoculum or inoculated with MI HRT-18 cells or S2
strain BCV (Figures obtained from trials A and B: see
text).
The % of inoculated mice in each group which
developed diarrhoea persisting for 1, 2 or 3 days is
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intestines were harvested and homogenised with appropriate volumes
of RPMI MM to dilute them 1:10. The homogenates were clarified and
the supernates tested for the presence of BCV by measurement of the
ITs on HRT-18 cells and by measurement of the HA titres. Guts were
harvested from 18 diarrhoeic mice inoculated with BCV and 15
diarrhoeic mice inoculated with MI HRT-18 cells. When the gut
preparations were inoculated onto HRT-18 cells, IF staining failed
to detect BCV Ags in any of the samples (IT <2.3). Non-specific
agglutination occurred when the gut preparations were titrated in
HA tests (HA titres = 10-80). The non-specific agglutinins were
successfully extracted with the organic solvent Arklone (HA titres
= <10), but no HA activity remained in the preparations from mice
which had received BCV. Control virus samples demonstrated that
Arklone treatment did not affect the ability of BCV to
haemagglutinate. It thus proved impossible to detect BCV by
measurement of either infectivity or HA titres in any of the gut
preparations tested.
Gnotobiotic piglet
A 10 day old, male, colostrum-deprived gnotobiotic piglet was
inoculated with a suspension of faeces containing SI strain BCV.
This virus had originated from a field case of BCV enteritis. It
had been passaged by Dr. D. Snodgrass and Dr. A. El-Ghorr through
2 gnotobiotic calves (calves F690 and L965) and the faeces from
calf L965 used to inoculate the piglet. The inoculum was prepared
by making a 1:5 dilution of the faeces in PBS, homogenising and
then spinning the suspension at 1000 rpm for 5 min on a bench
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centrifuge. Filtration was avoided, in order to maintain the
maximum possible dose of virus. Ten ml of supernatant fluid were
inoculated orally and a further 1.0 ml inoculated into each nostril
(day 0). The piglet was monitored daily for any clinical
abnormalities and faecal and nasal swabs collected. Attempts were
made to detect BCV in the faecal samples using the diagnostic ELISA
and by IGEM (El-Ghorr et al, 1988), the latter technique being
performed by Mrs. L. Inglis at MRI. Attempts were made to detect
BCV antigens in the nasal swab samples by IF staining of
acetone-fixed nasal epithelial cells using lamb anti-BCV serum
(serum 5000) followed by pig anti-sheep Igs FITC conjugate. Serum
samples were collected on days 4 and 12 and tested for BCV Abs in a
SN test. The piglet was killed on day 12.
Inoculation of the piglet failed to produce any detectable signs
of BCV infection or disease. The piglet remained bright throughout
the experiment, and its temperature and appetite were normal. The
appearance of the faeces was unchanged by inoculation and no virus
was detected. A few samples, including the preinoculation sample,
gave moderate OD readings (around 0.5) in the diagnostic ELISA.
These were blocked if a 1:20 dilution of either lamb anti-BCV serum
(serum 5000) or lamb anti-rotavirus serum (serum 3626) was added
before the detecting Ab, suggesting that other components of the
piglet faeces were binding in a non-specific manner in this test.
IF staining of fixed nasal epithelial cells also failed to detect
any BCV Ags. The serum samples collected on days 4 and 12 both had




A male, Friesian cross Limousin colostrum-deprived gnotobiotic
calf was inoculated at 2 days old (day 0) with a preparation of the
field faecal sample from which S2 virus had originally been
isolated (El-Ghorr, 1988). This sample had been stored at -70^C
for several years, so it was first tested in the diagnostic ELISA
to confirm that BCV was still present. Absence of rotavirus and
other contaminating viruses was demonstrated by PAGE followed by
silver staining (Herring et al, 1982), and by EM. A 10% suspension
of a bacteria-free filtrate was prepared, and 19ml inoculated
orally and a futher 5 ml inoculated into each nostril of the calf.
It was inoculated IM on days 25 and 35 with 2.5 ml and 3.0 ml
respectively of cell culture adapted S2 virus emulsified with FIA
in a ratio of 1:2. The experiment was terminated on day 50, when
the calf was removed from the isolator and a large volume of serum
collected for use in routine laboratory tests.
The calf was monitored clinically each day, and its demeanour,
rectal temperature and appetite (volume of milk drunk) recorded.
During the first 11 days of the experiment, a bag was fitted to
the rear of the calf by means of a harness. This allowed the
faeces to be collected each day and their total mass and % dry
matter (DM) were measured. During the latter course of the
experiment faecal samples were collected with a swab. The faecal
samples were tested for BCV using the diagnostic ELISA and by virus
isolation in TOC. Nasal swab samples were collected by gently
rubbing a 15 cm swab as far as possible up both nostrils. The
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swabs were placed in 1.5 ml virus transport medium and mixed on a
vortex mixer. Virus was detected by isolation in TOC or by IF
staining of acetone-fixed nasal epithelial cells using either MAb
S2/1 or rabbit anti-S2 serum (serum 5317) followed by the
appropriate anti-species Ig conjugated with FITC. Serum samples
were collected from the calf twice a week and titrated against S2
virus in IF, SN and HAI tests. The serum samples were also used to
probe S2 virus proteins in Western blotting experiments and tested
against the S2 MAbs in epitope blocking assays (EBAs).
Results relating to the alimentary and respiratory tracts
The observations and results relating to the alimentary tract
are summarised in Table 7.2. The calf was moderately dull on day 5
at the onset of diarrhoea, but remained bright at other times. The
animal was never pyrexic. His milk consumption dropped on day 2
and did not return to normal until day 8: the calf was particularly
reluctant to drink on days 4 and 5. Diarrhoea commenced on day 5
and continued for 4 days, as demonstrated by the marked drop in
the % DM of the faeces. During this time the faeces were brown and
very fluid, and occasionally contained strands of gut lining and
specks of blood. The faeces remained soft for a further 3 days
before returning to normal on day 13. The mass of faeces excreted
per day remained approximately constant at around 50g, with the
exception of day 7 when 235g were excreted. BCV was detected in
the faeces from day 4 until day 9, and was then intermittently
detected until day 15, after which virus excretion ceased.
Table 7.2
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Gnotobiotic calf infected with S2 strain BCV















0 5400 N NT NT - NT
1 6600 N 67 18 - -
2 4400 N 51 23 - -
3 4700 N 71 23 - -
4 3900 N 45 18 + +
5 3900 D 61 9 + +
6 5400 D 73 6 + +
7 5600 D 235 7 + +
8 5900 D 85 9 + +
9 6000 D 25 12 + -
10 6000 (D) 40 14 - -
11 6000 (D) 12 14 - -
12 6000 (D) NT NT + -
13 6000 N NT NT + NT
14 6000 N NT NT - NT
15 6000 N NT NT + NT
*A maximum of 6 litres of milk were offered daily.
**N = normal D = diarrhoea (D) = slight diarrhoea
NT = not tested
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The results relating to the respiratory tract are summarised in
Table 7.3. The calf never showed any clinical signs relating to
infection of the respiratory tract. IF staining of acetone-fixed
nasal epithelial cells detected high levels of BCV Ags between days
1 and 8, with lower levels detected between days 9 and 12. MAb
S2/1 proved to be a more sensitive probe and gave lower levels of
background staining than rabbit anti-S2 serum (serum 5317). The
binding of serum 5317 was blocked by first incubating the infected
cells with lamb anti-BCV serum (serum 5000), demonstrating that the
staining observed with serum 5317 was specific for BCV. IF was
never observed when rabbit anti-rotavirus serum (serum 4381) was
used as a negative control Ab. BCV was isolated in TOC from the
nasal swab samples on days 2 to 8, corresponding to the period when
large numbers of nasal epithelial cells were stained by IF.
Serological response to infection
The serum samples collected from the calf were titrated against
S2 virus in IF, SN and HAI tests (Fig. 7.3). Ab was first
detected by all 3 assays between days 7 and 11. IF titres continued
to rise, being further boosted after vaccination on day 25. SN and
HAI titres remained low until vaccination on day 25, when
significant boosts occurred.
The serological responses of the calf to individual viral
proteins and their antigenic regions were monitored by using the
test sera as probes in Western blotting experiments and as
competitor Abs in EBAs. In the Western blotting experiments, S2
Table 7.3
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Gnotobiotic calf infected with S2 strain BCV
Detction of BCV in upper respiratory tract
Days
Detection of BCV in nasal swab samples by:
IF* with:
PI Isolation in TOC
MAbS2/1 Rabbit anti-S2 serum
0 - - -
1 + + - -
2 + + + + +
3 + + + +
4 + + + + +
5 + + + +
6 + + + + +
7 + + + + +
8 + + + +
9 + JL1 -
10 + + -
11 + - -
12 + + -
13 - - -
14 - - NT
15 - - NT
* The number of cells in which BCV antigens were detected by indirect IF were
classified by eye as many (+ +), few (+) or none (-).
NT = not tested.
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Figure 7.3
Gnotobiotic calf infected with S2 BCV: IF, SN and HAI
titres.
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virus proteins were dissociated by boiling with LSB in the absence
of ME (non-reducing conditions), blotted onto nitrocellulose paper
and probed with the consecutive serum samples (Fig. 7.4). Abs to
the S, HE and N proteins were first detected at 11 days pi whilst
Abs to the M gps were first detected very weakly at 21 days pi. Abs
present in gnotobiotic lamb anti-MI HRT-18 cell sera (sera 5923 and
5926) also bound in these experiments to a cellular protein with a
MW similar to that of the HE gp. This reaction did not interfere
with the results obtained using the test sera, as Abs to the HE gp
were detected before the calf received any cellular proteins when
it was vaccinated on day 25.
The test sera were titrated against MAbs S2/1, S2/2, S2/3, S2/6
and S2/8 in EBAs. The mean OD values obtained with each test
sample were plotted against the serum dilutions, and sigmoidal
curves produced. End point ODs were defined so that they fell
around the centre of the straight line regions of these curves, and
so that the initial rises in Ab titres were detected. They were
taken as 50% the mean OD. . value for the HE and S
(no competitor)
MAbs, and as 65% and 80% the mean OD. . value for the N
(no competitor)
MAbs S2/6 and S2/8 respectively. The mean OD. . valuesJ (no competitor)
were obtained for each test plate from a set of wells to which
PBS/0.05%T was added in place of competitor Abs. The reciprocals
of the serum dilutions at the end point OD values were determined
from the curves. These serum titres are shown in Table 7.4, and
plotted against the days pi in Fig. 7.5.
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Figure 7.4
Serological response of gnotobiotic calf to S2 virus
infection, determined by Western blotting
(non-reducing conditions)
The proteins of S2 strain BCV were separated by SDS/PAGE,
blotted onto nitrocellulose paper and probed with
consecutive serum samples from the calf. Bound Abs were



















17 Gnotobiotic lamb anti-MI HRT18 serum (serum 5923)
18 Gnotobiotic lamb anti-MI HRT18 serum (serum 5926)
19 Gnotobiotic lamb anti-rotavirus serum (serum 3626)
20 PBS/0.5%T
21 S2 MAb: S2/8 (N)
22 CVL MAb: 5528 (M)
23 CVL MAb: 5529 (S)
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Table 7.4
Gnotobiotic calf infected with S2 strain BCV
Results obtained in epitope blocking assays
Days
PI
Serum titres obtained with MAbs*
S2/1 S2/3 S2/2 S2/6
(HE) (HE) (S) (N)
S2/8
(N)
0 33 16 0 0 0
S2 virus inoculated orally and intranasally
4 34 14 0 0 0
7 2042 74 1026 85 0
11 2587 4083 155 54 0
14 1838 1874 75 24 35
18 1632 1415 196 214 261
21 2671 1439 299 342 318
25 1752 1807 287 256 360
S2 virus noculatedIM
28 1987 1584 221 219 554
32 5261 3918 492 1117 1046
35 6918 5195 376 893 1083
S2 virus inoculated IM
50 84176 70431 6301 5013 1981
* Serum titres were defined as the reciprocals of the dilutions at the end point ODs. The
end point ODs were defined as 50% the mean OD (no competitor) values for the HE and
S MAbs and as 65% and 80% for the N MAbs S2/6 and S2/8 respectively.
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Figure 7,5
Gnotobiotic calf infected with S2 BCV
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The patterns of response obtained with EBAs using MAbs S2/1,
S2/2, S2/3 and S2/6 were similar. The titres rose to peak at day 7
(MAbs S2/2 and S2/6) or day 11 (MAbs S2/1 and S2/3). They then fell
to a minimum on day 14 (MAbs S/2 and S2/6) or day 18 (MAbs S2/1 and
S2/3) before gradually rising again. Abs directed against the
epitope delineated by MAb S2/8 were first detected on day 14 and
rose gradually to day 25. Vaccination on days 25 and 35
significantly boosted the titres.
Discussion
Oral inoculation with BCV resulted in the production of
diarrhoea in a significant proportion of neonatal mice, but the
virus had no apparent effect on the time of onset or duration of
diarrhoea. Neonatal mice must therefore be considered to be a
potential model of BCV infection, but their use is limited by the
very large numbers which would have to be studied in order to show
significant differences between groups receiving S2 virus and MI
HRT-18 cells. These results confirm the preliminary findings
reported by El-Ghorr (1988). Mice which received MI HRT-18 cells
probably developed diarrhoea due to the toxic effects of cell
components or media constituents present in the inoculum. Any
future experiments should include making a more rigorous effort to
detect BCV in diarrhoeic mice, possibly by undertaking a time
course study. The possibility of using other strains of BCV grown
in alternative cell lines and of using different strains of mouse
should also be investigated. Attempts could also be made to select
a more virulent variant of the virus by repeated passage through
mice.
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The piglet tested in this experiment did not prove suitable as a
model of BCV infection, and there is no documented evidence to
suggest that BCV can infect swine. It may be significant that the
CVs which infect pigs belong to antigenic group I, whereas BCV
belongs to antigenic group II.
Diarrhoea was successfully reproduced in the calf, and was
accompanied by virus excretion in the faeces. Virus continued to
be detected intermittently in the faeces after diarrhoea had
ceased, which supports the proposal that persistence of the virus
in clinically normal animals may maintain a reservoir of BCV in
infected herds (Heckert et al. 1990; Kapil et al, 1990). Infection
of the upper respiratory tract was also demonstrated, but infection
occurred in the absence of any clinical signs.
Consecutive serum samples were titrated in IF, SN and HAI tests.
The IF titres reflect the total levels of BCV specific Abs present
in the sera, whilst the SN tests measure the Abs directed against
the neutralising epitopes on the S and HE gps. At present there is
some controversy as to whether the HA activity of BCV resides on
the HE and/or S gp (Storz et al, personal communication): the HAI
titres are a measure of the Abs directed against the appropriate
epitopes. The Western blotting experiment gave a qualitative
indication of the Abs directed against each of the 4 structural
proteins of BCV, whilst the EBAs measured the Ab responses to
individual antigenic regions on these proteins. The former test
was less sensitive, as Abs directed against the HE, S and N
proteins were detected by the EBAs at a shorter interval pi. The
results obtained in the Western blotting experiments demonstrated
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that the serological response to the M gp occurred somewhat later
than that to the other viral proteins.
When analysing the results of the EBAs, it is important to allow
for the variations in the sensitivity and specificity of these
tests. The sensitivities of the EBAs can be estimated by studying
the results of the competition ELISAs described in Chapter 5. The
concentration of homologous competitor MAb/well which gave levels
of competition of 50% (MAbs S2/1, S2/2 and S2/3), 35% (MAb S2/6)
and 20% (MAb S2/8) indicates the minimum amount of Ab which is
necessary for a positive result in the EBAs. These can be
calculated as 0.021 ug (MAb S2/1), 0.040 ug (MAb S2/2), 0.032 ug
(MAb S2/3), 0.004 ug (MAb S2.6) and 0.237 ug (MAb S2/8). Assuming
that MAbs and epitope specific Abs present in polyclonal sera have
similar binding affinities, the EBAs based on MAbs S2/1, S2/2 and
S2/3 are of similar sensitivities, whilst that based on MAb S2/6
is more sensitive and that based on MAb S2/8 is rather less
sensitive. The end point OD for the EBA incorporating MAb S2/8 was
defined as 80% the mean OD, . . value, in an attempt to
(no competitor)
maximise the sensitivity of this test.
The specificities of the EBAs can also be established from the
results obtained in the competition ELISAs (Chapter 5). The 4 HE
MAbs all competed strongly with each other, even though other tests
demonstrated that they were directed against 3 different epitopes.
The HE MAbs also competed strongly with the S MAb (S2/2), so the
EBAs incorporating the HE and S MAbs were unable to differentiate
between Abs directed against epitopes delineated by these MAbs. The
curves obtained using MAbs S2/1, S2/3 and S2/2 in EBAs were
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therefore similar to each other. They were also similar to those
obtained in the SN and HAI tests, which is expected as the HE and S
gps carry the epitopes involved in neutralisation and
haemagglutination. The very high peak which was detected on day 7
by the S2/2 EBA is difficult to explain, but may have been caused
by other components present in the serum sample competing in a
non-specific manner with this MAb.
MAbs S2/6 and S2/8 were used in EBAs to measure the serological
responses directed against the N protein. The results obtained
using these 2 MAbs were very different: this was not unexpected as
competition ELISAs demonstrated that these MAbs were directed
against different epitopes (Chapter 5). When MAb S2/6 was used as
a detecting Ab in competition ELISAs, moderate levels of
competition occurred with the HE MAbs. The end point of the S2/6
EBA was therefore defined as 65% the mean OD (no competitor) value,
so that very high levels of HE Abs would have to be present before
they had a significant effect on the titre measured by this EBA.
The EBAs showed that the serological response directed against the
epitope delineated by MAb S2/8 was slow and weak compared to that
generated against other epitopes, but this may have been an
artifact caused by the relatively low sensitivity of the S2/8 EBA.
Although only a single calf was used in these experiments, the
results obtained confirm that colostrum-deprived, gnotobiotic
calves are suitable as experimental models of BCV infection. Other
reports suggest that conventionally derived, SPF calves may also
be suitable as models of BCV infection, provided they are deprived
of colostrum (Saif et al, 1986; Saif, 1987). El-Ghorr (1988)
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failed to reproduce clinical disease in colostrum fed SPF calves,








The main aim of this study was to establish the extent of
antigenic variation amongst BCV isolates. Efficient techniques
were first developed for isolating BCVs from faecal samples, and a
panel of MAbs were raised against S2 strain BCV and characterised.
This allowed a comprehensive investigation of BCV strain variation
to be undertaken. The structural proteins of BCV were also
analysed on a functional basis and the epitopes of the N and HE
proteins partially mapped. Neonatal mice and a gnotobiotic piglet
did not prove suitable as experimental models of BCV enteric
infection, but disease was successfully reproduced in a colostrum
deprived, gnotobiotic calf. In this Chapter, these different
topics are discussed in more detail, and areas worthy of future
research outlined.
Detection of BCV in calf faecal samples
Faecal samples collected from diarrhoeic calves were submitted
to the MRI for testing for BCV using a diagnostic ELISA. Positive
samples were used as the source of the BCV isolates which were
subsequently examined for the presence of strain variations. At
the start of these studies, the ELISA was based on polyclonal
capture and detecting Abs, but the capture Ab was later replaced
by MAb S2/1. There was therefore a danger that this MAb biased the
panel of BCV isolates used in subsequent investigations. In the
future, the diagnostic ELISA could be improved by replacing MAb
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S2/1 with a pool of 2 or more MAbs directed against epitopes
conserved between different BCV isolates (Czerny and Eichhorn,
1989) . Ideally these MAbs should be directed against both internal
and external virus proteins so that both whole and degraded virus
particles are detected (Crouch et al, 1984). A mixture of MAbs
S2/6 (N) and S2/7 (HE) would satisfy these requirements. To ensure
new BCV strains are not missed during diagnosis, it might be
worthwhile periodically examining a proportion of the faecal
samples found negative on the ELISA by EM of negatively stained
preparations.
Isolation of BCV
Tracheal organ cultures obtained from neonatal and young calves
proved highly successful for the primary isolation of BCVs from
faecal samples, and the viruses could then be adapted to growth in
HRT-18 cells. During isolation and adaptation, it was important to
monitor virus growth by a test which would not discriminate between
different strains of the virus. Measurement of HA titres using rat
RBCs was therefore chosen as the initial screening test, as all
isolates of BCV tested to date have been found to agglutinate RBCs
from this species. The only exceptions are some isolates
originating from cows with winter dysentery, which cannot
agglutinate either mouse or rat RBCs (Benfield and Saif, 1990).
Samples giving positive results in HA tests were confirmed to be
BCV specific by testing TOC samples in the diagnostic ELISA, and
by using anti-BCV sera to stain infected HRT-18 cells in IF tests.
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Viruses adapted to growth in HRT-18 cells were all grown under
the conditions previously found in this laboratory to be optimal
for the growth of M strain BCV (El-Ghorr, 1988). A more rigorous
approach would probably have resulted in the growth of these
viruses to higher titres, but this was not considered necessary for
these studies.
Monoclonal antibodies against BCV
The unique specificities of MAbs make them ideal tools for
analysing virus proteins. Studies using MAbs are always however
limited by the number of MAbs which are available, and it is
therefore important to obtain as large and as diverse a panel of
MAbs as possible. Four MAbs directed against CVL strain BCV and a
further 8 MAbs directed against S2 strain BCV were used in these
studies. Of the 8 MAbs raised against S2 virus, 4 were directed
against the HE gp, 1 against the S gp and 3 against the N protein.
The high proportion of HE and N MAbs suggests either that the
original preparations used to immunise the donor mice during MAb
production were rich in these proteins, or that the mice responded
more strongly to these antigens.
Characterisation of the structural proteins of S2 strain BCV
MWs
The MWs of the S2 virus proteins were determined by Western
blotting using both polyclonal sera and MAbs as probes. The values
of 116 (reducible to 64), 98, 52 and 21 (range 19 to 23) KD for
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the HE, S, N and M proteins respectively agreed closely with
published values for other isolates of the virus (King and Brian,
1982; Deregt et al, 1983).
Functional characterisation using MAbs
The 8 S2 MAbs and the 4 CVL MAbs were tested against S2 strain
BCV in IF, SN and HAI tests. This served to characterise the MAbs,
and also helped define the virus proteins important in
neutralisation and haemagglutination. The results obtained with
the CVL MAbs should be interpreted with caution, as their failure
to react in SN or HAI tests may have been due to lack of epitope
conservation on S2 virus.
The MAbs directed against the M and N proteins reacted with S2
strain BCV in IF tests only. Neutralising epitopes have so far
never been detected on these proteins (Deregt and Babiuk, 1987),
but MAbs directed against the M and N proteins of other CVs can
both neutralise in vitro and protect in vivo (Buchmeier et al,
1984; Lecomte et al, 1987). It is therefore possible that a larger
panel of MAbs might also detect neutralising epitopes on the M and
N proteins of BCV. The results obtained in SN tests with the MAbs
directed against the S and HE gps of S2 strain BCV clearly
demonstrated that these proteins bear the major neutralising
epitopes. This supports the findings of other groups (Vautherot
and Laporte, 1983; Deregt and Babiuk, 1987). Future work should
establish which epitopes are important for protection in vivo. as
MAbs which neutralise the virus in vitro do not necessarily also
protect in vivo (Deregt et al, 1989a).
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The 4 S2 MAbs directed against the HE gp all inhibited virus
induced haemagglutination of rat RBCs. The S2 MAb directed against
the S gp was also a weak inhibitor of virus induced
haemagglutination. Other groups have also reported that some S
MAbs cause HAI (Vautherot and Laporte, 1983; Dea and Tijssen,
1989a; Storz et al, personal communication). Since MAbs directed
against both the S and HE gps can cause HAI, it is possible that
haemagglutination is caused by the combined effect of both these
gps or by the individual effect of either one of these proteins.
The ability of the HE gp to cause haemagglutination has recently
been questioned, as whilst whole BCV particles agglutinated chicken
RBCs, isolated HE gps failed to cause haemagglutination (Schultze
et al, 1991). If the HE gp is not a haemagglutinin, HE MAbs which
cause HAI must do so either by stearic hindrance or by inducing
conformational changes in the S gp (Storz et al, personal
communication). These proposals are supported by results obtained
by the candidate in competition ELISAs, in which HE MAbs inhibited
binding of the S MAb, presumably because the HE MAbs exerted some
effect on the S gp. An alternative explanation for the failure of
isolated HE gps to cause haemagglutination is that these proteins
need to be incorporated as part of a larger structure before they
can agglutinate RBCs. Further work must be undertaken to establish
whether the HE gp is directly involved with haemagglutination, and
to prove that the S gp is indeed a viral haemagglutinin.
Epitope mapping of the N and HE proteins
The 3 S2 MAbs directed against the N protein each mapped to a
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distinct antigenic region in competition ELISAs. The S2/5 MAb
could not be used as a biotinylated detecting MAb, but its unique
reactions with the standard strains of BCV in IF tests confirmed
that it was directed against an epitope distinct from those defined
by MAbs S2/6 and S2/8. This is the first report of the presence of
distinct antigenic regions on the N protein of BCV.
The 4 S2 MAbs directed against the HE gp all competed strongly
with each other in competition ELISAs, so in these tests they
defined a single antigenic region. This region could be subdivided
into 3 epitopes on the basis of results obtained in other tests.
MAb S2/1 mapped to a unique epitope, on the basis of its failure to
bind to blotted viral proteins and its reactions with certain virus
isolates in ELISAs, IF and HAI tests. MAbs S2/3 and S2/4 were
differentiated from MAbs S2/1 and S2/7 by their failure to
neutralise CK and M strains of BCV. One antigenic region was
therefore defined by MAb S2/1, a second by MAbs S2/3 and S2/4 and
a third by MAb S2/7.
A larger panel of MAbs would allow a more complete definition of
the antigenic regions and epitopes of the structural proteins of
BCV. Identification of the epitopes important for in vivo
protection is particularly important, as this is relevant for
future vaccine development and facilitates accurate predictions
concerning the effect of antigenic variations at particular sites.
So far the antigenic regions of the BCV proteins have largely been
defined on a functional basis. A structural definition may be
achieved by analysis of degraded virus proteins, by generating and
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sequencing neutralisation resistant mutants or by studying
synthetic peptides.
Strain comparison of BCV isolates
Knowledge of the extent of strain variation is important when
considering methods of controlling BCV diarrhoea and during vaccine
development. Diagnostic tests should be based on the detection of
viral epitopes which are known to be conserved between different
strains of the virus. Previous studies of BCV strain variation had
been limited to examining a relatively small number of isolates.
These studies had demonstrated only minor variations in
physicochemical properties (Dea et al, 1980b) and in reactions with
polyclonal sera and MAbs (Dea et al, 1982; Vautherot and Laporte,
1983; El-Ghorr e_t al, 1989).
In the studies performed by the candidate, 5 standard strains of
BCV (SI, S2, CK, M and PQ) were first examined for strain
variations using polyclonal sera and MAbs. The study was then
widened by using the S2 MAbs to screen 28 TOC isolates for strain
variations, and from these results 7 viruses were chosen for
adaptation to growth in HRT-18 cells (MRI BCV isolates). In these
studies, strain variations were detected with the S2 MAbs on the
N, HE and S proteins. The M gps could not be analysed with MAbs,
as an insufficient amount of this MAb was available. Variations
were most commonly detected on the HE and S gps, and these were
most readily detected in SN tests. This finding was not unexpected,
as greater selection pressure is exerted on epitopes involved in
neutralisation. Other workers have also detected antigenic
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variations on the HE and S gps of BCV with MAbs (Vautherot and
Laporte, 1983; Deregt et al. 1989a; El-Ghorr et al, 1989). Strain
variations were detected on the N protein with MAb S2/5 in IF
tests: this is the first report of strain variation on the N
protein of BCV. The other 2 N MAbs, S2/6 and S2/8, failed to
detect antigenic variations on any of the isolates tested, and
these MAbs would therefore be highly suitable for use in diagnostic
tests.
Strain variations were never detected in these studies with
polyclonal sera, which suggests that all the isolates belong to a
single serotype. The MAbs detected wide variations in SN tests,
whilst cross SN tests with rabbit polyclonal sera failed to detect
antigenic variations on the 5 standard strains of BCV, and rabbit
anti-S2 serum failed to detect variations amongst the 7 MRI
isolates in SN tests. Shortage of time unfortunately precluded
raising polyclonal sera against the 7 MRI BCV isolates and using
these sera in cross SN tests. These findings emphasise the
importance of using both polyclonal sera and MAbs in studies of
antigenic variation. Whilst MAbs are excellent at discriminating
between different virus isolates, there is always a danger that a
biased panel of MAbs may emphasise antigenic similarities or minor
differences that are of no relevance in vivo.
This study is the largest investigation of BCV strain variation
which has been undertaken to date, and is important because it
clearly demonstrates that antigenic variations do occur. Whilst
the in vivo significance of these variations is unclear at present,
their very existence suggests there is the potential for
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significant variations to arise in the future. In any
investigation of strain variation, it is important to study as wide
a variety of isolates as possible. In this study, all the TOC
isolates derived from faecal samples which had been collected in
Scotland between 1987 and 1989. As discussed earlier, the
diagnostic test for BCV and the virus isolation procedure may have
led to some degree of selection of the isolates. Future studies
could utilise larger and more diverse panels of viruses, MAbs and
polyclonal sera. The data obtained in serological tests should
also be compared with that obtained using molecular techniques such
as hybridisation assays or sequencing data.
Animal models of BCV infection
Studies on BCV have been hampered by the lack of a small animal
model of enteric BCV infection. The virus has been successfully
adapted to grow in the brains of suckling mice following
intracerebral or intranasal inoculation, but such a model is of
little practical use (Kaye et al, 1975; Akashi et al, 1981;
Barthold et al, 1990). In the ideal small animal model system,
oral inoculation with BCV would result in diarrhoea, accompanied
by virus excretion in the faeces and a serological response. Such
a model would permit challenge experiments to be performed, in
which protective antigens and epitopes could be identified and
different strains analysed for their abilities to cause cross
protection. A small animal model would also be useful during the
early stages of vaccine development.
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In these studies, neonatal mice and a gnotobiotic piglet did not
prove suitable as animal models of BCV infection. The possibility
of using other small laboratory animals such as rats or guinea pigs
has not yet been investigated. El-Ghorr (1988) failed to
consistently reproduce diarrhoea in gnotobiotic lambs orally
infected with the virus. BCV diarrhoea was successfully reproduced
in the colostrum deprived, gnotobiotic calf, which was orally and
intranasally infected with S2 virus. BCV was excreted from both
the respiratory and enteric tracts, and there was a marked
serological response to infection. This study confirmed that
colostrum deprived calves are the only suitable models of enteric
BCV infection. In this study a gnotobiotic calf was used, but
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The pH was adjusted to 8.8 with concentrated HC1.
4X Laemmli sample buffer
2X Laemmli stacking gel buffer 5.0g
Sucrose 4.0g
DW 2.5g
Bromophenol blue 8 mg
2X Laemmli sample buffer (No ME)
4X Laemmli sample buffer 1.0 ml
10% SDS 400 ul
DW 600 ul
2X Laemmli sample buffer (with ME)
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10% SDS 400 ul









3% polvacrvlamide stacking gel
30% Acrylamide solution 1.5ml
2X Laemmli stacking gel buffer 7.5ml
DW 6.0ml
The solution was degased under vacuum and polymerisation initiated
by the addition of 15 ul N,N,N',N'-tetramethyl-ethylenediamine
(Temed) and 75 ul 10% ammonium persulphate solution.
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The pH of the solution was measured to ensure that it was correct
at pH 8.3.
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at pH 8.3.
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MW markers: Sigma MW-SDS-200 kit
Carbonic anhydrase (bovine erythrocytes) 29 KD
Albumin (egg) 45 KD
Albumin (bovine plasma) 66 KD
299
Phosphorylase B (rabbit muscle) 97 KD
B-galactosidase (Escherichia coli) 116 KD
Myosin (rabbit muscle) 205 KD
Coomassie Brilliant Blue Stain
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